var title_f35_42_36512="Livedo racemosa in polyarteritis nodosa";
var content_f35_42_36512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Livedo racemosa in polyarteritis nodosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An irregular, branched, vascular pattern (livedo racemosa) and a few healing ulcerations are present on the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_42_36512=[""].join("\n");
var outline_f35_42_36512=null;
var title_f35_42_36513="S aureus sputum";
var content_f35_42_36513=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sputum with",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    under high power magnification (1000x) in sputum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_42_36513=[""].join("\n");
var outline_f35_42_36513=null;
var title_f35_42_36514="Patient information: Heart murmurs (The Basics)";
var content_f35_42_36514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16655\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/42/36516\">",
"         Chambers and valves of the heart",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/35/34354\">",
"          Transthoracic echocardiogram (echo)",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/35/32306\">",
"         Patient information: Aortic regurgitation in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/53/36690\">",
"         Patient information: Aortic stenosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/60/19394\">",
"         Patient information: Mitral regurgitation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/31/12787\">",
"         Patient information: Mitral stenosis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/4/21571\">",
"         Patient information: Mitral valve prolapse (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/36/33346\">",
"         Patient information: Tricuspid regurgitation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/52/14146\">",
"         Patient information: Tricuspid stenosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/17/33042\">",
"         Patient information: Vagal maneuvers and their responses (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?26/59/27575\">",
"         Patient information: Mitral regurgitation (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Heart murmurs (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/heart-murmurs-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6759728\">",
"      <span class=\"h1\">",
"       What is a heart murmur?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A heart murmur is an extra sound that doctors or nurses hear when they listen to the heart with a stethoscope. A heart murmur usually sounds like an extra &ldquo;whoosh&rdquo; or &ldquo;swish&rdquo; in the heartbeat.",
"     </p>",
"     <p>",
"      Normal heartbeat sounds are made as the heart valves open and close as blood flows through the heart (",
"      <a class=\"graphic graphic_figure graphicRef58389 \" href=\"mobipreview.htm?35/42/36516\">",
"       figure 1",
"      </a>",
"      ). The heart valves are structures that keep blood flowing in only 1 direction. They work like swinging doors that open only 1 way &ndash; letting blood out, but not back in.",
"     </p>",
"     <p>",
"      A heart murmur happens when the sound of blood flowing through the heart or blood vessels is loud enough to be heard. This can happen when the heart is normal. It can also happen when there is a change in the way the heart valves work or the way blood flows through the heart or blood vessels.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6759743\">",
"      <span class=\"h1\">",
"       How do I know if I have a heart murmur?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people learn that they have a heart murmur during a routine exam. If your doctor or nurse hears a heart murmur, he or she might have you hold your breath or change your position while he or she listens to your heart. This will tell the doctor or nurse more about your heart murmur.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6759758\">",
"      <span class=\"h1\">",
"       Does having a heart murmur mean that I have a heart problem?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not always. People with normal hearts and blood vessels can have heart murmurs. Doctors call these &ldquo;innocent&rdquo; heart murmurs. Innocent heart murmurs are not caused by a heart problem.",
"     </p>",
"     <p>",
"      People of any age can have an innocent heart murmur. But innocent heart murmurs are especially easy to hear in people who are young, thin, or pregnant.",
"     </p>",
"     <p>",
"      Other heart murmurs are abnormal. These are caused by a heart condition. Common causes of abnormal heart murmurs are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Problems with the heart valves &ndash; The heart valves can leak too much and let blood flow backward. Or they can get stuck and not open well.",
"       </li>",
"       <li>",
"        Heart problems that people are born with, such as a hole in 1 of the walls inside the heart",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6759772\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. When your doctor or nurse first hears a heart murmur, he or she will want to know if it is innocent or abnormal. He or she will ask you questions and do an exam.",
"     </p>",
"     <p>",
"      If your heart murmur is innocent, you will not need any tests.",
"     </p>",
"     <p>",
"      If your doctor or nurse thinks your heart murmur might be abnormal or isn&rsquo;t sure, he or she might order a test to find out what&rsquo;s causing the murmur. The test most commonly used is an",
"      <strong>",
"      </strong>",
"      echocardiogram (also called an &ldquo;echo&rdquo;). This",
"      <strong>",
"      </strong>",
"      test uses sound waves to create a picture of your heart as it beats. It shows the size of the heart chambers, how well the heart is pumping, and how well the heart valves are working (",
"      <a class=\"graphic graphic_figure graphicRef77971 \" href=\"mobipreview.htm?33/35/34354\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6759787\">",
"      <span class=\"h1\">",
"       How is an abnormal heart murmur treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment depends on the heart condition that is causing the abnormal murmur. It also depends on how serious the condition is. If your heart condition is not serious, you might not need any treatment. But your doctor will follow your condition to see if it changes or gets worse.",
"     </p>",
"     <p>",
"      If your heart condition is serious, you might need treatment. Treatment might involve surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6759802\">",
"      <span class=\"h1\">",
"       Do I need to take antibiotics before I go to the dentist?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. In the past, doctors recommended that many people with a heart murmur take antibiotics before going to the dentist or having certain medical or dental procedures. But now, only people with certain heart conditions need antibiotics before going to the dentist or having a procedure. If you are not sure, ask your doctor if you need antibiotics for those times.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6759817\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/60/19394?source=see_link\">",
"       Patient information: Mitral regurgitation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/53/36690?source=see_link\">",
"       Patient information: Aortic stenosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/31/12787?source=see_link\">",
"       Patient information: Mitral stenosis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/4/21571?source=see_link\">",
"       Patient information: Mitral valve prolapse (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/36/33346?source=see_link\">",
"       Patient information: Tricuspid regurgitation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/52/14146?source=see_link\">",
"       Patient information: Tricuspid stenosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/17/33042?source=see_link\">",
"       Patient information: Vagal maneuvers and their responses (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/35/32306?source=see_link\">",
"       Patient information: Aortic regurgitation in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/59/27575?source=see_link\">",
"       Patient information: Mitral regurgitation (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/42/36514?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16655 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_42_36514=[""].join("\n");
var outline_f35_42_36514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6759728\">",
"      What is a heart murmur?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6759743\">",
"      How do I know if I have a heart murmur?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6759758\">",
"      Does having a heart murmur mean that I have a heart problem?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6759772\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6759787\">",
"      How is an abnormal heart murmur treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6759802\">",
"      Do I need to take antibiotics before I go to the dentist?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6759817\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16655\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/42/36516\">",
"      Chambers and valves of the heart",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/35/34354\">",
"       Transthoracic echocardiogram (echo)",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/35/32306?source=related_link\">",
"      Patient information: Aortic regurgitation in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/53/36690?source=related_link\">",
"      Patient information: Aortic stenosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/59/27575?source=related_link\">",
"      Patient information: Mitral regurgitation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/60/19394?source=related_link\">",
"      Patient information: Mitral regurgitation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/31/12787?source=related_link\">",
"      Patient information: Mitral stenosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/4/21571?source=related_link\">",
"      Patient information: Mitral valve prolapse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/36/33346?source=related_link\">",
"      Patient information: Tricuspid regurgitation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/52/14146?source=related_link\">",
"      Patient information: Tricuspid stenosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/17/33042?source=related_link\">",
"      Patient information: Vagal maneuvers and their responses (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_42_36515="Primary low-grade glioma in adults";
var content_f35_42_36515=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Primary low-grade glioma in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/42/36515/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36515/contributors\" id=\"au4439\">",
"       Lawrence D Recht, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/42/36515/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36515/contributors\" id=\"se4309\">",
"       Patrick Y Wen, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36515/contributors\" id=\"se4260\">",
"       Jay S Loeffler, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/42/36515/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36515/contributors\" id=\"de8764\">",
"       April F Eichler, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/42/36515?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      LOW GRADE GLIOMA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Primary brain tumors are cancers that originate in the brain. These tumors are very different from secondary brain tumors, which originally developed elsewhere in the body and spread (metastasized) to the brain.",
"    </p>",
"    <p>",
"     Primary brain tumors develop from glial cells. Glial cells provide the structural backbone of the brain and support the function of the neurons (nerve cells), which are responsible for thought, sensation, muscle control, and coordination.",
"    </p>",
"    <p>",
"     In this article, we will discuss the symptoms, diagnosis and treatment of low-grade gliomas, an important category of primary brain tumors. For information about high-grade gliomas, (see",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/52/8004?source=see_link\">",
"      \"Patient information: High-grade glioma in adults (Beyond the Basics)\"",
"     </a>",
"     ). More detailed information about low-grade gliomas is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44568?source=see_link\">",
"      \"Management of low-grade glioma\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CLASSIFICATION OF PRIMARY BRAIN TUMORS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Low-grade versus high-grade gliomas",
"     </span>",
"     &nbsp;&mdash;&nbsp;Primary brain tumors are tumors that classified according to their appearance under the microscope. Gliomas are classified into four grades (I, II, III, and IV), and the treatment and prognosis depend upon the tumor grade [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/42/36515/abstract/1\">",
"      1",
"     </a>",
"     ]. Grade I or II tumors are termed low-grade gliomas.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Types of low-grade glioma",
"     </span>",
"     &nbsp;&mdash;&nbsp;Low-grade gliomas are subdivided based upon the microscopic appearance of the tumor. The more common subtypes are:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Diffuse astrocytomas",
"     </span>",
"     &nbsp;&mdash;&nbsp;Diffuse astrocytomas are the most common low-grade glioma. They are usually diagnosed in individuals in their late thirties.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Pilocytic astrocytomas",
"     </span>",
"     &nbsp;&mdash;&nbsp;These tumors occur almost exclusively in people who are younger than 25 years of age. It is important to distinguish pilocytic astrocytomas from other low-grade gliomas because these tumors tend to progress very slowly.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Oligodendrogliomas",
"     </span>",
"     &nbsp;&mdash;&nbsp;Oligodendrogliomas can be slow-growing tumors.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Gangliogliomas",
"     </span>",
"     &nbsp;&mdash;&nbsp;These tumors have features of both gliomas and of tumors arising from neurons, the other type of cell within the brain. These tumors tend to grow very slowly.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Mixed gliomas",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some low-grade gliomas consist of mixtures of various tumor subtypes (eg, diffuse astrocytoma and oligodendroglioma). These tend to behave similarly to diffuse astrocytomas.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      LOW GRADE GLIOMA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Low-grade gliomas do not spread outside the brain, but instead grow into the normal brain tissue, creating symptoms as the tumor grows locally. This can disrupt connections between normal brain cells and can also create pressure on the nearby brain. The brain cannot expand when there is a tumor growing within it since it is confined within the skull. As a result, even a relatively small, slow-growing tumor can cause severe brain problems, particularly if the tumor is in a critical area of the brain.",
"    </p>",
"    <p>",
"     In many people, a seizure is the first sign of a low-grade glioma. Seizures, which also occur as a result of other conditions, are caused by disorganized electrical activity in the brain. Seizures can cause a loss of consciousness (passing out), involuntary movements (jerking or fits),",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     loss of muscle control throughout the body.",
"    </p>",
"    <p>",
"     Seizures can be controlled with medications. In people with a low-grade glioma who are diagnosed after a seizure, there may be no other signs of the tumor once the seizure is controlled with medication.",
"    </p>",
"    <p>",
"     Other people have symptoms due to swelling around the tumor (called cerebral edema) or blockage of the normal cerebrospinal fluid that circulates within the brain (called obstructive hydrocephalus). In either case, symptoms can include headache, nausea and vomiting, diminished consciousness, weakness or numbness, and loss of mental sharpness or difficulty concentrating. The area of the brain affected by the tumor",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     the swelling determine the specific symptoms.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      LOW GRADE GLIOMA TESTS",
"     </span>",
"    </p>",
"    <p>",
"     All of the symptoms described above, including seizures, can be caused by neurologic illnesses other than tumors and by non-neurologic diseases (eg, infections, endocrine disorders). A clinician will need to do a careful history and physical examination, as well as basic laboratory and x-ray tests, to determine the cause of symptoms. The presence of a brain tumor is often established by x-ray or imaging studies.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Imaging studies",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a brain tumor is suspected, the physician will want to obtain an imaging scan of the brain. This is done using either magnetic resonance imaging (also known as an MRI) or computed tomography (also known as CT or CAT scan). A major difference between an MRI and a CT scan is that the MRI uses a magnet to image the brain, while CT uses x-rays. Both give a detailed image of the brain's structure, and both can usually show the presence and location of a tumor.",
"    </p>",
"    <p>",
"     CT scans are generally more available and less expensive than MRI scans, so a head CT is often the first test that is ordered. However, the MRI provides much more useful information when a brain tumor is suspected and may be recommended after a tumor is confirmed.",
"    </p>",
"    <p>",
"     Sometimes, the findings on the brain CT or MRI are sufficiently clear that the diagnosis of a low-grade glioma is fairly certain. In such cases, a biopsy may not be necessary. However, in most cases, a biopsy is recommended to establish the type of tumor that is present (see",
"     <a class=\"local\" href=\"#H13\">",
"      'Biopsy'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     It is important to characterize a brain tumor as a low-grade glioma, high-grade glioma, or a different type of tumor altogether. A non-invasive x-ray test that may help in this distinction is a positron-emission tomography, or PET scan. During this test, a radioactive glucose (a sugar) is injected into the bloodstream, which then circulates to the brain. Differences in how the brain absorbs the glucose often help to identify a tumor, and may help to distinguish between a low-grade glioma, high-grade glioma, and other brain tumors.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A biopsy is usually required to establish the diagnosis and subtype of a brain tumor and plan appropriate treatment. Biopsy involves the removal of a small amount of tissue from the brain so that it can be examined under a microscope",
"    </p>",
"    <p>",
"     A brain biopsy may be done in conjunction with surgery to remove the tumor. Alternatively, a small sample may be removed from the tumor by stereotactic needle biopsy, which involves the insertion of a needle through the skull into the precise area of the tumor, using x-ray guidance. Although both surgical biopsy and stereotactic needle biopsy are usually safe, brain damage is a potential complication.",
"    </p>",
"    <p>",
"     A biopsy may be delayed until symptoms worsen or there is evidence of tumor growth or a change (on imaging tests) that suggests that the tumor is becoming more aggressive. The decision regarding the optimal timing of a biopsy requires the physician and patient to carefully weigh the risks of the biopsy against the benefit of knowing the specific type of tumor that is present.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      LOW GRADE GLIOMA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of a low-grade glioma must consider the best way to manage symptoms and remove or reduce the tumor. The optimal treatment of low grade-glioma (particularly the timing of treatment) is controversial, and treatment decisions must balance the benefits of therapy against the potential for treatment-related complications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Symptom management",
"     </span>",
"     &nbsp;&mdash;&nbsp;Seizures, cerebral edema (swelling in the brain around the tumor), and obstructive hydrocephalus (increased pressure within the brain due to blockage of the flow of cerebrospinal fluid within the brain) can all result in serious symptoms. Each of these requires a different therapeutic approach:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The same medications used to treat epilepsy are usually successful in controlling seizures associated with brain tumors. However, seizures may be more difficult to control in people with brain tumors, particularly low-grade gliomas. If medications are not effective, surgery to remove part of the tumor may be recommended in an attempt to reduce seizure activity.",
"      </li>",
"      <li>",
"       Cerebral edema usually can be treated successfully with steroids; the most commonly used steroid is dexamethasone (Decadron). Dexamethasone use can be temporary if specific treatment of the tumor is planned, and the treatment is expected to decrease edema. Dexamethasone may be used for a more prolonged period of time if treatment is not currently planned. Dexamethasone may be particularly useful in the late phases of the illness, such as if the tumor recurs and there is no other way to control cerebral edema.",
"       <br/>",
"       <br/>",
"       One of the problems with long-term use of dexamethasone (particularly high doses) is the potential for side effects (eg, ulcers, bleeding from the gastrointestinal tract, behavioral changes, thinning of the skin, loss of bone strength, high blood sugar). Thus, the dose of dexamethasone is tapered to achieve the lowest dose that effectively controls symptoms, yet minimize long-term complications.",
"      </li>",
"      <li>",
"       Obstructive hydrocephalus may require surgery to bypass the blockage and lower the pressure within the brain.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Treatment of the tumor",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery, radiation therapy, and chemotherapy may be used to treat a low-grade glioma, either separately or in combination. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44568?source=see_link\">",
"      \"Management of low-grade glioma\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;The objective of surgery is to remove as much of the tumor as possible while minimizing damage to the normal brain. While people with juvenile pilocytic astrocytomas do particularly well after removal of their tumors, the benefit of surgery on survival with other types of low-grade glioma is less clear.",
"    </p>",
"    <p>",
"     Low-grade gliomas grow into normal brain, and there is often no distinct boundary between the tumor and normal brain. As a result, efforts to remove all tumor cells inevitably remove some of the normal brain and can leave behind tumor cells. The remaining glioma cells continue to grow, eventually causing additional damage to the remaining normal brain, and a recurrence of symptoms. Thus, surgery, even when extensive, rarely results in cure of adults with low-grade glioma.",
"    </p>",
"    <p>",
"     Whether or not all patients should have surgery after initial diagnosis is an area of controversy:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Some physicians recommend removal of as much tumor as possible in all patients as soon as the diagnosis of a brain tumor is made. This recommendation is based upon studies suggesting that patients who have immediate surgery survive longer, possibly because the tumor is less likely to change into a more aggressive form.",
"      </li>",
"      <li>",
"       Other physicians recommend that carefully selected patients initially be observed without therapy, until the tumor grows or symptoms worsen despite medical therapy. The rationale behind this approach is that low-grade gliomas may progress very slowly, surgery can create more symptoms than are caused by the tumor, and surgery done later may be equally effective in prolonging survival.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The physician and patient must try to balance the benefits of removing tumor versus the potential for surgery to damage to normal brain. The amount of tissue removed and whether surgery is possible are influenced heavily by the location of the tumor within the brain:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If the tumor is in an area of the brain controlling one or more critical functions (eg, swallowing), surgery may result in severe damage. In this setting, the physician may recommend against surgery or recommend limiting the amount of tumor removed during surgery.",
"      </li>",
"      <li>",
"       If the tumor is in a less critical area of the brain, the physician may recommend trying to remove as much of the tumor as possible.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Other accepted reasons for surgery include increased pressure within the brain, symptoms caused by the tumor or a bleed (hemorrhage) into the tumor, or seizures that are unresponsive to medications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Radiation therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radiation therapy (also called radiotherapy or x-ray therapy) uses high energy x-rays that are carefully aimed at the area of the brain affected by the tumor. Radiation therapy is generally given in a series of treatments over several weeks. The total radiation dose, which is based upon the number of treatments and the amount of radiation administered per treatment, is carefully calculated to maximize the killing of tumor cells and minimize damage to the normal brain.",
"    </p>",
"    <p>",
"     In people with low-grade gliomas, radiation therapy may be recommended in three circumstances:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Radiation can be given after surgery, with the objective of eradicating tumor cells that were not removed at the time of surgery. The effectiveness of immediate radiation therapy after surgery is unclear. Because the benefit is uncertain and radiation has the potential for long-term neurologic side effects, postoperative radiation is often not recommended (see below).",
"      </li>",
"      <li>",
"       Radiation therapy may be the preferred treatment when a low-grade glioma has been diagnosed in a critical area of the brain that cannot be surgically removed, and therapy is felt to be necessary.",
"      </li>",
"      <li>",
"       Radiotherapy can be used later in the course of the illness, when there is evidence that the tumor has recurred and is causing symptoms. The use of radiation therapy at this time will depend upon how much radiation was given previously, since radiation cannot usually be given in full doses to the same area of the brain more than once.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A major problem with radiation therapy is treatment-related side effects. Radiation kills both tumor cells and normal cells, although tumor cells are somewhat more sensitive to the effects of radiation. Nevertheless, radiation therapy cannot kill all tumor cells without damaging adjacent normal brain, and this results in treatment-related side effects.",
"    </p>",
"    <p>",
"     The most common side effect is damage to the surrounding normal brain cells, resulting in gradually worsening impairment of mental sharpness and ability to think and concentrate (called impaired cognition). This tends to be worse with larger radiation fields, tends to worsen over time, and is more of a problem in people who survive for several years after radiation therapy. It is difficult to know for certain whether impaired cognition results from the radiation or whether it might be due to the disease itself. Nevertheless, the possibility of impaired cognition is one of the main reasons why radiation therapy is often delayed until it is absolutely necessary.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Regardless of the initial form of therapy, low-grade gliomas generally progress over time; the time frame may be long, sometimes as long as ten years or more after the original diagnosis. The tumor may also develop an aggressive (more malignant) phase after a variable period of time. This aggressive phase is characterized by more rapid tumor growth and progressive worsening of tumor-related symptoms.",
"    </p>",
"    <p>",
"     Treatment options are limited in the late phases of the disease since surgery and radiation therapy are unlikely to be useful or possible. In such cases, chemotherapy may be considered.",
"    </p>",
"    <p>",
"     Chemotherapy refers to the use of medicines to stop or slow the growth of cancer cells. Chemotherapy works by interfering with the ability of rapidly growing cells (like cancer cells) to divide or reproduce themselves. Because most of an adult's normal cells are not actively growing, they are not affected by chemotherapy, with the exception of bone marrow (where the blood cells are produced), the hair roots (follicles), and the lining of the gastrointestinal tract.",
"    </p>",
"    <p>",
"     Effects of chemotherapy on these and other normal tissues cause side effects during treatment. In general, side effects are more frequent when two or more drugs are administered simultaneously (termed combination chemotherapy, see below) and with higher as compared to lower doses of chemotherapy. Most chemotherapy drugs that are used for the treatment of brain tumors are given into a vein, although some (temozolomide, for example) are effective when given by mouth.",
"    </p>",
"    <p>",
"     Chemotherapy is not curative, but it can improve symptoms (for months rather than years) in some patients. Tumor shrinkage (which may be accompanied by an improvement in symptoms) has been seen in selected patients using various drugs or combinations, such as temozolomide (Temodar) or the \"PCV\" combination (procarbazine, lomustine, and vincristine). Patients with the oligodendroglioma subtype (especially those with the chromosome1p deletion) are most likely to benefit from chemotherapy; response rates in other types of low-grade gliomas have generally been disappointing.",
"    </p>",
"    <p>",
"     The use of chemotherapy in conjunction with radiation therapy earlier in the course of low-grade glioma has not been adequately studied. Thus, benefit from this approach has not been established, and it should only be used in the setting of a clinical research study. (See",
"     <a class=\"local\" href=\"#H20\">",
"      'Clinical trials'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating gliomas requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/learning/\">",
"      www.cancer.gov/clinicaltrials/learning/",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"      www.cancer.gov/clinicaltrials/",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"      file://clinicaltrials.gov/",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     Low-grade gliomas are cancers that develop in the brain and tend to be slow-growing. Although people with these tumors are only rarely cured, most are able to maintain to work, attend school, and perform other tasks for a number of years. Careful management of seizures, brain swelling, and other complications with medications, combined with the timely use of surgery, radiation therapy, and perhaps chemotherapy, can help preserve a high quality of life and minimize disability.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H221\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H491979\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/48/9986?source=see_link\">",
"      Patient information: Brain cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/34/6690?source=see_link\">",
"      Patient information: Astrocytoma (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H491987\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/52/8004?source=see_link\">",
"      Patient information: High-grade glioma in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35784?source=see_link\">",
"      Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=see_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/1/2071?source=see_link\">",
"      Diagnosis and classification of low-grade gliomas",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44568?source=see_link\">",
"      Management of low-grade glioma",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.nci.nih.gov/\">",
"      www.nci.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.com/\">",
"      www.nccn.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-ACS-2345",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Brain Tumor Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.abta.org/\">",
"      www.abta.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Brain Tumor Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.braintumor.org/\">",
"      www.braintumor.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Neurological Disorders and Stroke",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ninds.nih.gov/\">",
"      www.ninds.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Patient Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://cancer.about.com/forum\">",
"      file://cancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/42/36515/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/42/36515?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36515/abstract/1\">",
"      Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001. Cancer 2006; 106:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36515/abstract/2\">",
"      DeAngelis LM. Brain tumors. N Engl J Med 2001; 344:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36515/abstract/3\">",
"      Piepmeier J, Baehring JM. Surgical resection for patients with benign primary brain tumors and low grade gliomas. J Neurooncol 2004; 69:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36515/abstract/4\">",
"      Bampoe J, Bernstein M. The role of surgery in low grade gliomas. J Neurooncol 1999; 42:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36515/abstract/5\">",
"      Shaw EG, Tatter SB, Lesser GJ, et al. Current controversies in the radiotherapeutic management of adult low-grade glioma. Semin Oncol 2004; 31:653.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f35_42_36515=[""].join("\n");
var outline_f35_42_36515=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           LOW GRADE GLIOMA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CLASSIFICATION OF PRIMARY BRAIN TUMORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           LOW GRADE GLIOMA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           LOW GRADE GLIOMA TESTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           LOW GRADE GLIOMA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f35_42_36516="Heart chamber anatomy PI";
var content_f35_42_36516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F58389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F58389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Chambers and valves of the heart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 526px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIOAhgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiq91eQWoHnyKhPQE0N2GouTsixRVBNWtH6SirMVzDL/AKuRW+hpKSZUqc47omooopkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUE4oAKZJKkYy7AVmapq0dqCqkF65XUb6a4UsGNZTqqJ3YfAzq6vRHWXOuWVucPJz7Ullrtnd3Cwo+Hb7ue59K8l1Vpmy2TmqVjeyxyqQ5V1OVPcEVzPFNPY9yOQU5U7qWp75RWb4e1RNX0yO5XCv92Rf7rDr/AI/jWlXammro+YqU5U5OElqgooopkBRRRQAV5Z4g1J9U12Zo2PkofLjx3A7/AInJ/Gu78V6idM0WeZCBM/7uP/ePf8Bk/hXmukpl9x6CuTES1UEe/k1C0ZYiS8l+pfnkNvank5xXPDXrqzud8cjDmrut3PykZ4rk2JlmwPWuOpNp6H02Dw0ZxbqK9z2Twj4nGpBIp/8AWk4B9a6+vM/hjprSXz3bD91ApAPq5/8ArZ/Su41vWbXSFi+0N+8lJCqPQdTXoUZtw5pnyGZYaCxbpYdX8jUorJstctLlQQ23PrWnHKkgyjBh7VspJ7HmzpTpu0lYfRRRTMwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqWr3Qs7GSU9hV2oL22jvLSW3mGY5FKn1pO9tC6bipJy2PJb7VXurxm3HGfWtPT5llTa3euY1mwn0XVpbS4O4qcq4GA6noR/n1q7p1yVYEGvMUmpe8fc1KEJUk6W1tC9qdrjPHBrlLyMwTEiu83Lcwe+K53VrTOeKVSPVFYKvyvlkWvBevnS75WkZjayfLKo7ejY9RXr8brJGrxsGRgGVgcgg96+eYyYZMdq9J+H/iHldNvJCVbi3Y9v9nP8v8A9VbYatb3GednuW86+sU1qt/T/gfkd/RRRXefJBRRUV1MltbSzyHEcaF2x6AZNA0m3ZHAfEPUDPqMVih/dwDc3u5/wGPzNY9sBDbE9zVOe4kvr6W4nOZJWLNip7uTZDj2rzJS5pOR9tSoexpQorpv69Tn9buMuQDVHT49z7jRqDb5/wAa6TwNpX9oaxbRMB5SnzJMjOVHb8eB+NYJOcrHs1KkcNh3J9Een+HLSPQvDiG6YRlVM07HjBIyc/QYH4V5ve3k2v61LdSFvK3YiQ/wp2FdX8TdVMdtFpUX37jEkp9EB4H4kfp71zumIlta7j1xXZWd2qa2R8zl1NxhLFz+Oe3p/X4Dr2cWkAVGwR71X0DxbPaXqo7FoiehNYmu3xkdgprPsYiW3HrXM6rUvdPbhgac6L9qr3PoLTr2O+tlliIII59qtVieEdNfTtHiWckzyAO4P8PHC/hW3XqwbcU2fAV4whUlGDukwoooqjEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/HGgf23peYFH22D5oieNw7rn3/mBXklnKUfa2QQe9e/15h8SNBNpdjVLOLEEpxMFHCv6/j/P61x4ml9tH0uRY63+y1Nnt69ihYXOMDNWrtVmjyOtc/ZT8DmtWOf5etc8ZXR61Wi4yujB1K32sSKhs52jcYYqwOQR1BrXvgHBIrCnjKtkVlJWd0ejRl7SHLI9o8H68mr2KxzOPt0Q/eDGNw7MP6+/4V0NfP2n6jPZTpLBI0cqnhlODXqHh3xzZXyiLUWW1nA+8T8jfj2/Gu6jiFJWlufJ5pk1SjJ1KCvHt2/4B2Ncp8QtS+yaUtqhxJdHB9kHX9cD86uap4s0iwtmlW7iuZP4Y4HDFj+HA/GvK9Y1efVtQlurgn5j8iZyEXsBTr1ko8qerIynLalSqqtSNox79WSxOFIqO+m3LiqXnkVFJPu61wc2h9bGj71ylKMzjPrXqXw1to7PTLzVbllSLGwMeyryx/l+VeYygMcitVdbvW0SPSdyraK5c7Rhm5zgnuM806M1CXMycyw08VRVKDtdq/oW72+l1fWJ72bOXb5V/uqOg/Kn31x5dtgHtWfbyhBUV7L5nGaObqJUVzKKVkjMYGac55rvvh3ohu79buVP9Gtjnn+J+w/Dr+VcfawZcYGSa9x8O6Yuk6TDbDBcfNIfVj1/w/CtcNT5pXfQ4s9x3sKHs4by0+XU06KKK9M+FCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq+oWcOoWU1rcruhlXaw/r9e9WKKGr6DjJxakt0eFX9lJpeqXFnKfmicrn1HY/iMGpEk4611vxVtFSSxvFXDMGic+uMFf5tXCebxXk1I+zk4n6Bg631uhGq93v6ouySDFZ9wwJ4pzOTUexmPSs27nZCCiQbcmpFjJHFWorVm7Vehsie1Ci2OddRMoQmpFhNbS2WO1L9k9qrkMHikYjQGoHhYV0LW2OtV5IBQ4FQxJgmMijkVqvAKryQio5TeNZMp+YRSPJnFPkjxVdwRSNo2Z1PgWKO98Q2UUv3QxfHrtBIH6V7RXzhZXktldRTwttkiYOp9COa9y8JeIYfEGn+au2O5j4liB+6fUexruwdRWcep8nxHhKilGutY7en/AA5u0UUV3HyoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUU0uBTTMo6kU7MVySiovPj/vCgTxk/eFFmF0S0UgYHoaWkMKKKhvLmOztJrmc7YokLsfYCjYaTk7I4P4sXq+XZWSkF8mZueg6D+teeoCTVrWdQfVdVuLyTP7xsqD/CvYflTIE3EYryKs/aTcj9DwOH+qYaNN79fUEi3HpWhaWeccVZsbPcQSK37HT844qoU7mOIxagijaafkDI/StFbJUXkVqCBIUqjeXIUGujlUUeQ686stCnMiIO1UJ51Xpim3l4Oeaxri6yTzWMp2PQoYeUty9Lc5qs0mT1qg1171GbmsnM744do0Cc1BJVcXPvS+cD3pXNFTaGSLVaVc1aLA1DIKlm8HYz5FwaveH9XuNF1OK7tj8y8MpPDr3B/z6VBKAaqSDBqU3F3R0OEasHCaumfRmi6nb6vp0N5asCjjlc5KN3U+4q9XiPw78Rto+qrbzN/oVywWTP8AAegb/H2+gr26vXoVfaxv1PznNcveAr8n2Xqv68gooorY8wKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKl3fRQZDMNwrKk1lWbCmuL17VJX8QX0IYhY5WXGfSp9PZnYZNetSwSUOaR51TFPm5UdS9+zDg1n3WoOueakRfkrM1BcA1dKnHmsZ1KkrXK95rMiKfmrDl8USwyH56TUuFauK1OQiQ12+whbYyhVk3uej6b40JYB2rrNP8TRSBdzAivB7CQ+YOTXU2MrgLhjXJWwkLaHXSqyvZnvNed/FLXfLRdHtyCXAec9wM5Vf0z+VdtrWow6Tpdxe3B+SJc47segH4nArwO4uZr68lubhy80rF2Y+pr5nFVeVci6n2HD+B9tVeImvdjt6/8D/IfCMmtrTbfcw4rNtY8kV0+lRYA4ripxuz6XF1eWOhrafa5xxW4irDHVWyARKrapebFIBrtVoq58zPmrTsRalfBcgGuZv9Q5PNN1K8JJ5rnbqcknmuWrVPdwWCSWpZuLwsTzWfLcdeagkk96rSSZrlc2z3KdBIsNce9MNx71TYk0w5qLs6VSRoLce9SpP71lqWqVGOapNilSRqpN71J5mRWcjVKr1Skc7pk7moHGRT92aYaZUVYgB2tXtnwy1wanoa2krZubMBDn+JP4T/AE/D3rxRxzXReA9YOj+ILeZiPJk/dS5OAFJHP4HB/CtcPU9nPyPOznBLF4VpfEtV/Xme9UUUV7B+ahRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXHaj8SvCmm6xe6ZfalLDc2UscF05s5zDA8gBQPME8td2RjLV2NABRWF4J8UWXjDQI9X0yK5itnllhC3Cqr5jcoeASMZU456Vu0AFFFFABRRRQAUUVQ1/VIND0LUtWu1ke3sLaS6lWIAuVRSxCgkDOBxkigC/RVDQNUg1zQtN1a0WRLe/to7qJZQA4V1DAMASM4POCav0AFFFFAHi+pHf4m1Q/9PUg/JiK3NKHIrCu/m8Qam3Y3Up/8fNdDpK9K+lelJeh4W9Rm7GP3dZepDANbCDEdZGpng1x0X7x0VF7py2p/cauF1YfvT9a7rUvutXEar/rD9a9Poc1Pch08fMK6vS0MksKDqzAfrXK2J+cV1mjSJDc28spIjR1ZiOwB5rnru0bnXQTc7I6r4t6vvkt9JiPC4nlPvyFH5ZP4iuBt0yRUmsahJq2r3N7KNrTPu29do6AfgABUlqvIr4OpP2k3I/XMHhlg8NGl16+vU0bKIDBNb9mwUCsWFsAVdgkY8KCT7DNXB2OPEJy3N8XmxMZrE1O7LE81HPNIv3lZfqMVlXkxOaqc9DLDYZKVypeTZJ5rKnkqe5fJNZ8rc1xzZ9BQp2Qx2JNMAzSqMmpo0zWZ1t2IxHmniHParsNvmtvSvDmoamhaytXlQHBbhVz6ZPFaRg5bHLWxUKS5puyOXMOO1JsxXZXvhDWLWFpZrB9ijJKMr4H0BNczOijpVSpyjuiKONpVleEk/R3KopwNRSSFTgKSfpTd8vXyZP++TTVKb2RcsTSW8l95aBxSFqhJmx/qZP++DUTvMP+WUn/AHyav2FT+V/cZfXKDfxr70WGbNLC2Gqg8sg/5ZuP+AmmrcODyrD8Kn2U10Zp9ZotaSX3n0n4Q1FtU8O2V1J/rCmxz6spwT+OM/jWzXnnwc1COTQrm2klUSpcFgjNg7Sq9B9Qa9DHNexSbcE2fmWPpxpYmcI7XCiiirOQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyWX4SPq/jHxfe+IdRlOg6zdWlyunWkigT+SgGJ90e4AMAQEcZ79qx7b4UeI4PFdvci40htMg8WT+IhJ58gmaOUAGPy/L2hhtHO/Bz2r3KigD55g+B2stYwW+oSaJciLS9UtFDs7qs9xK7wuMx/wAJZST1BHGatL8GfEEem6pa2eqWFg9/oFlYTvbvJ+/vIWUyPJ8oJVwGUvndhjkdq98ooA8Gb4OavcXsUzroVlpreIrHVW0S3d3tLeCGN0lWPMahnk3AkbFXjrUN18HvEv8Awi0Ogwv4cl09dRvpxFNGrNDDNjylheS3kEZU5LBUHsw6j3+igDwvwf8ABKVde0298cmy1WGy0iCyRYrqYnz43Y7iMKGTacDdn6VP+z54J1HR9Q1fUdcF0Y9PaTRdF+1wtFILJJWk37WGcOWXB9E9MV7bRQB5BffCi8m+KraxDeWieFJ7uLV7jT23b2v40dVcDGChLBzlskjp3rmdN+Dvi1NS1S8urnw7byX2kX+nTLYAQRSvMrCJjHHbpgAsM7mkbjIPYfQtFAHhNv8ABTUo9b8P/wCnWKaEbXTv7etFLk3VxZx7UKDaAUY7c7sHjPtVnwZ8JdZ0L4iR69qF+l95d5cTi+S8WKaWOVcbJY/sxaTHAwZ8DGVA6H22igDn/FUGuo1tqHhydJZrXd5umzkLFeIcZAfrHIMfK3K8kEYORZ8M+IbHxFZyTWRkjmhfyrm1nXZNbSd0kTqp/QjBBIINa9cx4o8NNd3a61odyNN8Q26bUudu6OdBz5M6fxxn8GU8qRzkA86jbztRupQQd8ztke5NdPpYxivP/CGrreyPZ3kRtNVhAaa2c5yP76H+ND6j6HB4r0LTuAK+kqNcmh4Ub8+ptg/JWPqR4Nauf3dY2onrXLQXvG9V6HN6lyrVxOqj94a7i/5Vq4zWMBjXp9Dmp7lGzfEgFdC8gSyPqw2iuXtWxLmttHMka56V5Ga1vZYeT6vT7z6Ph/DfWMdBPZav5f8ABsPt1ya2LC2kuJBHCpZj+n1qnYW7SypHGuXY4Ar0LSNOS2jWGEZdvvMe5r5KjT5j7/M8csOrLdlOw0aOHDTHzX9McD/GtiO0kCZSLav0wK848ffFG30Z5dO8NIk9/GxSa8kXckZHUIP4jnuePrXj+u+J9Z1192ralc3QByEd/kU+yjgfgK7Uox0R8vOdXEPmm/69D6oWB3yEAfHXaQazdT0mC7Rklj8uTs4GCD/WvlWK4likV4nZHU5DKcEV6D4L+Jmq6dewwa3cy6hpjEK/mnfJGP7yt149DkH260O0tGEY1KT5qb1Or1vTp9OnKSglD92QDhqw5OteuanZW2qWATeksEqiSGVDkHIyrA/jXlF1A9vdSQyjDxsVI9xXnYilyPTY+wyjMFi4NS+Jf1cjjXOK0LWHOKrQJlhTPEOof2faCCE4nlHX+6vrTwuHliKipx3ZvmGNhhKTqT2RW1nXfs0htrDaZFPzSdQPYVKnijxNdhA2sXyKowFilMYA+i4rC0mxa4kHGa7rS9D2qpZa+5wuCpYeCikflePzGpiajnVfouiM6KXWrr/X6lfyZ/vzuf5mrUGkSHBYsfrXVWmnKoGFrQWywOldSlGOyPJnVlLY5BdN2dqnisCe36V1H2HJ6Uoswnaq9sjBqT3OeXTPanjS89q6DygO1OVBml7Zi5Tnjo2e36U06MR2/SuqRVqQomKj27K5DjH0kjt+lNSxngOYZJIz6oSP5V2PloT0pTbRnsKft+6DkfQ5VZtYTiPUr9R7TuP61ai1rxFAMR6lOf8AfAf+YNb62sZPQVJ9hiI6Cs5TpveK+4te0WzMi18Y+IrcHzWguf8ArrFjH/fOK0ofiDeqALjSo3PcpKV/mDUh06M9hUT6ZGewrGVPDT3iaKrWj1Oq0LxDFqqAmFoX/ulsj863ByK4vQ7b7PONtdhCcoK8rE0owl7mx6FCo5x94kooormNwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiigkAZNABRVC81iwsxm5uFQf7pP8hWe/jDQl632fpE5/9lrSNGpLaLfyIdSC3aN+iuTuPHukxNtiS7nH95IgB/48RVCf4grnFrpkrj1kkC/oAa1jg68tombxNJbyO7qpq0vkaVeS/wByF26+imvNtT8bazOpFsIbNfVF3N+bcfpXF3Op3+p6vDFe3k8437truSBgZ4HQV1U8tqXTm7GMsbCzUS/faHb6tBCXeS3vIDvtruE4lgb1B7g9CpyCOCK0vDOu3EGoR6P4jSODU2z9nnTiG9UDJKZ6OB1jPI6gkc1PbDGKu3ml2WtadJZalCJrd8HGSCrDkMpHKsDyCOQeleliI9UedRl0Z0ZbCVjX7ZzWFDq974YmjsPEs5uNNdglrrDDHJ4EdxjhX7CThW77Twdi8bJNYYfVmtbRGNfH5Wri9aPzmuw1A/Ia4vWD8xrvexjS3MpX210VomIo89dorlFJe4SMfxMBXZW65YKo56AV8zn09IQ9WfecIUveq1X2S/X9DrvCViFjN2/U5VPp3NYHxl8WtomnrodgxW+vI988gODFEeij3bB/D6132mQR2dmqzMFht4jJK3YADLH+dfLXiPVrjXtdvNSu2ZpbiQuATnavZR7AYA+leZCPJGxVer9Zrym9v6sZwBY1NHblu1TWcG4jitu1ssgcUm7G0KdzDFmx7Gl+yMD0rr4NOBXO39KgubIKcY/SlzF+yPTvg7rH23wvJpU+fP05t0Z/vROScfg2fwIqLx7a+XqUNwBgTJg/Vf8A6xFZHwf/AHHiW4j7TWki4+hVv6V2Hj2IPoqyY+aOUEH2OR/hU1lz0ysvn9XxyS2en3/8E4hZY7aF55fuRjJxXLxJLqd888o5ds49PatLUXaW2jtx/E2W+g/z+laWh2ITbx6V7+Q4RRo+2e8vyPN4qzByxHsE9I/m/wDgfqbHh3S1iCkiuwt4lwABWdYRbUAArcs4skV7NV2PiuZ1HctWsA44q+tuCOlOt4sAcVdVAFya82pUdzrhT0KBtwOtUbrCk1o3coUHmuf1C7AJ5rSinJmdVqIyaYCqr3YHesu+1AKTg1jzagSetehGmkct2zp/t4XvQ2pgDrXHPqDZ4NRG+c9zVckR2Z2B1YKeop39tADqK4v7Q7etIZJD3NP2cWVqdsNZBPWpk1kf3q4EzyDuael04HU0vZQYtT0BdYH94VKmrqepFed/bXHc/nT1v3Hc/nU+xgO8j1TSdQWS5UA121scoD7V4z4SvWl1GNc969ksv9Sv0rx8wgoSSR6GEba1LFFFFeadoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUVycRmparXjhYzmqirsUnZHGa/AbmQjGRWKNJH9yuoubqLeckVWa8hx2r2qVWUYpJHk1KalK7ZhHTAo+6KhezC9q2p7yPsRWXcXKnNdVOc3uc84xRj3sYVTXM6UBJ4gz/dDH9K6HVLgbHwe1c94b+fWZm9Iz/MVu76BHSLO0h6itezOAKyIhzWlbtgVnVV0TT0LV9FFc2ssFzGksEilHjdQysp6gg9RXn8/2vwbkZnvfDQ+sk2nj+ckQ/FlHqOndyycVnzNnNYwp9VuaSn0Ma5niubZJ7eRJYZFDI6MCrA9CCOorkdXGS1WtV0250CaW70GIy2DkvcaYDgAnkvB2Vu5ThW9jycxr+21O1FzZyCSJsjOMFSOqkHkEdCDyK35uj3CC6rYzdPXdqcOezZru9Bi87VLZOo3gn6Dn+lcTpQzqsf4/yNek+DIQ19JIR9xOPqT/APrr5XOfexMI+X6s+/4el7LLq1Tzf5L/ADLvxL1F9M+H+ryQtsluAtqD7OfmH4qGFfN0SZavdvjnLs8GWMP/AD1vg31Co3/xVeIWq5cVyyMaC0ua2nQ9OK6C0g6cVnabHwK6G0TpWDep6UFZF60tx5fSs+/g+c8V0NpH+7rO1KMAmm9gg7yLnw0XZ4vtv9qOUf8AkNv8K6/x1/yLdwfRl/mK5HwC4j8XWJPfzF/ONh/Wuy8aJv8ADV57BT/48Ke9NmPw42m/NfmeX20fmOrH0rp9Jhxg4rC09MhD6iur0yP5RxX2mAh7PDU15I+Kzus6uNqy/vP87G1Yx5xXQWcQAFZNioGK2YmwKyxEm3Y4aKsaVuBS3cyop5qqk21D61kareFQea4403KR1uaSIdUvsZANctqF6eeaW/vCzHmsK7n3N1r1qVNQRwSbkxtxK0hJqqwY8VYg+c1NcNb2cPnXThEzgdyT7CipVUFds3pUpTajFXKK2zuelWI7BjWdPr8jOVsLdQnZ5Bkn8Krvdapc/fuZEHpH8v8AKvHq51Qpuyuz6LD8M4yuk2lFeZ0cenn0qT7AfSpPhTaTS+NbU3Mss8apIxWRiw+6RyD9a90fT7J+Xs7dvrEp/pSpZtGquZRZzY/KKmBqeym03a54E+nsT0qNrBh2r3uTRtNkUhrC25/uxgH9Kpv4V0dv+XTH0kb/ABrdZjDrc894afkeFNYv6Uw2TjtXtsvgnS3OVa5T2Vx/UVVl8B2hH7q6mX/eUN/hW0Mwo9X+BnPDVOiOE8C2THU1YjgGvZ7ZdsSj2rn9F8MDS5dwnWX/AIBt/qa6RRgAV52NrRqzvB3R1YaEoR94WiiiuI6QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsvXHKWzEVqVm64m+ykA9K0pO0kTNXizyvU9UMcrAt+tZcmt4/i/WqXiBZBcuMGsJopCe9fTwS5UeK467nStruR1/Wqz6wW4z+tYi20h7GrEOnysc7TWiZPLEsXN4ZEPPan+DhuvLtz6KP50PpsghYkdqteGIDbQTGRSrmTGCMcYFS3eSB25XY6hDirUT4GazhJkdakE4C4zSkrmS0Lss1VXbNM8zNNJJpxjYTlcqXvKGvOfEelSxXsmoaQVivG/10TcR3IHZvRvRuvrkcV6NdAlTXN6lFkmlUipKzNKMrM5PwzqEV7qSgK0U8ZKywSDDxnHQj09COD2r13wUmBdt/uD+dePX2mmbVbe4tZja36HbHcAZ6/wALD+Jfb8sHmvTPhvrQnlutN1KMWmroA5gLZWVBx5kR/iXke4zggcZ+WzSEvrEW+3+Z9vlNaKy2rT/vL9P8ih+0BIF0nw3CDy73EhH02AfzNeR2SfMK9P8Aj22690KLsts7fm//ANavOrGP5hXDNnTho+6v66m7YLhRW7aDkVj2YworZtOorDqejbQ6C1H7qsnVT8xrWtWHlViau+GNUzKn8RDoN59k1+wmzgJOm76Zwf0zXpvidkfSr23yNzRsFyep7frXik0+JODgg17PpMaaqsOpTENCyK0adi2Bkn6fz+lOKumjHENRnGr2MPw94aklgiluyYo8DCgfMf8ACutt9Ot4wFigBx+NUfFniKw8LaWL3UjudziG2QgPKfb0Udz/APWFeD+I/iL4h1qSRBfSWdoxOLe1PlqF9CRy34mvQq4yrOyvZLojxqeDg25Wu3u2fSK2jqPlgYfRaCGQ4IIPoa+Rba8uYJvOgnljlHO9HKt+YrtdC+J3iPTpYxdXbalbA/NFd/MSPZ/vA/j+BrFVpp3TZtLBxatZP5H0JJJhSa5/VpwQeam8JeJdN8W2Us2mF0mhAM9rL9+PPcf3l9/zxVTxNavDEZ4uYs4Yf3f/AK1evgMXGclCpv0PDx2ClTTlT26rscvey/MeazSS78U+4kJaprCLe4JFe3KXKjzYRuSForGza4nOFXoO7HsBXNSvJqFz510ef4V7KPQV0+r6X/aBjH2h40j6IFBGfWs1/D1wv+ru0b/eTH9a+PzTFyxE+Sn8K/E+/wCH8LQwcPa1/jf4L/PuMtYYEAzgmrf7sD5QKoPo+pR/dMUn+6+P51WkF7an9/BKo9cZH5ivGcJI+uhiqM9pHpXwgtzJ4juZ8fLFbkZ9ywx/WvYa8z+B0Qk0rUbz+/MsI/4Cuf8A2cV6ZXqYWNqaPhs/qqrjZW2Vl+AUUUV0HjBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFRzxCaMoeM1JRQnYNzidS8DC6kZ0uUBPZk/+vVdPh4g+9eqPpDn+td9RXYsfXSspfgjmeEpN3a/M42DwDYqB5txMx/2VC/41oW/g/SYRho5Zf8Afcj+WK6KioljK8t5MpYakvslS106ztABbWsMeO4UZ/PrXlnj64A8UXi54XYB7fItevV8/wDjK7e58VakUyx+0Migc52nH9K6subdVyeuhjjIpQUV3Fa+5VEBZj0A6mtKztJZMNMOT/CO31pmj6cttH51yV8zuT/D7CrFzf8AVLcbR/e7mvQxGLp4ZXm9exzYbBVcXLlpLTv0LbJFAAZnC+1Qve26j5FZvwxWXMzkbvmZycc96URMoJYsT9MAV4VXOa0n7isj6GjkNCC/eNt/ci495G4wYiPxrNvokmBKg5pkl7ZxvtlvbRG/utOoP86mR1kQNG6Op6FGDD9Kzhm2Ii/e1+RtPJcLJe7dfP8AzOP1O3aOUOOxrttH0ez1/SnS6DpLGyS29xC2yW3fBw6N2P6EcEEEis7UrAXURwNsnbP9a2Ph7IVW5gfh0ABB9if8a0xleGKhGrHRp6r1/wCGFgqE8IqtCeqkk0+9n+dmee/Fy61S21LRbPxIsRnEDR299ENsd4obIO3+CTnleR3U84HNWZGRXqX7QNlFeeH9BeaNXjDzRMCPXaR/6Ca8StLmXSnVL12ksicJcnrH6CT2/wBr8/U+dNXZ3YaXLBX2O5tW+UVqWsmCKwrSQFRg5BrRhkxzmsD1FqjpIrgCPrWBrNxknmllvNiYzWHfXJkJ5qlqZP3S/wCF9Hm8Q65HZxnbEP3k0n9yMEZP15AHuRXt2o39j4d0SW+uU2WNlGAsSdW7Kg9ycfzrF+HmgDRdBjaeErqF3iSYsMMq/wAKe3HJ9z7V578ZfEJvtVTRrSbdaWfM2xvlebvn12jj2Oa1S5UebUk60+VbHBeKNavfEmt3Go37Zklb5UB+WNeyr6AVnx2xbtV2C23EcVq29nwOKlyOqFLoYYszjpTHtyvaup+xjHSq81jx0pKRo6VjI0XULvRtUt7+wkMdzA4dT2+h9QehFfSnh3V4fE3h2DUkjVBMDHPEOQkg+8v05BHsRXzjNalW6V6b8EbiRLjVbIsfKaJZwueAVYLn/wAe/SrjI5K9L3ebsSarp72epy27chTlT6qelUNc1uPw9Bbkw+dJMThd23AHfofWu48W26/a7efHLKVP4H/69eE+KtRbU9Znk3ZhjPlxjsFH+PWvcxWLcsLF9Zaf5ng4LCL6010jr/kdMPiCmRnT2x/11/8ArVch8e6a3+sguk+iqf615rgnpS7DXgcqPpOZnq0HjHRpTg3Dxn/bjP8AStex1GzvjizuoZmxnajgt+XWvETG1KqsCCMg0cqHzM+htL1W+0p82U7xLnJTqpPup4rqtL8eSBwup2ylD/HBwR+BPP5ivmfTvEusae6+XeSSIP8AlnMfMU+3PT8MV2ujeOLG+kWLUYfsMh481SWjJ9x1X9aaco7MyqUqdT40fSumapZanGXsZ1kx95ejL9Qeau14ZaXMkBS5srggH7s0L8EexHWu+8L+MftLx2mq7VlPCz8BWP8Ateh962hWT0Z51fAuC5qeqO1ooorc4AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAjuZktreWeZgsUal2J7ADJrwjTLX95JqF4cyyEsM9sn+dejfEXUmVINNifAkHmz467QflH0JB/75rgppPNbG7ao6DFdsK31Oi6j+KWy/Uzp4V42t7PaMd3+gk07zvszhRzjsKwvFWtLomnh1G+5mysIPQEdWPsMirGtajDodpNczsZNyjyk6F254+nevKdc1e61i88+7YZA2qijCoPQCvGlOVWTnN3Z9NCnCjFQpqyRW1HVL29ufPubmWSXsS2MfQdvwqpcXl1cACe4mkUdncmnFNxqWO1LdqYrNlIZrU0bU73S7gTWM7wv3x0I9COhpyWPHSpRZ4HSlctU2etaPqcesaZFexrsLfJIn91x1/Dv+NauhH7PrUTrwJgUf344/pXnvw/vWt76TT3x5VyMrns46fmMj8q7oO8Th0++h3D6jmou1sVyp6P+tLGn8VLCTUfAlyY1LNZTJc4HXbyrfo2fwrwaMAgqwBU8EHoRX1FpU1vqFr84LWt3EY3B67WGCK+bNf0ufRNau9PulKy28hTnuOx+hGD+NaS7nNhpWvBmbAJtF+a3V59M/ihHzPB7p6r/s9R29K37e8jngSaCRZInG5WU5BFZcM2Ko3EUtjK91pYBVzumtc4WQ92X+636Hv61DVzsUnDbY3bm5966H4aaEdd8QCeYD7FYkTTZ/iOflX8SPyBrhIL+K+h8yBiRnaykYZW7gjsfavozwPoC6D4ctLMIRe3GJrnPUOQPl/AcfXNOMTDEVrR06jvGfiFfDuh3WpsN1w37q3X1lYHBPsME/hXzfGHmlZ3Ys7HJJPJJrtfi5r51fxIdPtpQ9hp5MSFejycb29+Rj6D3rmbCDJHFOTJw1Oyv3LNlb9OK14YQAOKbbRbQKuKMVi2enCNhEhBOMVO9mPLzipbSIs4rWlt8Q5xQiaj6HE31qAx4rtvg7bFb7U7gDhYFiJ/3mB/9krmtRT5iK9R+H1gLDwpASuJrpzO5746KPyGfxrSGrOPFPlp+ph/F7UfsOhoqNiaXKLzzzjJ/IGvCFBY12nxZ1gar4qmiifdBZjyFx/eH3v1yPwrlLWLPNa1KnMkuxz4ejyXfVjooeBVhbcelTxxe1WkirBs7YwKP2YelAth6VpiKl8n2pXNORGRJaj0qu9t6VvGDNBsiwyBTTJlBFTQNdv9EkxA++3Y5eB+Ub/A+4r07SdRtdXszdWJYKp2vG/3kPv7e9eX3NoV7VBY62PDt/HeGeKPHBWRsBweo96e5k1y6n1L4F8RG5VdOvXzMoxC5H3gB0PuMV2lfNdr4rFysF1oGnanebsPHKsPkxqwP9+TaDg913dK9S0DUvGHimy8xLvRNDVfllWON72cH1yxREz16OO3NdNKbfus8bGUUn7SGzPQqyT4k0QazFpA1axbVJCQtos6tLwCTlQcgYHU1jnwJZ3nPiHU9Y1wnql3dFIT9YYgkZH1U10Ok6Tp2jWottIsLSxth0itoViX8lAFbHCcB4H+Ji3XwXi8deLhBaoomadbSNtvyztEoVSxOThRyep7CuQ8V/G5dY0qzt/BKX8OoSazZadcun2OZ40n3MBG3mPEXYKwBJIUqQ204r0fTfhj4U07SpdLtrG7/sqWN4msJdSupbba5y2InkKA55yBkHkHNWF+H3h0wWcM0OoXUVndw31sl3ql1cCGaHd5bL5khwBuPA4PGQcDABj/AAu8Z6t4k1rxTpmqadJHFo181nFdkRguFC8ShZDmQ5LZRQmPQ8U+++KujWXjSLwxNaXZ1KeV4IBFPaSCR1GQpVZi8e7oPMVBnriun0nwvpGka5qWrabbSW97qLb7rbcSeXK/HzmItsDcD5goPXnk1kwfDXwpBra6tDpsiXi3raku28n8pblhhpRFv2BiOvy88egoA4Twl8bnk8CaBrHibw/qcl/q1xPbW8ekWyyrO0bP/q080v0UKc/xZx8vNblj8V7FNUmtdRgviZNbttFgiWyWF4JZo96iQmZtwGDlgFIPG09a39M+G3hTTH09rHTZI10+6e8tIzeTtHbytncUQuVUHJ+UDHPSn6h8OvC2oNePdaaxlu75NSllS6mjcXKDasqMrgoQOPlIoA5yP40aHO9pHaaVrdzPdTX0EcSRwKc2ihpSS0oGMHI55wenGdbwb8TtH8V6xZ6dZWepW0t5p39qWz3McYSaHfsONrsQQ2RhgOmRkYNWLH4ZeEbGW0ltdJKyWr3UkTG6mYq1ygSY8uc7lAHOcdsVd0LwL4c0K+0+80rTvIubCyOnWz+fI2y3L7ymGYg/Nzk5PvQB0tFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWZ4lm+z6BqEm4qfJZQR1BIwP501vqGvQ8r1y8N/q15cg7hLIdpH9wcL+gFZ6jd93n6UAkEEdRXEeO9bvLPUPsdhO9uhjDSbOCSfQ9R+FcuIrOvUv02Xoe9hMOsNSUOu79TO+JV6txq1vbxSh1giw205CsScj64xXJRxljU0cRY1oW1t04rO9joUW2QW9rnHFaUFqB2qzb24Aq7HEB2qHI6IU7FVbcBegpDAh6MM1om3LAelMltsDkVNzTlMllktp0liYpIhDKw4II716baXSX9jBeRkfvV+cD+F+4rgAnmq0b8uBwa1fB2oC0u5LC4z5VwQFP8Adft+fT8qownHqj0zwvd8SWbDBTMkZz1BPI/AnP41zvxq0Fryzg8Q2wBaELb3Sgc4z8r/AK4/Kp4pZbadZYjiSM5Hv6g/Wu2t2tdRsWjuEE1jdx7ZEPdT29j/ACrSDurM4KydOaqI+YA2DTt2RWr400KXw5r91YyBjGrboXPSSM/dP5cH3BrFgDySKiAszHAAHJNKx1KSaujo/AfhS91bXTq+lmCKfTwspNwhaG4cH5YnA555+Ycrjv0PpWufECC38OajvjlsvEWPs5sZT+8gdgf3gPRkwCVcZBOOhyB0fg/QBoGi2+nKQ1yT5k7DoZD1A9gAB+Ge9eK/Fa9XxN4kYwSeUlgTBazIORg/MT/eDHseMY+taXstTh5fa1Lx2/r8znLWEs9dDY2+0DisPRLkm5FnfosN7glQPuTAfxIf5jqP1rqYsAVhJnq0UmrkyLgVKi5OKiDVZtMFxWZ0t2Rs6Ta7iCRV/VNsUJHGaLFliiBrK1i88xioNabI5LOcyjYWR1TWLa0XIE0gUkfwrnk/gMmvT/FGq22g6JdXoRUht4wsMQ6Z6Io/Suc+HFiN11qMiAkfuYiexI+Yj8CB/wACNc58cNW+az0aMnIxcTenOQo/mfxFXDSNzlxL56qguh5Ud88zO5LOxLMT3JrTtIcKOKqWkeSK14U4FS2dFOI6OPnpVpIs06CP1q2kdQdMYkCQ+1SCGrIWnbRSLsYl9fRWk4hENzPOQGCQwM3Hu2No6dyKW2m1i54gsbazU/xXcnmMP+AJx/4/WyVp0Qw4pp2M503LqY954buLiMvf6nczf9M4AIE/8d+b/wAerCbRrSydmgto0k7vtyx+rHk16hBCJYORXL63ahHPFW2zmjCN7F34dX3y3Wmyv1/fQgnuPvAfhg/ga9L8H6t/ZWrozn9xNiOTJwACeG/D+Wa8O0+5OnarbXS5/dSBiB3HcfiM16s+wndEweNgGRh3U8g/lRezuiJwUk4PZnu1FZvh29/tHRbS5Od7Jhs/3hwf1FaVdyd1c+blFxbi+gUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfLPirXvEFt418UXTarq9ppFl4jtbaTUo9TnMemwsASGtAfLaNuhJ6E9Oa6p/ibqem6jqkNodOt7WfxTJpp1XUJp7i1tYfKVw7BpgBuzwEZE46c175Wfrmj22tWqW95JfRxq+8GzvZrVicEYLROrEc9CcdOOBQB82W/jXXvE/ivwf4iX+yodXgsNZ2f6PIbdhDwMp5m7kL/AHuM556V0fw98b654g+LGi3ep6tbafp+r+HIrmLTpBJ5UsnmEOsIMgHm5BbdgkJ8uDjdXt3h3Q9N8OaPb6VololpYW4IjiQk4ySSSSSSSSSSSSc1pUAeJfGn4u3/AIG1m4tNI+xXElpbw3M1pdWm0sjybSUmNwhbg9EikwQdxAzjm9R+IXiXwhd/FS8bVbG8utPvLeSy0u/SUkRSSRIHRfOysQWTB2jBYqcj7p+kaKAPCfEnjXxh4a1/VRqVrpM+t2fhSTUzHZy3clqWF4UUCJpApxHgltgfIPzbeKp3/wAbdZa81dNJTQ7m1tpdIjgmVHkVvtSZlyVkwdrZAxjGMHJr6CooA8O0j4p+JW8RWllqEWjS23/CUz+GpzBbSxu+xcrMpMrBeoypDfWvbxJGZWiDqZFAYpnkA9CR+B/KnVh694U0XXpkuNRsUN6i7I7yFmhuIx6LMhDqPYGgDcrjPiTqBhsYLFMZnO9+eiqRj8z/ACp40LxPpBzoniIahAOlprUQkP0WeMK4+riQ15t448W3P9sy/wBvaRc2BgCwma2b7XAMHJ+dAGAyTyyLWVV2jodeCinVTeyHDkgV5d42mWfxNd7TkIVj/EAA/rmu8k12wbRLnUrG8t7mKJflaKQMC56Lx3z2ryje0srO7FmYkkk5JPrXLFHt3T2LNumSK1raPpVOzjziti3iwBSbOinEliTirCJRGtWY0zUG+xNbpkUy7jwKu20fHSmXcdMzvqc/INkqP6GotQi2y7l471aukP60+7QMBx2oG1c6fQ9RGp6erO+buL5Zh6+jfj/Oum8N3nk3BtH/ANXKSyH0bHI/ED/Oa8p068l0u/WeLkdGU9GXuDXfbg8Uc9rL8rASRuOcHt+R7VSdtTkq07rlL3xQ0Vdc8PmaP/j908NJHx99D95f0yPoR3rjvg/4e+0aq2r3UO63tOIdw4aX1/4COfriu9j1B7zyFiAEs527fQ9/y5rbsrSz0mx8qHZb2cAaRmxgKOSzH9a1WrucUm6cOUuyxf8AEru52GVwI/ruOD+hNeWav8MLnf52hSrNG3JglYK6+wPQ/jivZdQjWTwe0tvhhIiTgj0JB/lWRZSiSBGU845xW/s01ZnnxxU6c24nhuqeBNZlhMF5o92dp3K0a5KMOjKy9CPUVR0/Tdcsr+20/W4PJWd/Kt7+4xFE7dkkJ4Rz0HZj054r6EuLgpGS7nHuajbSIb/w7dQanAkqapi1WGUcFGPJx9Mn8Kn2COj+06l7pK54bc29zZrbNdRGNbmITRE4+dCSAf0NSWsuGFehfEHQDqnm/wBmRkvpirbwwoM5jUAFR7jBP515YHeJyrgqwOCDwQa5qlPkdj2MLiViIX6nTG9IjwDVMLJdXCRxKXkkYKqjqSTwKzo7jPU12fw709rrUnvmH7m1HBPdyMD8hk/gKhJt2NpyVKDkd5ptvHpmmW9vIQIbaPMjD25c/nmvnnxncXWp+Ir3ULuPYbiTKgHIVQMKufYACvdPFl79mso7UECS8O3nrtHX8+B+dcjq+hxS2gPlgnvxXYqfNE+f+tezqXevc8utIsYrWhj6V1OheBpdZjuBpt3D9sh+b7JL8pdfVW6H05x9azr7SbzS5/J1C1lt5fSRcZ+h7j6VzTjKO57OHrU6vwMqxJipwKEQnoCfpUvky4z5b4/3TWZ2XS3GUUEEcHrRSKClT7wpKfEPnFMTOk0tMwc+lYHiKP5jW7ZTrHB1FYOtSCVzV30OVRblc4+8TBzXoXhKc3Xhu1YnLRFoG/DkfoRXD3qfKa3vh7MQt/bk/L8kgHp1B/mPyo6E1FZnvnw2mL6FLGxz5c7AD0BAP8811dcJ8L5eNQiJ/uMB+YP9K7uuyk7wR89i48taQUUUVocwUUUUAFFFFABRRVW11Gyu7q6tbW8tp7m0ZVuIo5VZ4SwyA4BypI5Ge1AFqiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAJABJ6CvDdSka7N1KeJLiQsPbJyTXr/AIluhZaDfTc5EZVcerfKP1IrxsnNc2IeyPVy2OkpHmfxNtbSW+tYntIo7tULyXEQ2SOScD5xg446e9cjb2t/EwNrdJOv/PO5Xn/vtf6g13/xPgBudPuR9542jP8AwEgj/wBCNc3p8eSKzTsj0FBSlcLPUjbAf2lZXFsB1kVfNj/76XJA/wB4Cuj0+4t7uES2k8U8Z/ijcMPzFJapgCobrQtPuZTOYPKuf+e8DGKT/vpcE/jWbaZ1xjOK01/r+uhqKKtQryKz9MtZbaNklu5rr5sq0oXcB6fKBn69a2rSEsRUpFuWmpbtk+WoLwgEg1qwQYSql6gGcirsYKV2c7Km+Uf3RyTSSfMTVq5IHAqtUM6IrQoXUWa6nwk5fSJ42OfJkBX2Df8A1xWDKuRXafDPQn1a01UxttdQgTPQnk1UU5OyMMQ4wjzSNjwnBGtxdS8l8Dbn+HPXH1wP8mua+MfiJYLVNBtmYTybZbojoF6qn4nDH8K6OeSfwjb319qcBRYoj5Yb7skn8K/if0rwjVL641PULi9vJDJcTuZHbpkn+Q9q1WiscKjz1OfdHtfwX+INtLYxeG9emxKuY7WWTGxo8cRsT0I5A9Rgeme6uvCd1FcO+lXiLExyI5c/L7ZGc18ohD1Fel/CrxTqVtc3GnvqVxseL9wkkhZVK9lB4HH8q1p1Pss5MXg1Z1I/ce1Wfh1438/WbmJ4UGdikhc+5OOPamW17/aviy1cAi3gRvLU/Tr/AJ9K5WDU2unxqF1LJID0diQPwrR07Ubew1aCZ3AjBwx9jxW55ZLYP/p9/wA4kFw+fruNVtY8NaNrDvLeWhS5brNAdjE+pHQ/iK3Nb0Kdrs6lo22QzfNJFuADf7SnpzVKPTtcuSENoIAeC8jjA/I5pNJ7lwnKm7xdjzm/8AtHc7NPvhLubCI8eG/Mdfyrt/C+ito+mQ2DOj3DMXlZD8pY/wCAAFdOljbaFbOwlEt/MpAZuCRxkqOwGR+lc9rcxt9HnZWxLMRAnrz94/lmsXTinodv1qrOm/aPQ5LxJL/at5cOhz5Xy2p9NvT8+fzq3olwNR0tWb72Oar3sIgNuF4IxmodJuFtrzUEBAQTMR+J/wAc1ucDd3cfo10dG8TQXIB2o3zBepU8EflXr8f9meINPimUQXlu3zI2A20/0P614m83mX3mnARckn2qT4Yald2OoXE1ux8iR/mQ9GGf5+9Ak7bHZ+J9Hk0ybzI+bZz8pHb2NZMFuZ/uck16gptdZ04gjfDIMEHqp/xrzPVWh8Nai8Go3cFun30eWQICvODyfY/kaAI7nSC6/v4Fcf7S5rLuPD9o2f3JQ+qMRWnD4/8ADoJSPWbS7IOClq32hs+mI8nNV73xXZzgmw0nXLkHoRp0sIP0MoQEe/SpcU90awrVKfwSaOdufDsob/R5VZfR+DUH9g346Ih+jVt2+o61dv8A6J4XuVXPBvLuCIf+OM5/SteOy8UTKM2/h+xz3NxNdEfhsj/nWboQZ2RzSvFWdmcdJpupRJzAzD/ZYGse7jlU4lR0PowIr0Ofw14glXM/iW1T1Flpojx9PMeT/P6Zk/hB5AVvtd1q7B6gzJCD/wB+kSpeHXRm0M3mvjin6f0zzi9X5TU3g3UbGw1C9a+vba2TyDzNKqDO5fU/Wuq1H4Y6FdxN5UUwmwcG4uJJ1Y++9iar+HfAb+HfOurzTbS2WT93EFjXLc53DHQf41nKm4bnVDFxr/Dozqvh9430C31ecrqH2lGgIAsoZLok7h0ESsT3r0D/AITQTf8AIO8N+Jrz0/4l5ts/+BBjx2646/XGB8NP+Q9P/wBezf8AoS16XW9H4Tysdf2upgWOt6hJZahd6h4dv7CO2iMscTyRTzT4BJUJEz/NwAACck8e/wA//D7S/iF4Y8UnxXcaHLNc+LYLsz237xjb3HzSW/noUXyVzhPvEAE529K+n6K1OM+cpvE/xVXw3qE2nprt1dro0U0hutFWKS31AzqHigTyR5qbC3OH4Gd3atK68PeKbL4reGtS17U9V1VX0me3kvbPSEEXmNLuW3kRUcIhDAFmI6feHNe90UAeA+ENS8ZWek+FbPWY9b8P6MdKeSaTRdAR5hd+cw8t4Vt3ES7MEYjGSetd58XtV8V+H7LSNa8I211qcVtcFL7S4LYSvcxuhCsMKXG1sH5SOpzwK9CooA+ffG2v/E/RtH02105dfu9ej0uO5ubmGwiktZpzJl4gkdrISwUleZIhhQRkn5nTL410jWPHfiPQrDUEm/tPTbuSzWy3f2jbiBVmii3KSSM9VII2kZzX0BRQB8/azrXxah0Xw/ITdW76lFcXNxNDYea9lIxJggdI7aZtirtz+7DE5Bda9r8JT39z4Y0qbWDGdSe2ja4McUkSmTaNxCSKrrk9mUEdMVrUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAct8RpjF4fCD/lrMqH6YJ/oK8wr0D4nzYhsIP4WZ3P4AD+prza7u49PgmkuTkQrvwOrjtiuOs/fPdwEbUUcn8SZUaTT4AQZEDuw9AcY/kawNOTpVO9upb6+luZzmSRtx9vatLTV6VD0R201qbMC4FTqM1HEOKsRrWR2bIsW0WTW5YwgYrIgcLWnHdrGuc1aOepdmqxVE7VhancqM8iq+oauFBAasp/MufnlJWM9u5ptk04W1Y0zmWXCjK9zT6QAKMKMCr+l6ZNqEhEeFjU/M56D/E1CTk7I3lONOPNN2RRwWOAMk9q9h+C9nJbaPfvNG0bPOMbhg4Cj/GuesNJt7FQ0Ufz4++3LGvQPAJB0u49fPP8A6CK66VHld2eDjcwVeLpwWhk/GKD7X4VuLcDLGJ3A91wR/KvlxR82K+s/HCiTYjDK+Wcj6mvl7V7H7Bq9za9RFIVBPcdv0xTrLZhls7pwG29vvXpU0CzWVzFcW5KSxsGUj1FXNOQEDNaX2QSdq5ebU9r2acdToLLXdO1aHdcTLp94PvK5wje4b+h/WpZrmxjw02sWzKP7kgY/kM1ykunDPSoDpuegrdV2ebLK6bd02kdjb/FK/wBIKwaSontkOMXWSCP9kAgj8/wqe/8AjJrtzavFa2lnayMMecoZmX3AJxn6g1wjWGO1MNttqHVl3OiGBopL3T1L4brd3trd6zqdzNc3dy/lh5WyQq+h9Mnp/s1peIrlRrFvbsci3j3Ef7Tc/wAttWvBVsIPDOlwgfej3n/gTFv61wl3rEtxqd5NFaySyySsQWOB14rekjycbK8mkaes332a1mvGQOYlJjjLbfMbsoPvXEQapq7xtI/9jW7yMXbfePI2SSeVCD+ZroRb3F1cxvqbBuyxrwqZ9K5K0sPM1CWFxlkcr+tbHASSTa/qjmyttQtVjfhnt7JlP5s7Z/IV3HhrwPcRWyi617VyCOUiaOEfmiBv1rQ8J6PDbANsG71rtokCqABQBz+n+D9EiuR/aUd/fwvw63eo3Ey/Xazle54x3NbHiTwH4astM+2aToGlWs0Lb2aC0jVnBIySQMk9Dk1aZciui0llvtLeCf5gAY2HquKAOE051EaqoCqBgAcAVaujlMVQSNra7mgbrG5U/gcVPLJkCgCzYqB0q6xwKoWjgDmppZhjrQA24l2g81Wtbe41C4EVupYnqew+tSWlrNqd4sEP1JPQD1rtYo7TQ7Lao69f7zmgCDSfD9tZAPNiebrlhwv0Fc18S50aS0iRlLDJIB6Vc1PWrmfcFcxxn+FfT3NcVrUpkuwM/dUCsqz907MDG9ZeR0vwxg3X17Pn7kYT/vo5/wDZa9DrjPhjEBp15L3aUL+Qz/Wuzp0laCJxsr1mFFFFaHKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRUN7d29jaTXV9cRW1rChklmmcIiKOSzMeAB6mnW08N1bxXFtLHNBKgkjkjYMrqRkMCOCCOc0ASUUVVXUbJtSfTlvLY6gkQma1Eq+asZOA5TOQueM4xmgC1RRRQB5p8SnJ1yBc8Lbjj/AIE1cVqdlHqVhJbSHYWUhHxnaf8ACuy+I/8AyMC/9cF/ma5WuGp8TPocL/CieR3ljPYXz210m2RD+BHYj2q9ZyBDjvW54+lie/s4lwZo4zvPsTwD+v51mWMKTAK+B71LOumXYpxgVP8AaFA61GNLOPkm49xTl0on70/5Cpsb3A3gXoab9pnuDiFSfftVhLK2i5b94fenmQAbUUKPai9gtchitljIeY75PTsKe7FjzScse5Ndd4d8P79slxGHlYcIwyF/+vThBzdkY4jEQw0eaRz2mWD3cy7gyw5+Zv6CvS9AsIkgUlQI4xhRVO+05oUyByvoK09OkzartPbmu2nTUEfO4vGTxMtdEugl+24nAAA6Yrc+HsoNpexfxLKG/Mf/AFqwrocVP4LuPs+veUThZ0K49xyP5Vocht+LU3Sr/wBc/wCpr5++Jdg1vq8d4B8k67T/ALy8fyxX0X4mjyIn9QVNeTfELSWvtJnSMZliPnJ74HI/LNRUjeJ04Sp7Oqmeb6S4IArorUZxXJaVJtkArq7I8A1wPc+oi7xLjw5HSomiAFWgflqOQ8UCTM+VRzWdcH5q1JRkGsm6OHpGnQ960WEWkFjCRxDDGp/BB/hXEaCY0sXkcAsTXdwyCZlkj5Ese5fxXI/nXlFrebLQguFX1JwK76Z8pibtplm6nDXhfICR5Zj6Csbw7F9pu5rrHEjsw+hNR3ty14DbWpPlMf3sn94eg9q3dItxAiqoxitDmOy0lQiLW2hyKwrBwEFbED5FAE9aXh6YpeNH2df1H+TWbU2nyeVqEDdBuAP48UAZfiaA2+vztjCyYce+f/r5rMlfmp/i9JdW+q6G9rIUWV/LYD+L5hgH25Nc7/a3n65c6cFACJw+eScDP8/0qOdXsbrDycFNdm/udjVtr6GYOIJUkMbbW2nODVpZCy15jpMtzBY6ktuXWUyRINvXJLdP5V6R4OkbU9QNsYz/AKPII2kbkOQPm/l+tKFTm3NcThHSbcXdL/gf5nd6Hbx6VpXnzjE0g3N6+wrIv7h7mYySnnsOwFY2uX/iyXUhp8l74bhnjTzPLWGaQkHv99cfrWXNB4ubJOraDEPT+zJnz+P2ha0ORprc1rpgD1rl7mTzZ3fsTx9Khv7bxMYpWl13TBxjEWluo/8AHp2rF/s/Wzy+uxg+iWSgfqx/nXNXeyPTy6Nk528j2X4aFf7EuFDAt9oJIzyPlXH8jXXV8+aGNc0y9WZPE15GrfLIILWDBX6Mp5+teqw+HdWuIUmHjzXysgDAxW9gFIPTANsT0960pSTjY58bTlGpzPZnXU2V1jjeRzhVBYn0Arlh4SvjzJ4y8Su3dt1qufwWAAfgKtWHht7H7Q/9s6vfSSwtHtvbgOmT32hQAfp71qcZjw/FjwRNoFnrUWuxNp13efYIJPIl3PPjOzZt3Dgg5IxyOeRWzdeMNGs9RtLG8nuba5u7xrC3WaynjE0wGSEJQBlx/GDtPY14nZ/s8SWvg/SUjubT/hJreSE3BMzG0ws+9pEHl7vMZFRCcDIXHHU62t/BzU77W59UeHQNRx4km1dLO9ZvLmtpIkUxu3lNtOUBI2sDgc8UAe7VheJ/FFl4cu9Et76K5kfV75NPgMKqQsjKxBfJGF+U8jJ9q8tf4PX0Y8canbrokniPV76aTT5bzzJ7eO2kZGZJImXZu+Q87HwQOuKp+F/g/wCItKvbB5rrS0tLbxFDrK28cxIjiETK6qEgjQMWYYCoq4HagD3uivLfjL8OtV8XXem6j4Xv7bTdVjhm0+6mmLAS2cylXUbQSWUnKjgZJ5Fcv4v+D2vX/iG1l0F9As9M057L+z5VRYbqOOEAMsjiBpHyBxiVRxyp7AHrvhDxRZeKrW/uNPiuY0sr6bT5BOqqTJE2GIwT8vp0PsK3a8G1T4O+Iv7JkuNE1LTbPxNHrV/e210XfYLW6BVkYhM7wCDjBAI685qDxP8AAq9nvbGLS7yK50i106CzhgkultJbaSNgxkikNtOVLsNxKbGyTkkcUAfQFFMgVkgjR2LOqgFicknHXOB/IU+gAooooAKKKKAK2pafZarYy2Wp2lve2coAkguI1kjcA5GVYEHkA/hXzv4Y0PxD4T+Fs114U0OXS/FFxrzW7TLpAef7G056qUyYgMHsABwR1r6RooA8E1z/AIWHoOteJG0yJtW1CLTLJBq8eixRyTsZT5rJhf3jKnSMswHXHY6Os+IfFmn6hpb6JdeKdU0ia0vlmmu9B2TLdCIGANGtsjKu4jDbdpJIJIBx7VRQB8+HxP8AEpbTwxNMmuXEstlCL6xtNKNvcGdpPmd5JLSSAAL1TdERTPCPjHxvr2vxRW9xqOp2w1fULO/hfTIxZxWqAiM+cIhmTJxt3sTgZXnn6Gqpp2m2OmRSR6bZW1nHLI0zpbxLGHdvvOQAMse56mgD5q1GXx1cfDmx0O603VrCwuPDNyWt9N0MAz3xlZRbyIkJEC7MHgJnJ+bNeq6tH4o034I6RL4W8+DX9O0+0lNobcO84SNfMgKMpIJG4cDdkACvS6KAPBtT8SfEX/hFrG9+y+IYNS1e6u54Ireyj26bCB+4hnUWs0hJxnO0ct8zADjJsI/iFqd/f+ILe2v9N8TP4RgKzSWG1ZLmO4Zmh2uhUOyj7uARuB4FfR9FAHgd34k+Klx4at9ajsL6yi1HVSrWYsx9p0+zVQqnYIZXy7hiSYpCBjAAOa9G8Dal4m/4V7aXWt2/9r68rMsixRPZGZQ5AbZPHEVbb6qoJHHBrtqKAPEPH/iWU63G2o+Htd09vJUFXgSfu3I8h5MiucTxV4eLhZtTW1YnAW6JtyT6YkAOa9Y+J9vmOxuQBwWjY/XBH8jXAsoZSrAFTwQec1xVbKTPdwjlKjGzOQ8S6dBeI2p6XcJcRqP3u2QNx6gisaxbGK6bxB4f0L+zL25m0mx85YiFlWFVcMeB8wGepFef22kwoR9nub2A/wCxcMR+TEj9KnSx2QlNdDsopGx1p+9j3rnoLPU4wPI1hn9rm2R//QNlWA+uxDmHTboeqyPCfy2v/Oot5nSp90/69DYzRWR/al7H/wAfOi3gH96F45B/6EG/SrFrq1nKy/aftVlGTzJdWssaj/gRXB/OhRb2FKvTgrydvXQ6jwzZC5ujLJykWCB6t2r0rRwsUZOPmrg/DU+m3Ee3R9WsbtmOT5VwjnPToDXXWk89udk6ceorupQ5I2PmcbiPb1XJbdDXlj8zO7nNUoI/s8hUD5SeKuQzLIODUjIG61ochTuE3KazBJJaXcVxFw8bBhW1IB0rOu4gQaAO9ugmo6UJYxkMglT8s/8A1q4fVYNy7wK3/A1+ZLeWxlPzQ/NH/uk8/kf50mvWXlzsQuI5OV/qKAPm7xDpv9ja/LAn+pf95F/unt+HI/CtXTpN0a10fxK0gT6d9rRT51qc8d0PX8uv51xmkT/KATXFVjys+lwNb2tNN7nSK3y0yRs1XWXjrQXrI7bBL92sW8Pz1rSPxWTej5qBvY9s8JXHneHdInzkCBV/74+T/wBlrwnxhb3WjeJ76zmORBMfLBHBQ8qfxUivVPhtqkJ8MywSvh7SUnH+w3I/UNXO/E/TW1y9tr/TI2mkWLy5UAwflPykDvwccegrfm00PIjSXtWpLQyPDOrWV6UhKiG6xjax4c/7J/pXTKWibnpXj0sLRuQQVZT0PBBrqfDviyS3CW2q5kgAwJQMuv19R+tawq9GcuIwLXvU/uPUdMuwwAJroLOXOBmuKtGSWNJ7SRZIm5DKcg1efW106S3+0I/kucGUdFPvWraSuzgjCU5cqWp3CnIrDhv7i38TTWF2xaKdRNatgDAA+Zf6/wD66iv73T70Q6de7/KvFBilHCM2eAG9elLDJbfbbPTLi7STU7R98Z2EFkweCemSp5+malvXQ2hTtF8y3Xb8fv3NP4q3cUFroU8sCzF7gBQ38J+U7h78frXl8Mpj8czkcje5P02k12XxLuzdeEPDN6cErcbWI9Rwf1U1wsQJ8WXrdcLK3/jhrKbvL7jvw1O1J37SN+3a0sUuJ4cM1yGu1UjPAUHH5nP412XwivF1G2luHVVliDK+0YG4nOfxBryvSmElna7yf3U7RY/2XHNd78IpxY+HPEsrDJt/mI/4Cf8ACnGd2uxnXw6VOXV3X6r/ACLGptLD4h13XblSsUcSxW+R97IB4/HA/OoYJv7C0FJNWuGaSR9zE5Y7m/hHf/Jp1rp3n6hrV7flngeUIkeTjEeCD+Y/Q+tcrDdS/wBmJrWoEyW1u89yQT96Q7VRR+uPSnsyLKcLN7W/LRL8bmtf6nBLqEmnxtumjTzZMdF5wB9ec1WkBKnHWuB8Jaq39vz3F2rO15lWKjJDMcjA+vFd+wlDcooHu3P6Vz1HzO56WHpKlBRQ4EMoZehr0T4c6q09rLp875eEbos9dncfgf515nl47n5BlWXLLWno98dP1G2vIskRvkj1HQj8s0qcuV3DE0fa03H7j2yio7eaO4gjmhbdFIodW9QelSV3nzmwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc948tDdeHZiilmgYSgD0HB/Qk/hXk7HaOQx+ik17vIiyRsjgFGBBB7ivGNasJtL1CazlzhDlT/eXsa5a8dbnrZdUunTZyfipJ7zSP8AR4pPLV97E/xAe1cTCCGr1VD/AKLB6qCv61ian4dtro+ZZ7beY9VP3G/wrA9RSSOZtjV5DxV/T/CetXQJttOnlUHG5QCPzro9J+HevTzIbqzEEPU75VyfbAJNChKT0RpLE0qablJGNoulm6YSzAiEHgf3v/rV2NlHGhUbQFHQDpWwngvUo41WNrVVAwBvPH6U8+E9WiGQIJPZZP8AECu6nTUEfNYrFSxE7vbojPvtM0jVF26jpdhdr6T26SfzFUF8E6AB/odvcWB7fYbya3A/4CjgH6EYq/cW97ZOVureWPHcrx+B6GnQXeKs5jOHhe/s23ab4n1eMf8APOdYZ1/Nk3f+PVe0yHxHBdxC/wBS0y8s+d+2yeGUcHHPmMp5x2FacVwGFPZ/SgAmNU52yKnkbIrK1JppbOZbKVVmH3W4OCD0pN2HFczsSWl21hfw3UZ5RuRnG4dxXo0wi1XTFkgbKuN6H39P6V4/ebbqztjM6xXWQyKxwd46iux8E66kV2dOnkwrAOgP8JP+P86SkXKm0rlDVVtpkuVdoysXyTK3RcjJBz7GvEr60bSdZntefLDZjb+8h5B/KvoPx3p1vb2l9dm0MsVygWdUOCwHB/HBJ/CvGvEmlT/2NBMF3iyACS5/1tux+Q/VehHasqquj0MBL2cr9HoUYX3KKk8wZxuGao2Um5BWa8jm5dgxBBrjsfQOVka9/K0VuSnB9aoq7SQkuckd6tXf7yxyeuAarRr+7bHpmmhS3Oh8GYxenJz8g69ua6QEg5HWuT8HyhLm6Vs7TGCfbDDn9a6umc0tzE8S6DHqsZnt1WO9UE8D/Xex9/f8/bzy4tWRmR0ZHU4ZWGCD6GvXq53xhpiTQHUIVPnpgTY/iXoG+o6fT6U0xLscZoes3ei3AaJi8BPzwsflb/A+9eoaXq1jqulSXK4aNUJmiIyU4yQR36V5dLbhxkVPod9No+opOmWiPyyx9nXuK2hUtozkxODVT3o7nqAnsY/C8ki77qx3botvDRZOOCehByf0q3rNoo1bS9dtJhKgaITkHkoTgP8ATHB//XWDpZi0oi5gzN4dv/lZOphLcc+3Uf5FXprabw7HFK5M1pbSlGTGRJby9j7hlP5iqexzQVpaPV3+d9163/zKHia/nfw/caW4zHZarIUbuAwYgfmGP41TsgJNdnnUcSWbSfj5X+NamqRJcXniOMYYOsd3GfUZHP5Oap6ZGAVk7fYpV/IMP8Kze52pL2d1/V0mYtg+23u4xw4CyKfTB/8Ar/pXV+GdSFlpPjG0AJee2EsYHuSD+jiuV04K2qiJ+FkUofxGK6DRYd2pwoODdWUkDD1ZfX/vkUoPb+v63KxMUm7+v9fcdxqF5tEkChQHmNuf95oi/wCeSK8x+IV2NP8AC2kaTFw0yCWTnsOf1Y5/Cuh1/UCttPcA/wCr1wH8FQD/ANlrh/irOZvFzQ9FghRAPqN3/s1bSldM4KNHllFP1+a/4cZ4DtxJqqOekaM/44wP516DXnnhO5FlfwSHOw/IwA6g8V6DuUkhSDXMz1LWBhhlcDJU/pSN+7kyoyjdR/WnUUgPSfh1qf2jTXsXP7y25XJ6qSf5H+Yrr68f8Kaj/ZmtwSk/unPlSf7p7/gcH8K9grsoyvE8LHUuSpdbMKKKK1OMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5zxrog1TTzNAhN5AMpt6uO6+/t7/WujopSSkrMunN05KUeh4R/CF7DmkrpfHOk/2dqpmiH+j3RLqMfdb+Ifrn8a5quCS5XZn0dOaqRUl1Ok8Dak1nrMcLNiGf5CD69jXqTyLHGXkYKo6k14ZE7RSpIhIZSCDXSa94+0bzliudSjiaNQGjIYkNjnOBXRQnpZnmY+i3JSij0CTWbRCQGZ/wDdX/Go01y2I+ZJR+AP9a8p/wCE68Ps3y6tH+KOP6Vbt/F2jykBNVs/+BShf51vzLuee6U1vFnq0F9a3PypIpJ/hbgn86ztU8N2V8WkRTBMf4o+h+orkbXUop13wyxyr/eRgw/StrT9ZlhIG/en91j/AFpkGJf6be6W/wDpEZMecCReVP8AhUUc5NehW15bajCUYKdww0T4Ofw71zOu+HHt99xp4LxZJaLuo9vUUAc/eX0NpCZbh9sYIBOCetYV/DaWQmliklWCcZlSNs4B/jHfr6VZuL7FzJbXFuVjYYSRuUc+h44rA3+fKu2AwXsC7fIYkrKncDP48VjOR6GGou13p+Vun/D9CfyPtECWl1IN6/NZ3APDj0J/KromMf2SW6AhuFYxM3bPofYjkHsayoLptKuEEsfm2E2HRWGdn0z0IrW1B4jCZmIudNuBtJUcxn1qYvR9zetF80bq8X/T/wCCu+x6RoWopr+n3OnXjmO8iwCVPzFequM/54rhb5EsYLqwv0PlrMbedQMCEPnDf7jZGPTdjtVLTbm7014tQibzbmyP3geLiE9j9OfyrsvEsdv4l8OprenYl2QstzAvLSREfMh/2l5Yfj61d7+pzezUNF8L/P8A4PT/AIc8KvLN9I1W4spST5bYViPvKeQfyrNuF2Xh9DzXWeIbf7XabVY3F7YqG88DJubY/df6r0P1rmZ182JZF5ZetcslZnu0ZucNd0aMah7fb6iqiKVVgR04qxp77oB6ii7IUDPANZnS9rl7waQNSulP8Vucf99Kf5ZrqhHsH7rkf3fT6VyHhTd/wkEQTGWSQf8AjhP9K63cyf61dv8AtDkVRyy+IN+ThSAfQ0u2Rtyt5XlspVgSeQRilyrEHgn1paBHn+p6fLpd35M2GVhujcdGX1/+tWJOrpKx7ZzXo/imFJ9CmZgvmQMsiN3AJAI/XP4Vw2wTIAetMuPvI3PBOsi0lezuTusrkbCrchWPGfoehrvlcajpa2MbM9tcwtApfrFMnIVvy/8AHfevHlRreXkfKa9Asb+Sd7dlk8iLUAI3kHSK6TGHz23fLn6n0rWE9LM4sRQ97njv/l/X4E9lIZ4rDIIk8ibT5R9FJT+Y/wC+ag075tOJ/uJOv5qDWlaxeVql0Jk2MzRahGp7EN+8X8MuD/u1Sgt/ss2r2meIPM2+4CsP8KSWpUpJxdvJ/f8A8PY5icNHKk6feQg11OjyAaxaSr0FypHsJBXMJOjuU71v2E2I4GUfMEKgD+9Gdw/Ss6bOrFRurr0/r5XK/iYH+ztWj/uaoT+Yf/4muX8fnzfFM0rfxxQsfxiWuu8RqGGuheVaeOcH1B3YP/j9cr46jzq0T9ntLdv/ACGtadH/AF3OZL3ovy/SI7wcVOt2ucY+bH12nH64r0B8SY3jn1HWvLdOke1limiOHRgwP0r07zHwjSps3gHI6c9qzZ0NDiGQZzuT17igfMAQ3HtTgSDkVG67W3xjg9V/wpCFdXAzGwb/AGSMV7H4U1P+1tCtrkkeYB5cg9GXg/n1/GvHq734YXI2X1oWGdwmVe5zwx/Ra1ou0rHDj4c1Lm7Hd0UUV2HiBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBkeKdLXVdHmi25mQeZEf9oD+vT8a8ezjrXvFeG3URt7iaCRVLRuUORnkHFc2IWqZ62WzbUosrgmRysZHAyT6V5h4viLa9dk8ncAT+Ar1GIAGfAA5XoK4LxpbGLV3k/hmUOPywf1FYI9O19Dkfs5xR9nbtWhFjODVq3h3vwOKq4KncyLaa7sZxNazSwyr0eNiprrNF+IerWUirf7byEddwCv+YH8xVN7JSOlUpLSEsRuGacajWxFTCxn8SueyeF/HOm6rIiQztb3PURzfKxPseh/PNekabrygKl4wwSAH7596+TpLAgZXmtjTPEd9Y2xsb0fbdPJH7qUksmO6N1U/p7VtGt3POq5bZ3gz6O8WeGv7UtJJ9LlMNy3zZRuGPqP8815lcyMkR/tKIx31swBkUcgdmA7j1FdJ4Z8ZwWmgw3VtNPqFsjBJw4HmRA5wXHr0Ge/Xmul12wt/E2k/wBoaKYp5yvCNgLKO6k9j7/nVu0tUc0OalpJaX32/q67nm+oQrd2/lMEIYb4nB6E9/pk4P1BrD03UJtMmeKRC8DErLA/Q9j9DXQR2oaCSFQwkt3IML8NG3IMZ9QeRmsjW7VWQzozNLHhZNw5KnhX+v8ACfcVhUT+JHo4OUdaE9v6/r12NCO5/s+NLqydp9Mc/Mh+9GfT/P8A9erXh7XW8Lamt1ATLot4372MDJX6e4z+I4rldOvpbGUtHho2GHjblXHuK0mRI4JLizBl06XAni7wk/54NJT5lddP6+4ueHVKTjLVS/Hy9V0fUu67EsWtldEVPJwbnTWx8ssZGZYPzJwO341x2oWsVpdo1q++xuV82AnqFJIKn3Ugg1vxgCFdPuZytlI3nWVzj/Vyjpz2GeCO3WpJLZtUtJ4RbpDM8x3p08i76YHosgH0DChrmKpy9k03t/X9Pzv3Ry8EZikOPuNS3qGSI46gZqVAy5VwVdTtZT1BFK/6Vgen0Kvh66+zavZyk4G/Yx9A3yn9DXf9Mq4yp4KmvNr2HZIWToa7nSb43tlDLKR5rLyR3I4z+lUc046k7RJAc4byieGB5X2NSKuRy24djUmcZqFCgY7TtPpSJ3Ce1guIXinRnjcYYbiM1w+r6bJpV4EJ3QSZaJ/UZ6H3Fd7VbVbJNQ06aBhmQAvEfRwOPz6UwUrO5w7RLNH2zWzoaPd2dzpZG4zDzIh6SoMjH1XcPxFcrHLJDJuBOK3tPuyHjnhbbIjBgR2IovY1lHnVup2glW9sNI1EsSY5TbXXqu8YY/Q5J+rVFfo8Wuais2BJJa7mx03bAG/XNPsipnu7bGLfWIPNhx0WXk4/Bsj8qTVHa6/su/zl7m1eF/8AfUHP55rbf+vkec1ytrpZ/wCf5pr5Hn7Ex3Rx2Oa6LSZlwST/AKtllx6gcEfkawb2MkrKgzU9pcrEyMx+Q/K/0PBrGL1PSqxvFo6XVoiFu41yS1jwT3MTgf8AoKfrXJ+JpRdLpsnc2SL/AN8lk/8AZa1zqk6SxxELI8YZWPbDJ5bj3yoU1k3trJNBCu7/AFKFF47bi382NXJo5qVOTSb/AK/rQyoh8gHpXqFvMt3YwS4yksanHocc/rXl53RNtcYP867nwq8o0ZGkOYN7bfVf/rZzUmkkbCAqNp5x39acKAQeRyKD06ZpEi9a6HwDOYfEsCg/LMrRt+Wf5gVzTP8ALvU5xzV7Tbn7FqdrcjO2KRXOO4zz+lOLs0zOrHng490e20UUV6B80FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXj/i+EQeJL9AOsm//AL6Ab+tewV5r8SrXytXguBgLPFg+pZTz+hWsa6vG53ZfK1W3dHIJkM/HBxVPU9Mt9VhkjnGHUApIOq/4irtMtgxeV2+6yfKPbNch7Z5nfWbadqEttNhmQ8MOhHY1btyuOAK1fHlsBPaXS9XUxt9RyP5/pWDbP0FNmtNmoyloyB1xWPLblCQynPrWvC4x1qUhZBggEVN7GrjzGLbTGNtr8rV2S2SZNygVLLZoR8ootQYsq3Si4lHoytp9zeaLei5sZCjdGUjKuvdWHcV6l4B8RIZWfSWWASN+8sXYnymx95R/Eh7+nWvMJLqN3I2HHrRF5lvPHdWUjRyodyupwQa0hNxOSvhlUTSPeL9LPxNbzahpqiLVrQFL2zH33Hp7kYyrd/5cddTotoJxtuJrY7ZhjieB/wCL+X0OaxLLXb65lXV9NkFvrdnH/paqdou4hjnHcgDkfiOla0NwtzHFc2MQMMiu8SseXj/5awH3B5FbN32OCNN09+n9W9O3/AOY1uD+zZsBvNhcB4nH8anof6H3FO0nUHhcPC3DcMjfdYf3WHcGtS7slu7ZtNGJJCpuLKVf4lPJX68Hj1B9a5WAPbytHICpFYW5XdHppqtHklv/AFqdciWs1nJtR3snJ823DZktT/fX1H9ODTnjkibzrl/tEkUeyZUP/H5b9pFI/iXjnrwPQ1hWt89tPHcwOUkQ4bFdPp1zDMu63KW7w/PsxuMLHq6eqH+Je1Wnc5ZRcd/6/rv6dbGT4hsGCrqMGZEbAmb+/n7so/3u/owNc3qTFYAVOOa9CjhWKQ2zxLJZysUVN3ETNyYwf7rdVPqB71xmv6e1s0kRDFcbo2IxuXt+PY+4NRNa3OjDVLx5H8vQyI5POt89SOtdR4RKT6PLEcF4ZTwOoU4wfzzXI2R2SbT0YVatbqbTb0XFswDAYIPIYdwak1km1od9GrKMFtw96dgZ5UH6imRyrJFFIV8syKG2k9MjpT6DIGVD0Ur9DTBGAwbLZH+0adhs/KR9DTtsg/5Zsf8Ad5oA4zxFoosv9JgObeRsFe8Z/wAKx7JzBcBf4WrvNetp7jR7iOGCSRzg4A54IOa4E9QehU0GkHc6/SpXuNPkRHxcWTfaoOeSP4wPyDfga2dQuFki3RrtiW5juk9klU7l/BhiuP0u8FnewXBG5Vb5x/eU8MPxBIrq51iNjPbW8m9o43SN/wC+n+viP4gOKuOqMK6UZa/13/rzOXCBfMjb+Fiv61m3sXlk7enpVvWrgx3Nz5fBZ9w+h5/rVCOdpo2V+WFRazOtSUootaUdy5Jyfet9IUeHgAmua0t9sjx+nI+lbsExXil1HvHQxtVthkjGD2NdT4OcjQIf9l3Qj8c/1rB1Qhs1a8H3wjuJbKV9qTfNHnoHH+I/kKZlUV1c6oxg5MOF/wBg/wBKar/Ng5VvQ0+kkUSLhuo+63pQZjJokkUkZRz3XvToyTFHnrtApkbEhkb768GpBwAPSgPI9u0ub7RplpMeskKP+ag1arJ8KS+d4c09uuIgv5cf0rWr0Iu6PmaitJoKKxvGmuf8I14S1jW/s/2n+z7WS58nfs8zYpO3dg4zjrg1THjHTbbwho+v6w/2KLUooGihVWmdpJVDLEiou6RuSAFXJx0pkHS0V5Lr3xctpvEvhXTPCkwnt9Ue4N1cvpV1ctCIRgxiJNrby2Q2fuDDMuCM9J8LvH0PjvwWmv8A9n3NgcyCSAxySAbWYfI+xRLkLn5AcE7eooA7aiuMh+J/g6a0guo9bi+zzWT6ishikAFuj+Wztlfl+cbQGwSeACaaPij4Q+yvO2pzRhLqGyeKSxuEmWaZS0SmIxhxuAJBxg+tAHa0V5hqPxl0JNV8PW2kQXmp2+p3k9lNLHa3CvayRKCymLyizPkjK8EDnpU+o/GLwmqahHpOq2l1fWEqx3MNwtxCseZliOWWFzncwAAGD6gcgA9Iorh/E3xD0yz0zxIuiyS3uqaTa3LttsZ5LaOeKJn8uWZV8tT8uCpcHt1IqppnxV8PRaDos/iLUYrXUbrT7S8ulht5nhtjOqld7qGWIFmwN7Dt1oA9DooooAKKKKACioruQw2s0qgFkRmGemQK8F+G/wAYvEXia90yO6TSpEn0u61G+SDT54HsljJWNlMkpFwrMMfJjHIyMGgD3+ivI7b426TFoNtdTWWqalOulDVrxrK1ihWCEvtBZJJzgk9FVnPes6x+LkmneNfF7a3HqFx4bgl0qOzMMMP+hfaYNxMnzB2DMR034x24yAe20V598KvG2qeLr3xXDqmlG0j0rV7iwhlTYFKJtwj4kYmUZySAE5GD1qKL4weHWv3sZYNRgvIbm8t7qKSOPdaraoHlmkw5xHtIwRktnAFAHo1FeQ2v7QHhG507VLyOHUithZrftGogd5IWlWPKhZSFYM65RyrAHOKr+MPjRLZxSw6DoV6NTs9Ws7G8t79IuI7gFkKFZsEso+Uk4B+8BQB7NRXlmsfF+zgm8Q2Fto+vQX2jW7y3VzJYLcW1syw+btdkmAJx8oG8Zbocc1t6B8QrfWtSj03S9M1LU7mKC1lvri3SGKG189A67xJMD907iqbyBxyaAO4orwbwj8dLDSfh74eufGdzcX+u3ttc3cpgW3iPlR3EiBsM0ak4TAVMsdpwDXtujajbaxpFjqdg5e0vIEuIWIxlHUMpx9CKALlcz4/077doZlVA8lq3mjjPy9G/Tn8K6amuodWVgCrDBB7ilJcysXTm6c1JdDweY/umxxxgYpzfu5kA+7t2H8qv6/pr6XqUtrICVVgUY/xJng1Rblia89q2h9LGSkk1sZevWD6pbC2jZVdf3ilumen9a4W7tLjTrrybqMpJjI5yCPUGvS4iPtTgdfL/AK1i+MLVJtJM5UebAwIbvtJwR+oNCKTszip5GO0KcZpYZpYSDkkUwfMBUyBsYYZFM1NW2nEq5Bp5UEk1kwsYJQRnaeorYjYMgI71DNYu5kzxeTKcj5SeDUtswjbbnKNWhJGsgwQKpyWB/wCWbEU7icWtixHvguI7i2cpLGwdWHYiugtJ7d43uxmK2ldWu4oRj7LLn5JkH90nqPcj0rmo0mTAPzCtCwuZbK5WaIA8bXRhlXU9VI9DVRlYyq0edXW51E9tLNEUji8m7STzEMbcJMecKf7jgZX0PFYutCG6iivh9yYkSgDBhl7j6HqPx9K0YpYkWFYvOniZCYMNhmTq0BP99D8yn/EVRv5YYZ33kGzvwFkdlwEf+GUfXk/99jtWjOKF07P+v6/4Hc55hJDOAo8xHHUdGFOF3PaPFKGdJYzw4OMenNV5TLZXzRTgqyHay54Hv/8AXrSKrIuCAQaybtod0IKXvdTp9K1qDVbbyZgv2ghlMZztcHk4x05GcdjyO4L9Ttvt1q6Dc8sfKHcCTkDr9eM9s4I4Y1ws9tJav51szDBzgdvpWpa6rdXsUMjOUkiO0lT9/wBz/L0PPqc1zprUwdBxleBhuv7x1HVTkUskm5cMPmFaGp2c0s7XS5MrcsD/ABf/AF6pqqzKRj5hwQeoqTpszstBvU1HTFDDMkQEcg/kfxA/Q1fCNH/qyXX0PUVwejak+k3zNGA8bDbJGejD/Gu2sLpr62FzDCViJIAZhnigwaaLCuD9adTSeP3kZHuRTQuT8jkfrQIkyfU1zfi7Tty/2jAoHRZwOOezfj0NdATIv8IYexpGVbiGSKVDskUqwPoaA21PO3k2xA+1aOm3NzcRxLvIWMbVx6BiRn8SfwNY1wGTKMCGU4IPY1oaHNsUexNGxtZSeomrWskWWJZhgA7jnAFUYI1k3xsWCyKVJVip/AjkH3FdZelJ4uQORXMiPyLtoyOAcr9KLjsZEuk28E4ZZNQwDz/p8/I+u+tmPRLJ41dJ9SIIyD/aVx/8XUV4uWzVnTJfLkNu3Q/Mv+FDb7ijThe1kVLjQrX/AJ7aj+Oo3B/9npmj6DZS6xaxSy6hsZ+cahOD+YfNbNwPlP0rC0ydrfVLaYk/JMrH8xTTfcmpTguiO5fwxYxvhrjWCh+639r3f5f6yl/4Riw/5+NY/wDBvd//AByt5jjcjjcuelV5d8JXZmRGOAO4o5mYKnF9EY58L2G4MJ9Xz0P/ABNrv/45Tv8AhGLD/n41j/wb3f8A8craRw4yOvcUpXcMBirdjRzMPZx7HX+CPBuk3Xh6Fmu/EIZWdWCeIL9APmJ6CYDoRW//AMIHpH/P54k/8KPUf/j9RfDCUvoM6sMMlyykf8BWuvrtpu8UfP4mPLVkvM5y88H6ddeE9U8PNPqZsdRjkimkmv5bmZQ67TteZnI4HA6Zyccmue1D4U6bqvhq00LWtY1bU7GxaF7EXKWhNqYlKrt2wAOCpwRIHBHavRKKsxOC0H4XaLous6LqdtPcm40k3JhVILW3jfz0VW3pDCikgKMEAH1J4rY8AeD7TwRop0jS72+n05ZHkghujG3kBmLMqlUUkZYn5ix966WigDzWz+C3hK2tfFFt5V5Lb+IOJ45JRi3XzDIEhwBsUOd2DnkCm2fwa8P2tlb2q3N1sgvrW/RorWytmL2+7YGMMCb1O853ZPoRk59MooA86Hwk0aO6W7tNR1e1vk1m41yO4jkiLRzTqFkQBoypTAGAQT71Yb4WaI3hHUfDputS+xX2pHVJH8xPMEpkWTCnZjblRwQTjv3rvaKAOGPw2sI01+3stW1ez0vXDcPe6fCYDCzzoUd1LRM6nncAGAyBxjIONd/BDwvPd2t0j3CXENlBYs8ttaXXnJCgRGYTwSAPtUAlAucV6lRQAAYGB0ooooAKKKKAGyoskbxuMqwKkeoNchB8NPCVvbaPBBpJiTSI5YrIpczK0aS58xCwfLqdx4YkcmuxooA8m8YfBfT9YtLex0O4t9Eso7EaczRxXEk7Qb9xTeLhUZfQSJJg8+mOnk+GfhSWC+iuNMaYX32U3TNcSgym2ULCThgBtA/hwD3zXZUUAYmieFtI0PVNT1DSraS3uNSlNxdhbiQxySnGX8ssUVjgZIAJqvF4I8NxeJtS8QLpMB1fUoPs13OxZhLHgAqVJ2jIUA4AzjnNdHRQBxg+Gfhb+xLnRmtL99IuIhA9jJql28CoHVwEjMpVMFRjaBgZHQkVNqPw58K6jJqkl3pe+XUpLea5cXEqsz267YWUhgUKjjK4z3zXW0UAczF4F8Ox2muWwsZGi1tFj1EyXUztcAJsGWZiwO3jIIJ6nnmkh8CeH7fVINRtLW5tLyKOGLfa308AlSIARrKqOBKAAB84bjg8V09FAHGQfDLwpbWmm29lp9xZjTUkitZbS/uIJo0kcu6eakgcqWYnBYjmupOn2r6X/Z08X2myMP2d47ljP5se3aQ5ckvkdSxJOTnOatUUAcr/AMK48D/9Cb4b/wDBXB/8TR/wrjwP/wBCb4b/APBXB/8AE11VFAHmvjD4W+FJtMM+neFtDiuIMsVh0+Jd69xgL1715nJ4S8O8BPD+j7j3+xR8f+O19LV53438Nm3lk1GxRmhclplH8B9R7fy+nTCtB/Ej0sDWiv3c16Hli+EfDcboW0DSWBODmzj7/wDAaS68G+HJbaZF0LSoyUOGWzjBB9RxXQMNwxT05bB6Hg1zXfc9Rwj2PLrvwBFBG0qaPp80SjJMcKE49cYzWbDomj99K08/9uyf4V69bsVUAHDIcVg+IPD7Xd4lzZsiPNkyKxwuR3o5mWoxT1SOIbw9ozLldJ0//wABk/wqW00HRGUq2j6cSPW1T/CtK7tbjT5vJuk2sRkEHIYeoNRQNiXPrRd9zVQhvZGfDpdhZ3vnWmn2dvPGTteKBFZcjHBA9DW7aXPm/K/D/wA6iliWbnOG9agKPEw3cMPusOhqXqXFcm2xdvZngCsoBGeakt5lnj3L+I9KYu25tiD3GD7GqFszW9wQeo4Ye3rSsW3Zmql88KvaNJsilIdGzjy5R91ge3p9DU0rPeW6pPk5+dkzgBjycD0zk47EnFZOsKTEHHatK1l3IjjowBp8ztYj2ceduxV1CwM6qykiRVCAk5yAMAH6DioLa5aLEM42yD9a6QbHQZHNZepWiTKQeD2I6ij1GvIh80MCDUOmtslnTuG3D6GqXmSW8nlzj6H1ppuTDdpLn5Oh+lFh8x18UiTQ7WHIrG1KyIkMsJxIPfhhViKXABU5B6U+SXevNK4+U5yZRISwGJF+8K6rwZfeZbS2TdUPmp9OhH8v1rFvrPzf3kZ2ygfgfrVG1vZrC8STGyZDn2P/ANaqTuZTiemBiBgHimMinoNp9Vqhp+r2t9HuiLBgMspB+Wr6urDKkGgxtYZl0+/8w9RTwQRxS0mMcgflQBzfi3SFe3e/tkwyn98B3z0b/GuX059pb616S7xOjxzBvLdSjjB6Hg15zcWz2N1JDICMMdpIxuHY/jQXBs2I5tygVT1SMlUmTqnX6Uy2l5AJq9xIhU9CMGp2OhaqxjSNuFS3qmIxyp1XBqIxeTdeSx4ByCe4qfVZgEVVwd1UR0ZdkYNGGHQjNc5cLsmce9blu26ziP8AsgVlzYNw4IyM0IJ6nouh6imqabFOD+9UbJQf7w7/AI1el6RH3IrO8NRQR6HbLEAA4LM4HO7Jz/hV8ZIaOTg9j/WhnOLKAMSjrnDe/vS0kbdVYexFImVJRuo6e4pAem/DRcaHcHHW5b8flWutrnPh/EI/DULD/lo7sfzx/Sujrvp/Cj53Eu9WXqFFFFWYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUjqrKVYBlIwQRkEUtFAHnXi7wo9q0l9pcZeHOWgRclPceo/lXHyY3BlOVIyCK91rj/ABD4NhuVabSgkE2STEeEY+3p/L6VzVKPWJ6mGxtvdqfeeaqMSyHsTmmXEm2WEc8A5PpnpVu6t5rSd4LmNo5UOGVh0qu4Hn5cAo67T9RXOeqmnqR3lpDe27Q3C5U9GHVT6iuE1Oym0y8aGbleqPjhx6136ZGUf7y/qKz/ABHYfb9LcqP3tvl0Pt3FA4uzOMS5CY3HFWtyTR4OCDWRMhU4YcjsafaSlCVz7iixupGjYsY5njbp1FLfIBIsnrwag3/vUdeo61NeSBrc/XNLqVfQluk8yz98VDo8pMbQt1Q8fSrceDEqn0rJlJtLwOvTPI9RSWugPR3OhSYgYqNnJ4NMVg6BlOQRkGsqS4lNwfmxg9KFqU2kaU8KToVkXINYt3ZSwZxmSP1A5FbNvN5sef4h1qot1IszrMAVzj6UK5MkmJo1xvh8onlOB9K0qy7VFj1E4xhlNaEkyRuqscFulD3HF6aj6p31usq/MoNXCQOpxWbqIuFcsjHYemO1CHLY1fA8n2a8ubYtzMoKk9crnj8ifyrrSFP3kX6jg15dDcXME6TRS7ZEO5W9K9A0jVE1K2Em1kkXCuO2729qo5ZLW6L5QjlGz/st/jTRLg4cFD70+g4IweRQSKGPY1De2kF/btBdLuU/dbuh9RUiqF6U4YzyM0AebXUMlheS28ww8bYPv6Gn2V8sjlCNp7c9a7DXdCi1UmWJzDd7QoLH5Gx69/xrz+7tZ7C8eC4QxzRn/JHtTtc0jUNfUYvOgDoPnTke4rKkczFM9hV60utyDd171VuEEcpaMfKf0NJGktdS5anFmgPpWY53XDY5Oa0CfLtgPQVe8P8Ah27umjvJFVIc71Vz8zgegoRM3ZI661sRptjCsLFgijzR7nqRVoYbB6+hpYZd2JF6H1qPAil2D7jcp7e1Bj6jiOQR1oZckHow70tFAHr/AINj8vwzYL6oW/Nif61s1neHV26Bpw/6d0P5qK0a747I+aqu85PzCiiiqMwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKMUUAFFFFAFDV9JtNWgEV5Hux9xwcMp9j/kV55r3g+9sGeW1U3VqOQV++o9x/h+lepUVnOmpbnRRxU6O23Y8HIBwe4pJT/o8w9Vr17WvDOn6qCzRiG4PPmxDBP1HQ/zrg9e8I6jYKTbobuJuA8SnI+q9v1rmlSlE9ajjKdXTZnNoyTxAsquCOjAGsjUfDlndbpLYfZ5+wX7hPuO34VsSx+RIcAhR8rKRyppwNZnX5o89axu45pIjBIzx/e2qTj347VVlcnCepr0o5F1K3QPggiql9p1neuPtEI8wjIkXhvz7/jQWpnGxzYxUV6BIM961tY0NrKH7RbuZYQfmBHzL7/Suf8AObeQenaixpzpovaRNmJoW+8h/Q0+9gy3mqM+orPtn8u8yOjLirv2zZNtblTStqUmrWYsB2OrqeDwRUt3B5gEkf3h1HrSmNGwyH3xTkcrwelIq3RmZA+L+IDpz+HFWdU5njx1AzQkavqQYDopY0SAz3TDHfb+FMm2liW8jaRYnAJAHIFTQuEt18w4HQbqe8scQVXIFV79PNiV4/mA5470i9tSK7t4pQWX81rT8F3C211cWkjZE6jYCOrDt+IJ/KsFCyNlDkelIZCHV0JVgcgg4INUjGaUj0wx4H7o4P8Adb/GmGTacSAqfeobJ5WsLWQkzF41Yk/e5H61OHU8E/gaDEVWDDIOaWgAdgKQqD1FAC1h+M7SO60gTkgTWzDB7lWIBH54P51tqkY6pn8TS7YwcrEgPXJGaAPLza3MESzNBMsR6OyEA/jTkbzHUdhya9QLsc5OQeoPQ1yPivS0t5ILmxhCrM3ltGg43dsD3/pQXGXRkfhyyS91IGTBjgXzSp/iIPA/Ouy3Hfuzz1rD0LSbjSxJcTyIWdNrRL/CODyfUVtA5GR0oJk+Z3I418uWVB93O4fQ06dd0DkfeT5x+FGD5u72xUi85U9GBFAr9SvHcKVHmZVvQiplO5cgHHuKZAWEQVjyvBq7plub3UrW3Of3sioT6Ank0LUJNK7PZ7CLyLG3hHHlxqv5DFT0UV6J8u3d3CiiigQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGZqmhadqZJu7ZWkP/LRflb8x1/GuM1PwJdQlm06ZJ4+oR/lf6eh/SvRqKiVOMtzopYmpS+F6Hht1bT2spiuYZInH8Lrg1SuJCVCoCZAeOPzr3m6tobuFormJJYz1VxmuU1TwLaSqzadK9vJ2RzuT6eo/WueVBrY9GlmMH8asebIwOUlXqMMp6EVz1/4Vge6b7NOYUb5lUruH0613OreH9S01C11bEwr/wAtUO5R+I6fjWS43oB/EvKn+lZNNbndCalrFnOQ+E4AuZbqUy9mVQFH1Hf86wNb0u50y4XzwGjYfLIvQ/8A169BVsjkYPcU5kjmjaKdQ8TcEEZpF8zR5hDdPC2OStXpJ9kQeRHVT0JGM13NrDBZOUitoYn7OqDLD61ZdvMQpKFdD1VhkGjQr2jR55bMI1aaThn/AEHYVNFdI7YAIPvXSTaJp1wzxmJ4JPvBkY4/I8Vgf8I7qIvWSNEZV/5abwARRa5aqFG7bdcr6EU+1m8tzGx+U9PajVdMvbEpJcwkJ03qQRn8KqNFM8LTJG5jQ8uFOAfrRYfN1RNcgQyF0+6eo9KpSvhty9D1qYuZEz610Wk+E4pLZZb+eRGkAZUiA+UH1J/lTRMpWNvw1KZvD9mx6ruTPqAeK0XO8YcBvqKgsbH7DZRW1s4ljjzjPDcnNSBxnByD6GkYh5aD7oZfoacBgetFBAIwaBhRSCPA+WQg+jc0pDqMuvy/3l5FABTZwuLcsAdsu4Z7HBxTgQRkHIpsyloWVfvD5h9RQA8Hk7uQetRxLsBjznacfhTo23orDuKR/lkDdmGD9aAHUUUUANwRKzdm6/Wui8CQGbxLbHGViDSN+RA/UiufrvfhlZDbd3zfeyIV/Qn/ANlq6avJHPip8lKTO7oooruPngooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKADrWLqvhnTNRUl7dYZSc+ZCApz79j+NbJOOxpaTSe5UZyg7xdjzXVvA97bDfYyLdrn7v3GH5nB/P8K5WaCe3kaK6gkglX+B1Kkjsea90qveWVteoFu4I5lHI3qDj6elYyoJ7HfSzCUdJq54g2HXa4yOx7imHcg67l/UV6fqfgjT7lSbNntJPY71/I8/rXK6l4P1SzUvGiXMY7wnLY/wB08/lmsZUpRO6njKU9nb1OaKhirDqKTPlzq5+4RhqmkhkjZo2Qxyr/AAuMVEjCRM/mKzOq4s0aSI0cih42GCDyCKRI40t/ISNFhxjywPlx9KQblwp5XsfSn0BYzrLR9NSOQG1DksQSxOR6Yq/ko+xhgD7p9RUXmeXdHj92QAx9D2qycFdrjI7H0oBiUpYtw2GHvUbAxjJIZPX0p1AEUwZAXj5UdVNOD8DeNuenoakGOh6Hg0xBsBiPIHQHuKQDhTlYr0JFM2Y5j6f3aUHI4pgNkXJ3x4Vu47GlRtwzjBpaDxQA3hO2ATSsAylT0NCsrZBwQeophPlHBOUPQ+n1oAem4DDc+9OpAc9KKAIzmJwM5jY4HsfSvaPDWn/2XottbN/rMbnOP4jyfy6fhXnXgzSF1bV185Sbe3xK/uQflH5/oDXrNdNCP2jysxq3tTXzCiiiug8sKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopCcUALRQDkZHSigAooooAKKKKACiiigAooooAgvLO3vIvLuoI5k9HXOPp6VympeArGaRpbCeW1kPVT86H8Dz+tdlRUygpbo1p1qlP4HY8svfBmrW+TEkdyvrE/P5HH6Zrn7iCW2lMVxE8Ug6q6kEfhXudRXFvDcx7LiKOVP7rqGH61lKguh2QzGS+NXPCQgy+QCGOf0oRWTCg5Tt7V6xqPg/Srw7o42tX9YTgH8Dx+WK56+8B3UalrK6jmxk7HXYfoDyP5Vi6MkdsMdSnu7HGA1BFlJWjPTqv0rZu9C1S0JE1jOABnKrvH5jIrJdD5ytjoCDWbTW51RlGWzuPpJMlQy/eX9RQx2jNOIIODQMajBgCDRICfnT73cetRspjbcnK91qUHIBoARGDrkUvSmFcSblHX7w/rTyoYFTxkYzQA1kRx8y596b9ni7+YR6bqWI8bW4ZeCKfSHqMEIQfumI9jzT4Ibu4uI4IIkeSRgqgN1JqzY2VzfziGzheWU9lHT3PpXp3hbw3Fo0fmzFZbxxy+OE9l/x71pCm5s5sRiY0Vrqy34Y0kaPpUduxVpz80rr0Zvb2HStaiiu1KysjwJyc5OT3YUUUUyQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBAAOn5UtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVSvtKsL4k3dpDKxGNxX5vz61dopNX3GpOLujldR8D6Xcwstt5tq5GAVYsPxB/xFYs/gK8Cjyb2CVuhLqUz78Zr0SiodKL6HRDGVo6XPJ7rwhrFvki3WZQM5icH9Dg/pWY+k6in37C7X6wt/hXtdFQ6C6M6I5jNbpHh/2O6HW2m/79mnpp19J/q7O5b/AHYmP9K9topfV13K/tJ/ynkFt4T1e/wy2rwY4DzHZj8Dyfyro9J8BFSrardK+OscAIB/4Ef8K7yiqVGKMZ4+rLRaFXT9PtdOh8qygSJDydvU/U9TVqiitkrHG227sKKKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The heart has four main sections, or \"chambers.\" The top two chambers are called the right atrium and left atrium. The bottom two chambers are called the right and left ventricles. Each of these chambers has a valve that keeps blood flowing in one direction. The valves in this picture appear in gray. When the heart is working normally, blood comes in from the body through the right atrium and into the right ventricle. From there it goes to the lungs, where it picks up oxygen. Then the blood comes back through the left atrium, into the left ventricle, and back out to the body through a blood vessel called the aorta. The aorta appears in red. If a valve doesn't work properly, it will either let blood flow backwards in the wrong direction or not let enough blood flow forwards.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_42_36516=[""].join("\n");
var outline_f35_42_36516=null;
var title_f35_42_36517="Psychiatric aspects of organ transplantation";
var content_f35_42_36517=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Psychiatric aspects of organ transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/42/36517/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36517/contributors\">",
"     John Vella, MD, FACP, FRCP, FASN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36517/contributors\">",
"     Amy Waterman, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/42/36517/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36517/contributors\">",
"     Jonathan M Silver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/42/36517/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36517/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/42/36517/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 30, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of end-stage organ failure combined with the realization that life may no longer be possible without medical intervention can lead to depression, anxiety, noncompliance with diet or medication, and sexual dysfunction in the transplant patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/1\">",
"     1",
"    </a>",
"    ]. The administration of immunosuppressive drugs, such as glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , has also been implicated in causing psychiatric disturbances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]; these include euphoria, delirium, generalized anxiety disorder, and hallucinosis.",
"   </p>",
"   <p>",
"    These disorders frequently require treatment with psychopharmacologic agents. However, their administration may be hazardous because of adverse effects as well as specific interactions with immunosuppressive drugs.",
"   </p>",
"   <p>",
"    This topic review will discuss some of the more common psychiatric disturbances that develop in transplant recipients with specific attention to their impact upon pharmacologic management and prognosis. Discussions related to psychotherapy are presented separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PSYCHOLOGICAL IMPACT OF TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The altruistic act of kidney donation appears to confer psychologic benefit to the donor. In a study of donors followed after a period of 5 to 10 years, the majority of individuals, independent of the outcome of the procedure, expressed positive feelings towards having donated a kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/2\">",
"     2",
"    </a>",
"    ]. However, in another survey, donating was perceived to have had a negative impact upon the health and finances of 15 and 23 percent of responding donors, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/3\">",
"     3",
"    </a>",
"    ]. Despite this perception, donors of kidneys live longer than others, due most probably to the screening process, which only permits healthy persons to be accepted for living kidney donation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the graft recipient, transplantation means more than an operation; it requires a certain degree of personal strength and adequate coping skills. In a study of heart transplant recipients, patients were grouped according to their response to a psychological survey [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients in group 1 denied thinking about the donor",
"     </li>",
"     <li>",
"      Patients in group 2 were partial deniers who were aware that they avoided thinking about the donor",
"     </li>",
"     <li>",
"      Patients in group 3 accepted the death of the donor as reality and also reported having more or less close connections with the donor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eighty two percent of the patients interviewed accepted the donor heart immediately as their own, whereas the remaining 18 percent avoided talking and thinking about the graft and donor. Thus, transplant recipients use different defense mechanisms concerning their transplanted organ to help them cope with their medical condition.",
"   </p>",
"   <p>",
"    Kidney recipients also have particular difficulty asking",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    involving a possible living donor. Patients do not pursue living donation in part because of concerns involving and possibly risking the health of a living donor, pain related to the donor surgery, the possibility of kidney rejection, and an inability to ask someone to be a living donor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;End-stage renal disease and transplantation are associated with depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/8\">",
"     8",
"    </a>",
"    ], which impacts adversely upon compliance and may be associated with decreased longevity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 209 consecutive primary renal allograft recipients, suicide accounted for 15 percent of deaths at 2.5 to 7.5 years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, the crude suicide rate in kidney transplant recipients from 1995 to 2001 was 24 per 100,000 patient-years, a finding that was 84 percent higher than the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/13\">",
"       13",
"      </a>",
"      ]. In multivariate models, age greater than 75 years, male gender, white or Asian race, geographic region, alcohol or drug dependence, and recent hospitalization with mental illness were significant independent predictors of death as a result of suicide.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the renal transplant population, depression occurs early after transplantation and is also associated with both acute and chronic rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/14\">",
"     14",
"    </a>",
"    ]. In one study, for example, patients with failed renal allografts were significantly more depressed, perceived less benefit from the treatment regimen, and had less confidence in their care providers than recipients of successful grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depression is also common in recipients of other organ transplants. Among heart transplant patients, for example, the incidence of depression was as high as 17 percent in the first posttransplant year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific factors that increase a heart transplant recipient's risk for depression and anxiety-related disorders include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pretransplant psychiatric history",
"     </li>",
"     <li>",
"      Poor social support",
"     </li>",
"     <li>",
"      The use of avoidance coping strategies for managing health problems",
"     </li>",
"     <li>",
"      Low self-esteem",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors that may lead to depression include the disfiguring effects of immunosuppressive medication, such as high-dose glucocorticoid therapy, and antihypertensive treatment with beta blockers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Drug treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously, therapeutic options for depression were hampered by the side effects associated with traditional agents. By comparison, newer antidepressant medications are more effective and safer in both the general population and medically ill patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]; however, there is little published data concerning their use in allograft recipients.",
"   </p>",
"   <p>",
"    This diverse group of compounds possesses distinct pharmacokinetic properties which are unrelated to either the",
"    <span class=\"nowrap\">",
"     tricyclic/tetracyclic",
"    </span>",
"    antidepressants or the monoamine oxidase inhibitors. These newer agents include selective serotonin reuptake inhibitors (SSRIs), such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    . Agents with serotonin reuptake activity that also prevent the uptake of other neurotransmitters (such as norepinephrine and dopamine) include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    One problem associated with the use of these agents may be drug interactions resulting in elevated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    levels due to alterations in the cytochrome CYP3A4 isoenzyme system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it would be an oversimplification to suggest that a drug is metabolized by only one specific enzyme.",
"   </p>",
"   <p>",
"    Caution therefore dictates that levels of affected drugs should be carefully monitored in any transplant patient who requires treatment for major affective disorders. Appropriate dosage adjustments should be performed as necessary to circumvent toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NONCOMPLIANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncompliance with diet and medication is a significant problem among some transplant recipients. This is due to numerous causes, including psychiatric disturbances, adverse effects of medications, lack of knowledge concerning the need for medications, and financial concerns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/19\">",
"     19",
"    </a>",
"    ]. This problem is particularly prevalent in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noncompliance is one of the more important risk factors for acute rejection and graft loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/21-26\">",
"     21-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the risk of acute graft rejection was 4.2 times greater among recipients who were not compliant with medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although the exact risk is difficult to assess, the odds of allograft failure may be seven-fold higher among noncompliant versus compliant patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Certain subgroups of transplant recipients have an enhanced risk of noncompliance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/9,19,27-30\">",
"     9,19,27-30",
"    </a>",
"    ]. One large study attempted to identify such risk factors in over 1400 patients who answered a questionnaire concerning whether they had missed one or more doses of immunosuppressive medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/27\">",
"     27",
"    </a>",
"    ]. Multivariate analysis found that noncompliance was significantly associated with white collar occupations and a longer period of time elapsed since the transplantation, while compliance was most commonly observed among older patients and those who think that immunosuppressive drugs are highly important and exist in the body for only a short time.",
"   </p>",
"   <p>",
"    An overview of the literature reported that certain patient characteristics were closely linked to noncompliance among solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Younger and older age, and non-married",
"     </li>",
"     <li>",
"      Anxious and individuals prone to denial, as well as those with severe personality disorders or who are mentally retarded",
"     </li>",
"     <li>",
"      History of substance abuse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional factors underlying compliance include the particular transplant center and dosing frequencies of immunosuppressive medications, with higher dosing frequencies resulting in decreased adherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retransplantation among patients with allograft loss due to noncompliance can be difficult to justify due to concerns of repeat noncompliance resulting in the loss of the second allograft. However, if properly rescreened, there is some evidence that retransplantation among such patients can be successful. In a single center retrospective study, the outcomes of patients who lost their initial allografts to noncompliance and underwent retransplantation after a thorough evaluation were compared to a control group of retransplant patients who did not lose their initial grafts to noncompliance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36517/abstract/32\">",
"     32",
"    </a>",
"    ]. At eight years, both groups had similar allograft and patient survival rates as well as incidence of chronic rejection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/36/26179?source=see_link\">",
"       \"Patient information: Heart transplantation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10376684\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although follow-up of kidney donors shows that the majority of individuals express positive feelings about having donated a kidney, kidney recipients have difficulty asking a possible living donor to donate a kidney because of concerns about risking the health of a living donor, pain related to the donor surgery, and the possibility of kidney rejection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Psychological impact of transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      End-stage renal disease and transplantation are associated with depression, which decreases adherence to treatment and may be associated with decreased longevity. Depression occurs early after transplantation and is associated with both acute and chronic rejection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depression is also common in recipients of other organ transplants. As an example, the incidence of depression among heart transplant patients is 17 percent in the first posttransplant year. Risk factors that increase a heart transplant recipient's risk for depression and anxiety disorders include pretransplant psychiatric history, poor social support, using avoidance coping strategies for managing health problems, and poor self-esteem. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Selective serotonin reuptake inhibitors (SSRIs) are often used to treat depression, but may interact with and increase",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      serum concentrations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Drug treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transplant recipients may not adhere to their prescribed diet and medications, which may lead to acute rejection and graft loss. Risk factors for poor adherence include psychiatric problems, adverse effects of medications, higher dosing frequency of medications, lack of knowledge concerning the need for medications, financial concerns, white collar occupations, and a longer period of time elapsed since the transplantation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Noncompliance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We encourage you to print or e-mail the patient information topic on heart transplantation. (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/36/26179?source=see_link\">",
"       \"Patient information: Heart transplantation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/1\">",
"      Stewart RS. Psychiatric issues in renal dialysis and transplantation. Hosp Community Psychiatry 1983; 34:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/2\">",
"      Sharma VK, Enoch MD. Psychological sequelae of kidney donation. A 5-10 year follow up study. Acta Psychiatr Scand 1987; 75:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/3\">",
"      Schover LR, Streem SB, Boparai N, et al. The psychosocial impact of donating a kidney: long-term follow-up from a urology based center. J Urol 1997; 157:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/4\">",
"      Fehrman-Ekholm I, Elinder CG, Stenbeck M, et al. Kidney donors live longer. Transplantation 1997; 64:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/5\">",
"      Bunzel B, Wollenek G, Grundb&ouml;ck A. Living with a donor heart: feelings and attitudes of patients toward the donor and the donor organ. J Heart Lung Transplant 1992; 11:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/6\">",
"      Waterman AD, Stanley SL, Covelli T, et al. Living donation decision making: recipients' concerns and educational needs. Prog Transplant 2006; 16:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/7\">",
"      Pradel FG, Limcangco MR, Mullins CD, Bartlett ST. Patients' attitudes about living donor transplantation and living donor nephrectomy. Am J Kidney Dis 2003; 41:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/8\">",
"      McCabe MS, Corry RJ. Psychiatric illness and human renal transplantation. J Clin Psychiatry 1978; 39:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/9\">",
"      Kiley DJ, Lam CS, Pollak R. A study of treatment compliance following kidney transplantation. Transplantation 1993; 55:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/10\">",
"      Devins GM, Beanlands H, Mandin H, Paul LC. Psychosocial impact of illness intrusiveness moderated by self-concept and age in end-stage renal disease. Health Psychol 1997; 16:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/11\">",
"      Dobbels F, Skeans MA, Snyder JJ, et al. Depressive disorder in renal transplantation: an analysis of Medicare claims. Am J Kidney Dis 2008; 51:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/12\">",
"      Washer, GF, Schroter, GP, Starzl, TE, Weil, R. Causes of death after kidney transplantation. JAMA 1983; 250:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/13\">",
"      Kurella M, Kimmel PL, Young BS, Chertow GM. Suicide in the United States end-stage renal disease program. J Am Soc Nephrol 2005; 16:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/14\">",
"      Hilbrands LB, Hoitsma AJ, Koene RA. The effect of immunosuppressive drugs on quality of life after renal transplantation. Transplantation 1995; 59:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/15\">",
"      Dew MA, Roth LH, Schulberg HC, et al. Prevalence and predictors of depression and anxiety-related disorders during the year after heart transplantation. Gen Hosp Psychiatry 1996; 18:48S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/16\">",
"      Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med 1994; 97:24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/17\">",
"      Stoudemire A. New antidepressant drugs and the treatment of depression in the medically ill patient. Psychiatr Clin North Am 1996; 19:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/18\">",
"      DeVane CL. Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med 1994; 97:13S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/19\">",
"      Butler JA, Peveler RC, Roderick P, et al. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. Nephrol Dial Transplant 2004; 19:3144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/20\">",
"      Rosenthal JT, Danovitch G, Ettenger RB, Wilkinson A. Kidney transplantation at UCLA. Clin Transpl 1990; :255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/21\">",
"      Smith AY, Van Buren CT, Lewis RM, et al. Factors determining renal transplant outcome at the University of Texas at Houston. Clin Transpl 1987; :155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/22\">",
"      Burke G, Esquenazi V, Gharagozloo H, et al. Long-term results of kidney transplantation at the University of Miami. Clin Transpl 1989; :215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/23\">",
"      Matas AJ, Humar A, Gillingham KJ, et al. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int 2002; 62:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/24\">",
"      Butler JA, Roderick P, Mullee M, et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004; 77:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/25\">",
"      Vlaminck H, Maes B, Evers G, et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant 2004; 4:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/26\">",
"      Dew MA, Kormos RL, Roth LH, et al. Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation. J Heart Lung Transplant 1999; 18:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/27\">",
"      Greenstein S, Siegal B. Compliance and noncompliance in patients with a functioning renal transplant: a multicenter study. Transplantation 1998; 66:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/28\">",
"      Abbott KC, Agodoa LY, O'Malley PG. Hospitalized psychoses after renal transplantation in the United States: incidence, risk factors, and prognosis. J Am Soc Nephrol 2003; 14:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/29\">",
"      Shaw RJ, Palmer L, Blasey C, Sarwal M. A typology of non-adherence in pediatric renal transplant recipients. Pediatr Transplant 2003; 7:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/30\">",
"      Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005; 16:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/31\">",
"      Bunzel B, Laederach-Hofmann K. Solid organ transplantation: are there predictors for posttransplant noncompliance? A literature overview. Transplantation 2000; 70:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36517/abstract/32\">",
"      Dunn TB, Browne BJ, Gillingham KJ, et al. Selective retransplant after graft loss to nonadherence: success with a second chance. Am J Transplant 2009; 9:1337.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4850 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-24EF02F2C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_42_36517=[""].join("\n");
var outline_f35_42_36517=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10376684\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PSYCHOLOGICAL IMPACT OF TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Drug treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NONCOMPLIANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10376684\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/36/26179?source=related_link\">",
"      Patient information: Heart transplantation (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_42_36518="Systemic lupus erythematosus and pregnancy";
var content_f35_42_36518=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Systemic lupus erythematosus and pregnancy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/42/36518/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36518/contributors\" id=\"au5724\">",
"       Peter H Schur, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36518/contributors\" id=\"au7370\">",
"       Bonnie L Bermas, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/42/36518/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36518/contributors\" id=\"se862\">",
"       David S Pisetsky, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/42/36518/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36518/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/42/36518?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SYSTEMIC LUPUS ERYTHEMATOSUS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that can affect various organs of the body. Women with systemic lupus erythematosus have no increased risk of infertility from the disease itself. However, prior treatment with cyclophosphamide can increase the risk of infertility. Women with lupus are at risk for various complications of pregnancy, and those with antiphospholipid antibodies may have an increased risk of miscarriage. The outcome for both mother and child is best when systemic lupus erythematosus has been under good control for at least six months before pregnancy and when the kidney disease is in remission.",
"    </p>",
"    <p>",
"     This topic review discusses preparing for and care of systemic lupus erythematosus during pregnancy. Other topics about lupus are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=see_link\">",
"      \"Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SYSTEMIC LUPUS ERYTHEMATOSUS AND PREGNANCY",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of systemic lupus erythematosus has become more successful over the past few decades, making pregnancy a viable option for most women. It is not clear if there is an increased risk of a flare of systemic lupus erythematosus during pregnancy. Currently, between 7 and 33 percent of women who have been in remission for at least six months have a flare during pregnancy; this rate is comparable to the number of women who have flares and are not pregnant. In contrast, more than 60 percent of women with active systemic lupus erythematosus at the time of conception will have a flare during pregnancy. Women undergoing in vitro fertilization may also have an increased risk of a disease flare [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/42/36518/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/45/39641?source=see_link\">",
"      \"Pregnancy in women with systemic lupus erythematosus\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Pregnancy complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with systemic lupus erythematosus have an increased risk of pregnancy complications. These potential complications may include high blood pressure, preeclampsia, preterm delivery, unplanned Cesarean section, excessive bleeding after delivery, or blood clots in the leg or lung. There are also increased risks to infants of women with systemic lupus erythematosus, including low birth weight, fetal loss, and prematurity.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h3\">",
"      Preeclampsia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Preeclampsia is the medical term for a pregnancy complication that causes high blood pressure in the mother after 24 weeks of pregnancy. Another name for preeclampsia is toxemia. Preeclampsia occurs in approximately 13 percent of women with SLE. It may occur even more frequently among women with kidney disease, antiphospholipid antibodies (aPL), diabetes mellitus, or prior episode of preeclampsia (66 percent in one study) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/42/36518/abstract/3\">",
"      3",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     The only cure for preeclampsia is for the woman to deliver her infant. Delivery may be delayed in some women with preeclampsia who are less than 34 weeks pregnant in order to give treatment with certain steroids that speed fetal lung development. The steroids are given in two doses 24 hours apart. This treatment significantly reduces the infant's risk of lung complications related to prematurity. However, delivery would not be delayed if the mother's or infant's life is in danger. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/52/35650?source=see_link\">",
"      \"Patient information: Preterm labor (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Fetal loss",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fetal loss is defined as the death of a fetus at 10 or more weeks of pregnancy. The risk of fetal loss is increased in women with high blood pressure, active lupus, lupus nephritis, and those with low complement levels, elevated levels of anti-DNA antibodies, antiphospholipid antibodies (including anticardiolipin antibodies and lupus anticoagulants), or a low platelet count. In one center, approximately 17 percent of women with SLE had a fetal loss [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/42/36518/abstract/4\">",
"      4",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     All pregnant women with systemic lupus erythematosus should be tested for the presence of antiphospholipid antibodies (eg, lupus anticoagulants and anticardiolipin antibodies). Women with persistent, medium or high titers of these antibodies may be at increased risk of fetal loss or other complications.",
"    </p>",
"    <p>",
"     Women with a history of antiphospholipid antibodies and prior pregnancy losses may be treated during pregnancy with low dose aspirin, an anticoagulant, a combination of both, or no medication. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16642?source=see_link\">",
"      \"Patient information: The antiphospholipid syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Preterm delivery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients with systemic lupus erythematosus have an increased risk of preterm delivery. Preterm delivery is defined as delivery before 37 weeks of pregnancy. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/52/35650?source=see_link\">",
"      \"Patient information: Preterm labor (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The risk of delivering before term is increased in women with more severe systemic lupus erythematosus, those who require higher doses of glucocorticoids (eg, steroids) during pregnancy, women on certain immunosuppressive medications such as azathioprine and cyclosporine, and in women with other pregnancy complications. Careful management of systemic lupus erythematosus during pregnancy can help to decrease the risk of preterm delivery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Low birth weight infant",
"     </span>",
"     &nbsp;&mdash;&nbsp;Having systemic lupus erythematosus can increase the risk of a low birth weight baby, especially if the woman requires glucocorticoids (steroids), has kidney complications, high blood pressure, antiphospholipid antibodies, preeclampsia, or experiences premature rupture of membranes (when the water breaks before contractions have begun).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Kidney disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who have damaged organs before pregnancy may have a higher risk of pregnancy complications, because pregnancy increases the workload on organs throughout the body. This is particularly important in women with kidney disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Lupus nephritis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with active lupus nephritis at the time of pregnancy have an increased risk of fetal loss (up to 75 percent). Most women with lupus nephritis have worsening of their kidney function as a result of pregnancy. Women with preexisting high blood pressure, protein in the urine, or high levels of blood urea nitrogen",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     creatinine in their blood are at the highest risk for these complications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Pregnancy after kidney transplantation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with systemic lupus erythematosus who have received a kidney transplant have a slightly higher risk of miscarriage compared to women without systemic lupus erythematosus and a transplant, although approximately 77 percent of women go on to deliver a live infant. One-half to two-thirds of these women has a preterm delivery or low birth weight baby, and there is an increased risk of developing high blood pressure or gestational diabetes during pregnancy or requiring a Cesarean delivery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Lupus and newborns",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Neonatal lupus",
"     </span>",
"     &nbsp;&mdash;&nbsp;Neonatal lupus is an autoimmune disease that occurs in about 2 percent of babies born to mothers with",
"     <span class=\"nowrap\">",
"      anti-Ro/SSA",
"     </span>",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     <span class=\"nowrap\">",
"      anti-La/SSB",
"     </span>",
"     antibodies. Neonatal lupus is caused by passage of the",
"     <span class=\"nowrap\">",
"      anti-Ro/SSA",
"     </span>",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     <span class=\"nowrap\">",
"      anti-La/SSB",
"     </span>",
"     antibodies from the mother's bloodstream across the placenta to the developing baby after about the 20th week of pregnancy. Many women who give birth to a baby with the neonatal lupus syndrome have",
"     <span class=\"nowrap\">",
"      anti-Ro/SSA",
"     </span>",
"     or",
"     <span class=\"nowrap\">",
"      anti-La/SSB",
"     </span>",
"     antibodies but do not have a diagnosis of lupus or another autoimmune disease at the time of their pregnancy.",
"    </p>",
"    <p>",
"     Signs of neonatal lupus include a red, raised rash on the scalp and around the eyes. The rash almost always resolves by six to eight months of age because the antibodies are cleared out of the infant's bloodstream; most (90 percent) of these infants do not develop lupus in later years.",
"    </p>",
"    <p>",
"     The most serious complication of neonatal lupus is complete heart block, which occurs in approximately 2 percent of newborns whose mothers have SSA (Ro) or SSB (La) antibodies. Heart block occurs when there is partial or complete blockage of electrical flow in the fetus' heart, causing an abnormally slow heart rate. Women with SSA (Ro) or SSB (La) antibodies often have regular ultrasound monitoring of the fetus' heart during pregnancy. The goal is to detect fetal heart block at an early stage so that the fetus can be monitored frequently to assure that the heart is functioning well, and to be able to prepare the fetus when born for a pacemaker if it is needed. There is presently no proven treatment for fetal heart block prior to birth.",
"    </p>",
"    <p>",
"     Ultrasound monitoring of the fetus' heart is generally started at 16 weeks of pregnancy and continued until the 26",
"     <sup>",
"      th",
"     </sup>",
"     week of pregnancy. The majority of infants who develop complete heart block in utero will require a pacemaker. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/16/20741?source=see_link\">",
"      \"Patient information: Pacemakers (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Some women with SSA (Ro) or SSB (La) antibodies who do not have a diagnosis of systemic lupus erythematosus will later develop an autoimmune disorder, usually lupus or Sj&ouml;gren's syndrome. If a mother gives birth to a baby with neonatal lupus, her risk of having a child with neonatal lupus in a subsequent pregnancy is about 17 percent. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=see_link\">",
"      \"Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/11/44212?source=see_link\">",
"      \"Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Birth defects and learning disabilities",
"     </span>",
"     &nbsp;&mdash;&nbsp;Systemic lupus erythematosus does not increase the risk of having a child with birth defects. It is uncertain whether learning disabilities are more frequent in children of women with lupus, as they have been found to be more frequent in one research study, but not in another [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/42/36518/abstract/5\">",
"      5",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      CARE BEFORE PREGNANCY",
"     </span>",
"    </p>",
"    <p>",
"     Women with systemic lupus erythematosus should discuss their desire to have a child with a rheumatologist and high-risk obstetrical provider before trying to become pregnant.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      General recommendations",
"     </span>",
"     &nbsp;&mdash;&nbsp;These recommendations apply to all women who are considering pregnancy, not just those with systemic lupus erythematosus.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       All women should take a nutritional supplement containing at least 400 mcg of folic acid (the amount in most multivitamins). Taking folic acid can reduce the risk of a specific birth defect, called a neural tube defect. Folic acid should be started before trying to conceive and continued until at least the end of the first trimester.",
"      </li>",
"      <li>",
"       Women should stop smoking and consuming alcohol or any recreational drugs (eg, marijuana) before trying to become pregnant.",
"      </li>",
"      <li>",
"       If a woman takes prescription or non-prescription medications, these should be reviewed with a healthcare provider who is knowledgeable in the care of pregnant women with lupus, such as an obstetrician, obstetric nurse practitioner or midwife. Some medications are safe during pregnancy while others are not. In some cases, an alternate medication can be substituted for an unsafe drug (see",
"       <a class=\"local\" href=\"#H24\">",
"        'Medications during pregnancy'",
"       </a>",
"       below).",
"      </li>",
"      <li>",
"       Caffeine intake should be limited to less than 200 mg per day while trying to become pregnant and during pregnancy. The table lists the caffeine content of several common beverages (",
"       <a class=\"graphic graphic_table graphicRef58574 \" href=\"mobipreview.htm?15/56/16268\">",
"        table 1",
"       </a>",
"       ). (See",
"       <a class=\"medical medical_review\" href=\"mobipreview.htm?19/35/20026?source=see_link\">",
"        \"The effects of caffeine on reproductive outcomes in women\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Blood testing for rubella (German measles), varicella (chicken pox), HIV, hepatitis B, and inherited genes (eg, cystic fibrosis) may be recommended.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Preparing for pregnancy with systemic lupus erythematosus",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Women with lupus nephritis are encouraged to delay pregnancy until their disease is inactive for at least six months [",
"       <a class=\"abstract\" href=\"mobipreview.htm?35/42/36518/abstract/6,7\">",
"        6,7",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       The use of glucocorticoids (steroids) along with other immunosuppressive medications, such as azathioprine and cyclosporine, may increase the risks of having a small infant or having preterm premature rupture of membranes (when the \"water breaks\" before 37 weeks of pregnancy). In addition, use of glucocorticoids (steroids) during the first trimester may increase the risk of cleft palate. Despite this, glucocorticoids (steroids) may need to be continued to manage the disease (see",
"       <a class=\"local\" href=\"#H24\">",
"        'Medications during pregnancy'",
"       </a>",
"       below). This decision is best made with an experienced rheumatologist",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       obstetrical care provider.",
"      </li>",
"      <li>",
"       Other medications can also cause birth defects and should generally be stopped at least three months before getting pregnant, as discussed in detail below (see",
"       <a class=\"local\" href=\"#H24\">",
"        'Medications during pregnancy'",
"       </a>",
"       below).",
"      </li>",
"      <li>",
"       Men who take methotrexate, mycophenolate mofetil, or cyclophosphamide should stop these medications for at least three months before trying to conceive. This three-month period is necessary to allow for the development of sperm that have not been exposed to these medications. Women who take these medications should wait at least one to three months after stopping these medications before trying to conceive.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Am I ready for pregnancy?",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is common for women with long-term medical problems to be worried about how their health will be affected by pregnancy and parenting.",
"    </p>",
"    <p>",
"     Women with systemic lupus erythematosus often have a flare of symptoms during pregnancy or shortly after delivery. It is sometimes difficult to distinguish between the common discomforts of pregnancy and the symptoms of lupus. Pregnancy discomforts that are similar to those of lupus include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Fatigue",
"      </li>",
"      <li>",
"       Swelling of the hands, feet, or ankles",
"      </li>",
"      <li>",
"       Joint pain, especially in the low back",
"      </li>",
"      <li>",
"       Shortness of breath",
"      </li>",
"      <li>",
"       Numbness or pain in one or both hands (caused by carpal tunnel syndrome of pregnancy)",
"      </li>",
"      <li>",
"       Skin changes (eg, darkening of facial skin)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     It is important to consider the changes that a newborn may bring, including interrupted sleep, fatigue, and for many women, additional stress. Close communication with an obstetric and rheumatology care provider and support from family and friends can help to ease the challenges of being pregnant and raising a child.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS DURING PREGNANCY",
"     </span>",
"    </p>",
"    <p>",
"     During pregnancy, women with systemic lupus erythematosus need regular monitoring of their disease, even if it has been stable, and many women will need treatment of active disease. Care of women with lupus is usually shared during pregnancy between a rheumatologist and high-risk obstetrician.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Care during pregnancy",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      The first visit",
"     </span>",
"     &nbsp;&mdash;&nbsp;As soon as pregnancy is detected, most clinicians recommend that the woman with systemic lupus erythematosus have a complete physical examination, including measurement of blood pressure, and blood testing. The blood tests are important to measure the current kidney function and to determine if antiphospholipid and",
"     <span class=\"nowrap\">",
"      anti-Ro/SSA",
"     </span>",
"     and",
"     <span class=\"nowrap\">",
"      anti-La/SSB",
"     </span>",
"     antibodies are present (see",
"     <a class=\"local\" href=\"#H5\">",
"      'Fetal loss'",
"     </a>",
"     above).",
"    </p>",
"    <p>",
"     Women with SLE with high levels of antiphospholipid antibodies who have had a prior pregnancy loss or preeclampsia may require treatment with an anticoagulant (eg, a low dose of aspirin",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     heparin) every day during pregnancy, depending upon their individual situation. This treatment helps to reduce the risk of blood clots and miscarriage.",
"    </p>",
"    <p>",
"     To monitor the fetus' growth during pregnancy, it is important to have an accurate date of conception. Women who do not remember the date of their last menstrual period or are unsure of when the baby was conceived should have an ultrasound examination to determine their due date. A due date that is calculated by ultrasound examination is most accurate when the examination is performed in the first trimester.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      At subsequent visits",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most women with systemic lupus erythematosus will be seen every two to four weeks until 28 weeks of pregnancy. At every visit, blood pressure and urine testing will be done. After 10 to 12 weeks of pregnancy, the fetus' heart rate will be measured. Women with",
"     <span class=\"nowrap\">",
"      anti-Ro/SSA",
"     </span>",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     <span class=\"nowrap\">",
"      anti-La/SSB",
"     </span>",
"     antibodies should have more frequent ultrasound monitoring of the fetus' heart (see",
"     <a class=\"local\" href=\"#H12\">",
"      'Neonatal lupus'",
"     </a>",
"     above).",
"    </p>",
"    <p>",
"     During the pregnancy, blood and urine testing is recommended to monitor the activity of systemic lupus erythematosus; the frequency of testing depends upon the individual patient. This usually includes measurement of the kidney function (glomerular filtration rate, urine",
"     <span class=\"nowrap\">",
"      protein/urine",
"     </span>",
"     creatinine ratio), anticardiolipin antibodies (if testing previously negative), testing of complement levels (CH50 or C3 and C4), and testing for anti-dsDNA antibodies.",
"    </p>",
"    <p>",
"     An ultrasound is usually recommended between 18 and 20 weeks of pregnancy to ensure that the fetus is growing and developing normally. Regular ultrasounds may be recommended through the remainder of the pregnancy to monitor the fetus' growth.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      After 28 weeks of pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;After 28 weeks of pregnancy, most women will be seen every one or two weeks. At these visits, the woman's blood pressure and urine will be monitored. Fetal monitoring may include a biophysical profile and non-stress test.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Biophysical profile &mdash; A biophysical profile (BPP) score is calculated to assess the fetus' health. It consists of five components, nonstress testing and ultrasound measurement of four fetal parameters: fetal body movements, breathing movements, fetal tone (flexion and extension of an arm, leg, or the spine), and measurement of the amniotic fluid levels. Each component is scored individually, with two points given for a normal result and zero points given for an abnormal result. The maximum possible score is 10.",
"       <br/>",
"       <br/>",
"       The amniotic fluid level is an important variable in the BPP because a low volume (called oligohydramnios) may increase the risk of umbilical cord compression and may be a sign of changes in the blood flow between the baby and mother. Amniotic fluid levels can become reduced within a short time period, even a few days.",
"      </li>",
"      <li>",
"       Nonstress testing &mdash; Nonstress testing is done by monitoring the baby's heart rate with a small device that is placed on the mother's abdomen. The device uses sound waves (ultrasound) to measure the baby's heart rate over time, usually for 20 to 30 minutes. Normally, the baby's baseline heart rate should be between 110 and 160 beats per minute and should increase above its baseline by at least 15 beats per minute for 15 seconds when the baby moves.",
"       <br/>",
"       <br/>",
"       The test is considered reassuring (called \"reactive\") if two or more fetal heart rate increases are seen within a 20 minute period. Further testing may be needed if these increases are not observed after monitoring for 40 minutes.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Delivery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who have required glucocorticoids (steroids) to control systemic lupus erythematosus during pregnancy need an increased dose, called a stress dose, during delivery. The increased dose helps the body respond normally to the physical stresses of childbirth.",
"    </p>",
"    <p>",
"     Most women with lupus are able to have an uncomplicated vaginal delivery. However, since there is an increased risk of premature rupture of the membranes, a small infant, and preeclampsia, women with lupus are advised to deliver in a hospital with a neonatal intensive care unit (NICU).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Medications during pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medications that are typically used to treat systemic lupus erythematosus may be divided into three categories: those that should be avoided during pregnancy, those that may have a small risk of harm to the fetus, and those that are probably safe.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h3\">",
"      Drugs to avoid",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medications with a high risk of causing birth defects should be",
"     <strong>",
"      avoided",
"     </strong>",
"     , including:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Mycophenolate mofetil",
"      </li>",
"      <li>",
"       Cyclophosphamide",
"      </li>",
"      <li>",
"       Methotrexate &mdash; Men and women who take methotrexate should stop it at least three months before trying to conceive. This three-month period is necessary to completely eliminate methotrexate from the body.",
"      </li>",
"      <li>",
"       Biologic medications &mdash; There are insufficient data about the safety of biologic agents in pregnancy. Biologic agents include etanercept, infliximab, adalimumab, anakinra, rituximab, and abatacept. Until more data are available, biologic medications should be avoided in pregnancy whenever possible.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If you take one of these medications while pregnant, talk to your doctor immediately.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h3\">",
"      Drugs with a small risk of harm",
"     </span>",
"     &nbsp;&mdash;&nbsp;NSAIDs, aspirin, prednisone, and azathioprine have a small risk of causing fetal harm; their use may be acceptable if necessary to control systemic lupus erythematosus during pregnancy.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       NSAIDs &mdash; Nonsteroidal antiinflammatory drugs (NSAIDs), such as ibuprofen (Advil&reg;, Motrin&reg;) and naproxen (Aleve&reg;) cross the placenta and can potentially cause harm to the fetus, especially during the third trimester (after 27 weeks of pregnancy). Women who have trouble becoming pregnant should avoid NSAIDs while trying to become pregnant because NSAIDs may interfere with embryo implantation.",
"       <br/>",
"       <br/>",
"       A safe alternative to NSAIDs for treatment of pain during pregnancy is acetaminophen (Tylenol&reg;). A safe dose of acetaminophen is two 325 mg tablets or capsules every four to six hours as needed. No more than 4000 mg of acetaminophen should be taken per day.",
"      </li>",
"      <li>",
"       Aspirin &mdash; Aspirin crosses the placenta. Low dose aspirin (less than 160",
"       <span class=\"nowrap\">",
"        mg/day)",
"       </span>",
"       has been used safely in the treatment of pregnant women with the antiphospholipid syndrome. However, increased rates of stillbirth have been reported with aspirin doses greater than 325",
"       <span class=\"nowrap\">",
"        mg/day.",
"       </span>",
"       Women should speak with their obstetric or rheumatology care provider about the risks and benefits of taking aspirin during pregnancy.",
"      </li>",
"      <li>",
"       Prednisone &mdash; If systemic lupus erythematosus flares during pregnancy, most experts recommend starting prednisone at the lowest dose possible. Prednisone crosses the placenta but appears in only small amounts in the infant's blood.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Glucocorticoid (steroids) medications (including prednisone) increase the risk that the infant will have a cleft lip",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       palate (when the lip",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       roof of the mouth are not fused in the middle).",
"      </li>",
"      <li>",
"       Glucocorticoids (steroids) may increase the risk of premature rupture of membranes (breaking the water early) and growth restriction (having a lower birth weight infant).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Azathioprine &mdash; There are conflicting data about the safety of azathioprine (AZA) during pregnancy [",
"       <a class=\"abstract\" href=\"mobipreview.htm?35/42/36518/abstract/8\">",
"        8",
"       </a>",
"       ], although much of the research that has been done in patients who have received organ transplants suggests that this medication does not increase the risk of fetal anomalies. For this reason, use of azathioprine is generally limited to women with severe disease who have not responded to other treatments. Men who take AZA should probably discontinue the medication three months before trying to conceive.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h3\">",
"      Drugs that are safe during pregnancy",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Antimalarial drugs &mdash; There is no evidence that antimalarial drugs such as hydroxychloroquine increase the risk of miscarriage or birth defects at normal doses. These medications are safe to use while breastfeeding. Women with SLE should be encouraged to continue their antimalarial drugs during pregnancy as it may decrease the risk of flares, help manage antiphospholipid syndrome and possibly decrease the risk of neonatal lupus.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H28\">",
"     <span class=\"h1\">",
"      SYSTEMIC LUPUS ERYTHEMATOSUS AFTER DELIVERY",
"     </span>",
"    </p>",
"    <p>",
"     Some women will experience a flare of SLE after delivery. Women who have had active disease in early pregnancy and those with significant organ damage are at greater risk of disease flares. Thus, regular visits for SLE monitoring are recommended postpartum.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Breastfeeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Breastfeeding is recommended for most women with systemic lupus erythematosus. There is no increased risk of neonatal lupus related to breastfeeding. However, some medications enter breast milk:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       NSAIDs can be used, but aspirin should be avoided.",
"      </li>",
"      <li>",
"       Prednisone can be taken in low doses under 20",
"       <span class=\"nowrap\">",
"        mg/day.",
"       </span>",
"      </li>",
"      <li>",
"       Antimalarials, warfarin, and heparin appear to be safe while breastfeeding.",
"      </li>",
"      <li>",
"       Azathioprine, cyclosporine, cyclophosphamide, methotrexate, and chlorambucil should be avoided during breastfeeding.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The quality of information regarding medication safety in breastfeeding varies. A reliable source of up-to-date information is LactMed, which is available from the National Library of Medicine (",
"     <a class=\"external\" href=\"file://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT\">",
"      file://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Several topic reviews about breastfeeding are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/63/34805?source=see_link\">",
"      \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/61/37845?source=see_link\">",
"      \"Patient information: Common breastfeeding problems (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/25/17813?source=see_link\">",
"      \"Patient information: Breast pumps (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/54/31588?source=see_link\">",
"      \"Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h2\">",
"      Birth control",
"     </span>",
"     &nbsp;&mdash;&nbsp;Within a few weeks after delivering an infant, it is important to start thinking about birth control. A number of birth control options are available.",
"    </p>",
"    <p>",
"     Birth control methods that contain a low dose of estrogen are safe for most women with SLE. Low-dose formulations include those with 35 mcg or less of ethinyl estradiol; well designed studies found no evidence of an increased risk of SLE flares in women with mild disease who took a low-dose birth control pill [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/42/36518/abstract/9\">",
"      9",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Certain women with systemic lupus erythematosus probably should not use even low dose estrogen-containing birth control methods, including those with one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Migraine headaches",
"      </li>",
"      <li>",
"       Raynaud phenomenon",
"      </li>",
"      <li>",
"       A past history of a blood clot in a vein",
"      </li>",
"      <li>",
"       Presence of antiphospholipid antibodies",
"      </li>",
"      <li>",
"       Kidney disease and active SLE",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     An intrauterine device (IUD) is an effective and safe form of birth control for most women. &nbsp;However, women who are at high risk for infection and are taking immunosuppressive agents should avoid using an IUD. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/16/4355?source=see_link\">",
"      \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .) A full discussion of all birth control options is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=see_link\">",
"      \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H31\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7378865\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7378872\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/30/7651?source=see_link\">",
"      Patient information: Lupus and pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/42/22178?source=see_link\">",
"      Patient information: Lupus (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/49/36626?source=see_link\">",
"      Patient information: Lupus and kidney disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7378897\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"     <br/>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=see_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/52/35650?source=see_link\">",
"      Patient information: Preterm labor (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16642?source=see_link\">",
"      Patient information: The antiphospholipid syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/11/44212?source=see_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/63/34805?source=see_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/61/37845?source=see_link\">",
"      Patient information: Common breastfeeding problems (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/25/17813?source=see_link\">",
"      Patient information: Breast pumps (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/54/31588?source=see_link\">",
"      Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/16/4355?source=see_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=see_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7378911\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3338?source=see_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=see_link\">",
"      Neonatal lupus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41464?source=see_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41578?source=see_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/45/39641?source=see_link\">",
"      Pregnancy in women with systemic lupus erythematosus",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Disease",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niams.nih.gov/\">",
"      www.niams.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American College of Rheumatology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.rheumatology.org/\">",
"      www.rheumatology.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Lupus Foundation of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lupus.org/\">",
"      www.lupus.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/42/36518/abstract/1-12\">",
"      1-12",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 8, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/42/36518?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36518/abstract/1\">",
"      Guballa N, Sammaritano L, Schwartzman S, et al. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 2000; 43:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36518/abstract/2\">",
"      Erkan D, Sammaritano L. New insights into pregnancy-related complications in systemic lupus erythematosus. Curr Rheumatol Rep 2003; 5:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36518/abstract/3\">",
"      Repke JT. Hypertensive disorders of pregnancy. Differentiating preeclampsia from active systemic lupus erythematosus. J Reprod Med 1998; 43:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36518/abstract/4\">",
"      Clark CA, Spitzer KA, Laskin CA. Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. J Rheumatol 2005; 32:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36518/abstract/5\">",
"      Ross G, Sammaritano L, Nass R, Lockshin M. Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Pediatr Adolesc Med 2003; 157:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36518/abstract/6\">",
"      Hayslett JP. Maternal and fetal complications in pregnant women with systemic lupus erythematosus. Am J Kidney Dis 1991; 17:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36518/abstract/7\">",
"      Bobrie G, Liote F, Houillier P, et al. Pregnancy in lupus nephritis and related disorders. Am J Kidney Dis 1987; 9:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36518/abstract/8\">",
"      N&oslash;rg&aring;rd B, Pedersen L, Christensen LA, S&oslash;rensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36518/abstract/9\">",
"      Sammaritano LR. Therapy insight: guidelines for selection of contraception in women with rheumatic diseases. Nat Clin Pract Rheumatol 2007; 3:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36518/abstract/10\">",
"      Tandon A, Iba&ntilde;ez D, Gladman DD, Urowitz MB. The effect of pregnancy on lupus nephritis. Arthritis Rheum 2004; 50:3941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36518/abstract/11\">",
"      Chakravarty EF, Col&oacute;n I, Langen ES, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol 2005; 192:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36518/abstract/12\">",
"      Clowse ME, Magder LS, Witter F, Petri M. Early risk factors for pregnancy loss in lupus. Obstet Gynecol 2006; 107:293.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f35_42_36518=[""].join("\n");
var outline_f35_42_36518=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SYSTEMIC LUPUS ERYTHEMATOSUS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SYSTEMIC LUPUS ERYTHEMATOSUS AND PREGNANCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           CARE BEFORE PREGNANCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS DURING PREGNANCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H28\">",
"           SYSTEMIC LUPUS ERYTHEMATOSUS AFTER DELIVERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H31\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/56/16268\" title=\"table 1\">",
"           Caffeine source amount PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f35_42_36519="Posthumous assisted reproduction";
var content_f35_42_36519=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Posthumous assisted reproduction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/42/36519/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36519/contributors\">",
"     Shane T Lipskind, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36519/contributors\">",
"     Elizabeth S Ginsburg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/42/36519/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36519/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/42/36519/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36519/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/42/36519/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19187297\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assisted reproductive technologies (ART), including in vitro fertilization (IVF) and cryopreservation of gametes (eggs and sperm) and embryos, are intended to address an innate human drive - the desire to reproduce. These procedures, which enable human reproduction across a myriad of medical and social situations, also make it possible to create life using gametes or embryos from a genetic parent who is no longer living.",
"   </p>",
"   <p>",
"    Posthumous assisted reproduction (PAR) is the process by which ART is used to establish pregnancy and produce genetic offspring after the death of the parent. This distinctly modern phenomenon raises numerous challenges for patients, their families and clinicians, as well as society at large.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19874881\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmortem conception by artificial insemination using cryopreserved sperm has been available since the 1950s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. One of its first uses was to offer men in high risk professions (eg, astronauts, soldiers) an option for fathering children in the event of injury or death. Postmortem sperm retrieval was first reported in 1980. Development of now routine techniques, such as oocyte retrieval, in vitro fertilization (IVF), and cryopreserved embryo transfer, expanded the possibilities of parenting after death for both men and women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19873899\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have assessed the utilization of posthumous assisted reproduction (PAR), and an accurate number of births that have resulted from PAR is not known. Several factors likely contribute to the lack of information. First, PAR probably accounts for a relatively small proportion of all assisted reproductive technology (ART) procedures. In addition, individuals who request gamete or embryo banking for PAR may never actually use them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Lastly, both patients and clinicians may be reluctant to report these pregnancies and births in the medical literature to avoid drawing media attention to this controversial practice. Nevertheless, it seems inevitable that PAR will gain more public awareness and acceptance as utilization of ART and fertility preservation services increase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19187311\">",
"    <span class=\"h1\">",
"     USE OF POSTHUMOUS REPRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posthumous reproduction is intended to fulfill a couple&rsquo;s desire to reproduce. Since it is considered within the context of the untimely death or imminent demise of at least one genetic parent, it is assumed that at least one invested party, including the intended social parent(s), desires children through posthumous reproduction and that the requisite gametes or embryos are available.",
"   </p>",
"   <p>",
"    The motivation for posthumous reproduction may be shared by both the deceased and surviving parties or may originate from surviving parties alone. Survivors may wish to use gametes or embryos that were previously stored or request gamete retrieval from a deceased or terminally ill loved one. In addition, third party recipients might receive gametes or embryos from deceased genetic parents through anonymous donation.",
"   </p>",
"   <p>",
"    The following table outlines multiple scenarios in which requests for posthumous reproduction may arise (",
"    <a class=\"graphic graphic_table graphicRef83086 \" href=\"mobipreview.htm?9/17/9501\">",
"     table 1",
"    </a>",
"    ). Authorities disagree upon when posthumous reproduction is justified in these various situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/6\">",
"     6",
"    </a>",
"    ]. In the absence of clear medical, ethical, or legal contraindications, clinicians must ultimately decide if a specific request for posthumous reproduction warrants consideration (see",
"    <a class=\"local\" href=\"#H19187339\">",
"     'Consent'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19187318\">",
"    <span class=\"h1\">",
"     PROCEDURES FOR OBTAINING GAMETES AND EMBRYOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether intended for posthumous use or otherwise, the procedures used to obtain gametes and create embryos for assisted reproduction remain the same. Gametes are typically collected while the source parents are alive, but postmortem gamete retrieval is possible, when necessary. Strategies for procurement depend on the source and expected use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19187325\">",
"    <span class=\"h2\">",
"     Males",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods for obtaining sperm include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Masturbation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Electroejaculation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Aspiration of sperm from the epididymis or vas deferens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Epididymal biopsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Testicular sperm extraction (TESA) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      En bloc excision of the testes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Masturbation and electroejaculation are appropriate for retrieving sperm from neurologically intact men with normal semen production. Surgical techniques may be used to obtain sperm from men who cannot produce an adequate sample by ejaculation and may also be used to obtain sperm from critically ill or recently deceased men. Viable sperm can be retrieved from a corpse up to 36 hours after death. Live births have resulted from sperm retrieved postmortem, but limited experience suggests that earlier retrieval increases the probability of obtaining useable gametes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depending on the quantity and quality of sperm available, specimens may be used for insemination or in vitro fertilization (IVF) with or without intracytoplasmic sperm injection (ICSI). Although a single ejaculate from a healthy adult male can yield millions of viable sperm, IVF with ICSI is the most efficient fertilization technique and may be preferentially used when sperm supply is limited to what has already been retrieved or stored, as multiple attempts with IVF",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ICSI are possible from one cryopreserved sample.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19187332\">",
"    <span class=\"h2\">",
"     Females",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oocytes are most commonly obtained through controlled ovarian hyperstimulation and transvaginal ultrasound-guided oocyte aspiration. Embryos are created via IVF with or without ICSI. These procedures, as well as their success rates and outcomes, are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15546?source=see_link\">",
"     \"Intracytoplasmic sperm injection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/6/2154?source=see_link\">",
"     \"Pregnancy outcome after assisted reproductive technology\"",
"    </a>",
"    .) When the eggs or embryos from a deceased woman are to be used for posthumous reproduction, a properly consented recipient (gestational carrier) is required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15015?source=see_link\">",
"     \"Surrogate pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It may be technically feasible to recover viable oocytes from critically ill or recently deceased women without prior ovarian stimulation. In 2011, an Israeli court granted doctors permission to recover and freeze eggs from a 17-year-old woman who died in a car accident, but declined to permit their fertilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/8\">",
"     8",
"    </a>",
"    ]. A similar request to retrieve eggs from a comatose woman in the United States was rejected by the patient&rsquo;s medical team on ethical grounds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/9\">",
"     9",
"    </a>",
"    ]. Alternate techniques that might provide oocytes for assisted reproduction and posthumous conception when ovarian stimulation is not possible include unstimulated (&ldquo;natural cycle&rdquo;) IVF and surgical excision of whole ovaries or strips of ovarian tissue for either transplantation or in vitro maturation (IVM) of oocytes and subsequent IVF. The utility of these techniques in posthumous reproduction and in other areas of assisted reproduction remains to be determined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19874052\">",
"    <span class=\"h1\">",
"     CRYOPRESERVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to successfully cryopreserve gametes, embryos, and reproductive tissues for later use makes posthumous reproduction feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/10\">",
"     10",
"    </a>",
"    ] and allows time for mourning, deliberation of options, and resolution of legal issues. In addition, cryopreservation of surplus",
"    <span class=\"nowrap\">",
"     gametes/embryos",
"    </span>",
"    often permits multiple attempts at conception from a single gamete collection or in vitro fertilization (IVF) cycle.",
"   </p>",
"   <p>",
"    Thawed-cryopreserved specimens are capable of establishing successful pregnancies years after their initial storage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/11\">",
"     11",
"    </a>",
"    ]. Controlled thawing of frozen specimens allows for precise and convenient coordination of procedures, such as insemination, IVF, and embryo transfer, as appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102435926\">",
"    <span class=\"h2\">",
"     Sperm",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the male is the partner at risk, sperm are typically cryopreserved after the specimen is obtained. Depending on the quantity and quality of cryopreserved sperm available, the thawed specimens may be used for intrauterine insemination or IVF with or without intracytoplasmic sperm injection (ICSI) when pregnancy is desired. Although a single ejaculate from a healthy adult male can yield millions of viable sperm, IVF with ICSI is the most efficient fertilization technique and may be used preferentially when sperm supply is limited to samples already retrieved or stored, as multiple attempts with IVF",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ICSI are possible from one cryopreserved sample.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102435933\">",
"    <span class=\"h2\">",
"     Embryo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embryo cryopreservation is a proven clinical procedure with embryo survival estimated to be 60 to 80 percent after slow freezing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States, live birth rates after transfer of thawed embryos using non-donor oocytes from infertile women less than 35-years-old are approximately 38 percent with a mean of 1.9 embryos transferred. This compares favorably to the live birth rate of approximately 42 percent for fresh IVF cycles in similarly aged women receiving a mean of two embryos per transfer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102435940\">",
"    <span class=\"h2\">",
"     Oocyte",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although still regarded as investigational by the Society for Assisted Reproductive Technology (SART) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/11\">",
"     11",
"    </a>",
"    ], oocyte cryopreservation is emerging as a clinically useful technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/13\">",
"     13",
"    </a>",
"    ]. The number of live births from thawed-cryopreserved human oocytes is increasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. As oocyte cryopreservation promises to provide women with an opportunity to bank gametes for either fertility preservation or social reasons, we expect frozen eggs to be used in increasing numbers of posthumous reproduction scenarios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102435947\">",
"    <span class=\"h2\">",
"     Ovarian tissue and testicular tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryopreservation of ovarian and testicular tissue remains investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19187339\">",
"    <span class=\"h1\">",
"     CONSENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician&rsquo;s decision to fulfill the request for posthumous reproduction should depend on the presence or absence of informed consent from the deceased gamete provider, the relationship of the requester to the deceased, and the perceived balance of benefit versus harm. We consider perimortem gamete retrieval when the donor consented to the procedure or made",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    approval clearly known through a non-invested third party, such as their physician or attorney. Health care providers should speak to patients about their desires toward posthumous reproduction when discussing topics such as organ donation, advanced directives, family building or fertility preservation and document those wishes whenever possible. Written consent for posthumous use of gametes or embryos should be obtained before retrieval and storage. Advanced directives and living wills should be in place to ensure that the wishes of the deceased are followed and that children born as a result of posthumous reproduction have the right to inherit, if intended (see",
"    <a class=\"local\" href=\"#H19187381\">",
"     'Legal issues'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19874287\">",
"    <span class=\"h2\">",
"     Premeditated posthumous reproduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, the deceased has provided consent to use",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    gametes or embryos for postmortem conception. When the possibility of death is anticipated, individuals with chronic illnesses or soldiers entering combat situations may choose to cryopreserve gametes for future",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    posthumous use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/17\">",
"     17",
"    </a>",
"    ]. As long as the deceased delegates authority to use those gametes to a named individual, then the issues of autonomy and consent are satisfied.",
"   </p>",
"   <p>",
"    As part of standard procedure for in vitro fertilization (IVF), patients commonly sign an agreement regarding disposition of frozen embryos in the event that one or both of the genetic parents dies. When the agreement provides the surviving partner the right to use cryopreserved embryos posthumously, there is no question of consent or respect for autonomy. With increased use of assisted reproduction and an abundance of cryopreserved gametes and embryos, cases such as these are likely to become more frequent in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19874294\">",
"    <span class=\"h2\">",
"     Unplanned posthumous reproduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The more common situation for the majority of reproductive-aged individuals is that posthumous reproduction is not premeditated. In the absence of specific consent for the postmortem use of reproductive cells or tissues by the deceased gamete provider, the use of posthumous reproduction is more problematic. The key question is not whether the deceased wanted children while they were alive, but rather if they would have wanted a child to be born using",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    genetic material after",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/9,16\">",
"     9,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although some authorities propose that &ldquo;implied consent&rdquo; should be sufficient to honor a request for posthumous reproduction, an expressed desire to reproduce while alive does not constitute consent for posthumous reproduction and may fail to honor the reproductive autonomy of the deceased. This concept is well-illustrated by a study that surveyed 106 couples presenting for their initial infertility consultation and observed that 22 percent of these individuals, while highly motivated to conceive, would not permit posthumous reproduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, 25 percent of couples disagreed in their attitudes about posthumous reproduction and 25 percent of the participants inaccurately predicted their partner&rsquo;s preferences about it. Thus, acting in accordance with the wishes of the deceased may remain problematic, even when an intimate partner serves as the surrogate decision-maker.",
"   </p>",
"   <p>",
"    In addition to requests to use previously cryopreserved gametes or embryos, providers may also be asked to retrieve gametes from an incapacitated or recently deceased individual. In such scenarios, the ethical questions of posthumous reproduction are further complicated by the invasive nature of the procedures (eg, testicular biopsy, orchiectomy, egg retrieval, or oophorectomy) required for harvesting gametes from an individual who is unable to give informed consent. It is difficult to argue that gamete retrieval is a medically necessary procedure that confers direct benefits to the gamete provider. The requester, by nature, is invested in the process and may not be able to separate",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    own desires toward posthumous reproduction from the interests of the gamete provider [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/18\">",
"     18",
"    </a>",
"    ]. Given that harvesting procedures are time-sensitive and require swift decision-making by the care team and medical-legal surrogate, the physician may wish to consult a hospital ethics committee",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    require the requesting party to obtain an emergency court order to establish ethical and medical-legal grounds for the procedure. This may be difficult to coordinate on an emergency basis. For this reason, we recommend that institutions or practices develop protocols for handling requests for posthumous reproduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship of the requester to the deceased may also impact a clinician&rsquo;s decision to fulfill or deny a request for posthumous reproduction. Posthumous reproduction is often sought by the partner of the deceased, although other parties, such as parents and other closely-related relatives, may also be involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/6\">",
"     6",
"    </a>",
"    ]. There is no clear consensus on who should be allowed to use the genetic material of the deceased. Some authorities believe that surviving partners are the only party with an appropriate claim to the reproductive tissues of their deceased loved one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/6\">",
"     6",
"    </a>",
"    ]. Others view posthumous reproduction as justifiable under broader circumstances and would extend its use beyond the original parental project when certain conditions are satisfied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/6,20\">",
"     6,20",
"    </a>",
"    ]. For example, the deceased may have approved gamete or embryo donation in the event of",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    death, and an infertile couple may be willing to use such embryos. In all cases, appropriate counseling and informed consent by the proposed recipient(s) is are absolute requirements. Minimum waiting periods for up to one year in the case of known recipients have also been recommended by some authorities in order to allow for adequate grieving to take place [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19187346\">",
"    <span class=\"h1\">",
"     ETHICAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following basic principles create a framework for the ethical consideration of posthumous reproduction: respect for autonomy, beneficence, non-maleficence, and social justice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/19\">",
"     19",
"    </a>",
"    ]. These principles implore the clinician to carefully examine posthumous reproduction from the perspective of all parties involved. These parties may include the gamete donor, the gestating woman, the rearing parents, and, importantly, the child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19187353\">",
"    <span class=\"h2\">",
"     Respect for autonomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respect for autonomy honors the rights of individuals to make personal decisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/6,21\">",
"     6,21",
"    </a>",
"    ]. In posthumous reproduction, the autonomy of the prospective gamete donor is often weighed against the autonomy of the requester. Ideally, informed consent from both parties should be present. In general, both clinicians and survivors should strive to act in accordance with the expressed or presumed wishes of the deceased. When such wishes are not known, clinicians must ask whether the balance of benefits versus harms for the survivors, the future child, and society warrant honoring a posthumous reproduction request.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19187360\">",
"    <span class=\"h2\">",
"     Beneficence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principle of beneficence requires that health care providers act in the best interest of their patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/21\">",
"     21",
"    </a>",
"    ]. The desire to reproduce is considered by many to be a central human drive. Posthumous reproduction may provide peace of mind to a soldier or to the terminally ill, ease the pain and suffering of a surviving partner or family members, and give life to a child that may otherwise never have been born. By any of these outcomes, posthumous reproduction may be viewed as a beneficent act that promotes the well-being of others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19187367\">",
"    <span class=\"h2\">",
"     Non-maleficence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-maleficence is a key guiding principle in medical ethics that urges physicians to first &lsquo;do no harm&rsquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/21\">",
"     21",
"    </a>",
"    ]. As with any medical treatment, clinicians should only offer posthumous reproduction when the expected benefits outweigh the potential adverse outcomes. The general medical risks of assisted reproduction (eg, multiple gestation, ovarian hyperstimulation syndrome) are well known and do not impose any additional harms to posthumous assisted reproduction (PAR) participants.",
"   </p>",
"   <p>",
"    Risks to offspring should always be considered with assisted reproduction. In the context of posthumous reproduction, little is known regarding the psychosocial development of children born to parents who were previously deceased. Some authors have cautioned that the knowledge and possible stigma of being born to a dead parent could subject children conceived posthumously to undue psychological stress or harm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/20\">",
"     20",
"    </a>",
"    ]. However, extrapolation of data from children who otherwise lose parents at a young age or who are raised in a single-parent household suggests that the risks, if any, are likely minor. Further, it is tempting to argue that children conceived posthumously may do better than children from unintended pregnancies. Indeed, children born by posthumous reproduction are clearly wanted and may be highly cherished by surviving family as a living remembrance of their deceased parent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the end, one can ponder whether it is better for children conceived posthumously to be born to a dead genetic parent than to never be born at all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/18\">",
"     18",
"    </a>",
"    ]. Further study on the psychosocial effects of posthumous reproduction on offspring could help to better resolve this question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19187374\">",
"    <span class=\"h2\">",
"     Social justice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Social justice is a fourth principle of medical ethics, which challenges the physician&rsquo;s primary role as a patient advocate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/21\">",
"     21",
"    </a>",
"    ]. This tenant calls for the fair distribution of health care resources such that they provide the greatest benefit to society as a whole. Posthumous reproduction is a financially costly endeavor with few immediately tangible benefits for society. The costs of PAR procedures and",
"    <span class=\"nowrap\">",
"     gamete/embryo",
"    </span>",
"    storage are significant. Stored reproductive tissues may go unused or fail to result in children, resulting in little or no return on spent resources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/3\">",
"     3",
"    </a>",
"    ]. A complex cost analysis might determine whether the life created from PAR could ultimately result in a net loss or gain of resources for society. However, in the meantime, it is appropriate to question whether we should allocate health care resources toward this practice when many basic health care needs remain unfulfilled.",
"   </p>",
"   <p>",
"    Some insurers in states which cover costs of fertility treatment cover a single cycle of in vitro fertilization (IVF) prior to chemotherapy for cancer patients. Sperm cryopreservation is also covered prior to cancer treatment in some states. Posthumous reproduction would be covered only if the person using the embryos in order to conceive had a diagnosis of infertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19187381\">",
"    <span class=\"h1\">",
"     LEGAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Legal consultation can benefit all parties involved, and should be obtained prior to use of",
"    <span class=\"nowrap\">",
"     gametes/tissues",
"    </span>",
"    for posthumous reproduction. Properly documented consent forms and advanced directives concerning the collection, storage, and use of gametes or embryos for posthumous reproduction will diminish questions over ownership and use of reproductive tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/16\">",
"     16",
"    </a>",
"    ]. Clinics should consider insisting upon a court order before perimortem gamete collection or before permitting posthumous",
"    <span class=\"nowrap\">",
"     release/use",
"    </span>",
"    of stored gametes when consent for posthumous use is unclear. A living will may resolve issues of inheritance by naming unborn genetic children as heirs if this is the intent of the deceased genetic parent.",
"   </p>",
"   <p>",
"    A detailed exploration of the law surrounding posthumous reproduction is beyond the scope of this topic review, but it is helpful to be familiar with the major legal issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19874476\">",
"    <span class=\"h2\">",
"     Legality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laws concerning posthumous reproduction vary internationally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/22\">",
"     22",
"    </a>",
"    ]. The United States does not regulate posthumous reproduction at the federal level. State laws are largely permissive with case law presiding over the majority of pertinent legal issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/7,17,22\">",
"     7,17,22",
"    </a>",
"    ]. Israel, a country in which most young people are required to enter into military service, has national policies that deal specifically with perimortem gamete retrieval. In Israel, it is legal to retrieve and use posthumously obtained gametes at the request of a spouse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/23\">",
"     23",
"    </a>",
"    ]. The United Kingdom also allows collection and storage of posthumously obtained gametes, but forbids anything but immediate use of such gametes. Many other European countries forbid the practice outright [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19874483\">",
"    <span class=\"h2\">",
"     Ownership of gametes and embryos",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues regarding ownership of gametes and embryos are difficult because reproductive tissues are not clearly recognized as either persons or property [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. Application of principles concerning property and organ donation fail to suffice when the prospective child is considered. Precedent over legal ownership, storage, and use of reproductive tissues is growing, but far from resolved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/7,17,18,25\">",
"     7,17,18,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19874490\">",
"    <span class=\"h2\">",
"     Inheritance rights of children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children born from posthumous reproduction should be protected under the law and be afforded the same rights as children born to living genetic parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. However, questions of legitimacy, allocation of social security benefits, and estate division remain challenging. Some states will not recognize the rights of children conceived posthumously to collect social security benefits or allow them to claim inheritance rights unless named specifically in a living will [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/17,18,25\">",
"     17,18,25",
"    </a>",
"    ]. Others place time limitations for filing such claims, such that an estate may be closed within a &ldquo;reasonable period of time&rdquo; following an individual&rsquo;s death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19874799\">",
"    <span class=\"h2\">",
"     Third parties",
"    </span>",
"    &nbsp;&mdash;&nbsp;If third parties are to receive gametes or embryos from a deceased genetic parent, this should be fully disclosed and the recipients should be appropriately counseled. Informed consent from the donor and infectious disease testing is likewise mandatory in these cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19187388\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published guidelines from the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE) discuss posthumous reproduction, but for the most part allow physicians to determine when a request for posthumous reproduction should be honored [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/6,20\">",
"     6,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Notably, ASRM guidelines do not specify whether written or verbal consent from the deceased need be present in order to perform posthumous reproduction. The ASRM Ethics Committee statement makes the following points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physicians should not override prior denial of posthumous reproduction by a deceased gamete provider.",
"     </li>",
"     <li>",
"      Physicians are not obligated, upon request, to retrieve gametes from terminally ill or recently deceased individuals without prior consent or known wishes of the deceased, but should consider such requests within the context of the individual circumstances and applicable laws.",
"     </li>",
"     <li>",
"      The reproductive specialist is responsible for ensuring adequate screening and counseling of all parties and that appropriate informed consents are obtained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ESHRE task force recommendations are somewhat less open-ended. They stipulate that posthumous reproduction is acceptable when [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The posthumous reproduction request is from a surviving partner who was part of the original parental project.",
"     </li>",
"     <li>",
"      Written consent was given by the deceased prior to the use of",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      gametes or embryos.",
"     </li>",
"     <li>",
"      The surviving partner is appropriately counseled.",
"     </li>",
"     <li>",
"      A minimum waiting period of one year is imposed before treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ESHRE task force did not reach a consensus regarding justification for posthumous donation to parties other than the surviving partner. In cases where third parties might receive gametes or embryos from a deceased genetic parent, however, the committee advised that the recipients should be fully informed and counseled regarding the uncertain psychosocial implications for the prospective child.",
"   </p>",
"   <p>",
"    Although the published ASRM and ESHRE guidelines are not comprehensive, they do provide an appreciation for the scope of the problem and highlight issues deserving special attention. Reproductive specialists should be aware of these recommendations, as well as any local laws or hospital policies that might affect delivery of posthumous reproduction services. In addition, it is prudent for centers to have a set of standard policies and procedures in place, so they are prepared to answer requests for posthumous reproduction when they arise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36519/abstract/19\">",
"     19",
"    </a>",
"    ]. Legal counsel and consultation from appropriate ethics committees, mental health and social work professionals are highly recommended on a case-by-case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19187395\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posthumous assisted reproduction (PAR) is the process by which reproductive technologies, such as gamete retrieval, in vitro fertilization (IVF) and cryopreservation of gametes and embryos, are used to establish pregnancy and produce offspring after the death of a genetic parent. (See",
"      <a class=\"local\" href=\"#H19187297\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reproductive specialists are not bound to allow the use of previously stored gametes or embryos or to retrieve eggs or sperm from recently ill or deceased individuals, but may choose to honor requests for posthumous reproduction when no medical, ethical, or legal contraindications exist. (See",
"      <a class=\"local\" href=\"#H19187346\">",
"       'Ethical issues'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19187381\">",
"       'Legal issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Providers should be familiar with published guidelines and local laws concerning posthumous reproduction. Consistent institutional policies and standard operating procedures should be established to guide posthumous reproduction decisions. Legal counsel and consultation from appropriate ethics committees, mental health and social work professionals are highly recommended on a case-by-case basis. (See",
"      <a class=\"local\" href=\"#H19187388\">",
"       'Guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Authorities agree that posthumous reproduction seems justified when written, informed consent is obtained prior to the death of the gamete provider(s) and when requested by a spouse or life-partner with whom a parental project was already in place. (See",
"      <a class=\"local\" href=\"#H19187339\">",
"       'Consent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When posthumous reproduction is to be used by a surviving partner, a waiting period of one year is recommended to allow for adequate grieving and counseling. (See",
"      <a class=\"local\" href=\"#H19187339\">",
"       'Consent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If third parties are to receive gametes or embryos from a deceased genetic parent, this should be fully disclosed and the recipients should be appropriately counseled. Informed consent from the donor and infectious disease testing is likewise mandatory in these cases. (See",
"      <a class=\"local\" href=\"#H19874799\">",
"       'Third parties'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19187339\">",
"       'Consent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We consider perimortem gamete retrieval when the donor consented to the procedure or made",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      approval clearly known through a non-invested third party, such as their physician or attorney. (See",
"      <a class=\"local\" href=\"#H19187339\">",
"       'Consent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Providers should speak to patients about their desires toward posthumous reproduction when discussing topics such as organ donation, advanced directives, family building or fertility preservation and document those wishes whenever possible. (See",
"      <a class=\"local\" href=\"#H19187339\">",
"       'Consent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Written consent for posthumous use of gametes or embryos should be obtained before retrieval and storage. Advanced directives and living wills should be in place to ensure that the wishes of the deceased are followed and that children born from PAR have the right to inherit if intended. (See",
"      <a class=\"local\" href=\"#H19187339\">",
"       'Consent'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/1\">",
"      Shufaro Y, Schenker JG. Cryopreservation of human genetic material. Ann N Y Acad Sci 2010; 1205:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/2\">",
"      Gilbert S. Fatherhood from the grave: an analysis of postmortem insemination. Hofstra Law Rev 1993; 22:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/3\">",
"      Raziel A, Friedler S, Strassburger D, et al. Nationwide use of postmortem retrieved sperm in Israel: a follow-up report. Fertil Steril 2011; 95:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/4\">",
"      Shefi S, Raviv G, Eisenberg ML, et al. Posthumous sperm retrieval: analysis of time interval to harvest sperm. Hum Reprod 2006; 21:2890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/5\">",
"      Barton SE, Correia KF, Shalev S, et al. Population-based study of attitudes toward posthumous reporduction. Fertil Steril 2012; 98:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/6\">",
"      ESHRE Task Force on Ethics and Law, Pennings G, de Wert G, et al. ESHRE Task Force on Ethics and Law 11: Posthumous assisted reproduction. Hum Reprod 2006; 21:3050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/7\">",
"      Batzer FR, Hurwitz JM, Caplan A. Postmortem parenthood and the need for a protocol with posthumous sperm procurement. Fertil Steril 2003; 79:1263.",
"     </a>",
"    </li>",
"    <li>",
"     Conley M. Israeli Court Allows Family to Harvest Dead Daughter's Eggs. ABC News 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/9\">",
"      Greer DM, Styer AK, Toth TL, et al. Case records of the Massachusetts General Hospital. Case 21-2010. A request for retrieval of oocytes from a 36-year-old woman with anoxic brain injury. N Engl J Med 2010; 363:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/10\">",
"      Kindregan CP Jr, McBrien M. Posthumous reproduction. Fam Law Q 2005; 39:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/11\">",
"      Herrero L, Mart&iacute;nez M, Garcia-Velasco JA. Current status of human oocyte and embryo cryopreservation. Curr Opin Obstet Gynecol 2011; 23:245.",
"     </a>",
"    </li>",
"    <li>",
"     Technology, SfAR. SART National Data Summary 2010. 2012.",
"    </li>",
"    <li>",
"     Percentages of Transfers That Resulted in Live Births and Singleton Live Births for ART Cycles Using Frozen Donor Embryos and ART Cycles Using Fresh Donor Embryos, 2008. file://www.cdc.gov/art/ART2008/sect4_fig46-50.htm#f50 (Accessed on March 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/14\">",
"      Rodriguez-Wallberg KA, Oktay K. Recent advances in oocyte and ovarian tissue cryopreservation and transplantation. Best Pract Res Clin Obstet Gynaecol 2012; 26:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/15\">",
"      Grifo JA, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil Steril 2010; 93:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/16\">",
"      Nakhuda GS. Posthumous assisted reproduction. Semin Reprod Med 2010; 28:329.",
"     </a>",
"    </li>",
"    <li>",
"     Kindregan CP. Dead Dads: Thawing an Heir from the Freezer. William Mitchell Law Review 2009; 35:433.",
"    </li>",
"    <li>",
"     Bahadur G. Ethical challenges in reproductive medicine: posthumous reproduction. International Congress Series: Advances in Fertility and Reproductive Medicine. Proceedings of the 18th World Congress on Fertility and Sterility 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/19\">",
"      Bostwick JM, Coddington CC, Stewart EA. Case 21-2010: anoxic brain injury and a request for oocyte retrieval. N Engl J Med 2010; 363:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/20\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Posthumous reproduction. Fertil Steril 2004; 82 Suppl 1:S260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/21\">",
"      Snyder L, American College of Physicians Ethics, Professionalism, and Human Rights Committee. American College of Physicians Ethics Manual: sixth edition. Ann Intern Med 2012; 156:73.",
"     </a>",
"    </li>",
"    <li>",
"     Fisseha S. A Match Made in Heaven: Posthumous Fatherhood and Postmenopausal Motherhood. Virtual Mentor: American Medical Association Journal of Ethics 2007; 9:630.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/23\">",
"      Landau R. Posthumous sperm retrieval for the purpose of later insemination or IVF in Israel: an ethical and psychosocial critique. Hum Reprod 2004; 19:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36519/abstract/24\">",
"      Knapp C, Quinn G, Bower B, Zoloth L. Posthumous reproduction and palliative care. J Palliat Med 2011; 14:895.",
"     </a>",
"    </li>",
"    <li>",
"     Kindregan CP. Genetically Related Children: Harvesting of Gametes from Deceased or Incompetent Persons. Journal of Health and Biomedical Law 2011; 7:147.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15242 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-110.137.129.113-15BEC61BD9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_42_36519=[""].join("\n");
var outline_f35_42_36519=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19187395\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19187297\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19874881\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19873899\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19187311\">",
"      USE OF POSTHUMOUS REPRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19187318\">",
"      PROCEDURES FOR OBTAINING GAMETES AND EMBRYOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19187325\">",
"      Males",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19187332\">",
"      Females",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19874052\">",
"      CRYOPRESERVATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102435926\">",
"      Sperm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102435933\">",
"      Embryo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102435940\">",
"      Oocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102435947\">",
"      Ovarian tissue and testicular tissue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19187339\">",
"      CONSENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19874287\">",
"      Premeditated posthumous reproduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19874294\">",
"      Unplanned posthumous reproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19187346\">",
"      ETHICAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19187353\">",
"      Respect for autonomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19187360\">",
"      Beneficence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19187367\">",
"      Non-maleficence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19187374\">",
"      Social justice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19187381\">",
"      LEGAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19874476\">",
"      Legality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19874483\">",
"      Ownership of gametes and embryos",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19874490\">",
"      Inheritance rights of children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19874799\">",
"      Third parties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19187388\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19187395\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/15242\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/15242|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/17/9501\" title=\"table 1\">",
"      Indications for posthumous reproduction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15546?source=related_link\">",
"      Intracytoplasmic sperm injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/6/2154?source=related_link\">",
"      Pregnancy outcome after assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15015?source=related_link\">",
"      Surrogate pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_42_36520="Nodular basal cell carcinoma";
var content_f35_42_36520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65704%7EDERM%2F57990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65704%7EDERM%2F57990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This pearly papule with telangiectasias is representative of a nodular basal cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This erythematous, slightly scaly patch is representative of a superficial basal cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_42_36520=[""].join("\n");
var outline_f35_42_36520=null;
var title_f35_42_36521="Dual diagnosis: Severe mental illness and substance use disorders";
var content_f35_42_36521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dual diagnosis: Severe mental illness and substance use disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/42/36521/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36521/contributors\">",
"     Peter Buckley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/42/36521/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36521/contributors\">",
"     Andrew J Saxon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/42/36521/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36521/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/42/36521/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 7, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Dual diagnosis\" most commonly refers to the combination of \"severe mental illness\" (SMI) and a substance-use disorder (SUD). There is a high prevalence of individuals with these co-occurring conditions worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, seven to ten million people in the United States have at least one mental disorder in addition to a SUD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/2\">",
"     2",
"    </a>",
"    ]. While definitions vary, severe mental illnesses generally include schizophrenia, bipolar disorder, and severe recurrent depression. Posttraumatic stress disorder (PTSD) and other anxiety disorders are sometimes included as well.",
"   </p>",
"   <p>",
"    Alcohol and drug abuse can adversely influence affective stability, cognition, and behavior among persons with mental illness. Mental disorders place individuals at risk for substance abuse and dependence. The comorbidity of the two conditions can complicate clinical management and is associated with poorer outcomes than either a mental disorder or SUD alone.",
"   </p>",
"   <p>",
"    High rates of undertreatment of one or both conditions have been observed for dual diagnosis in several countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States (US), treatment of the two conditions is often split between mental health and SUD specialty settings, contributing to low rates of detection and poor coordination of care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, and treatment for dual diagnosis are described below. The disorders as they present in isolation from each other are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mental disorders and SUD co-occur at high rates. As an example, in the US, a study of a nationally representative sample found that 15 percent of persons with a mental disorder had a co-occurring SUD in the prior 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/3\">",
"     3",
"    </a>",
"    ]. Fifty-one percent had a SUD at some point over their lifetime. Conversely, the 12-month and lifetime rates of a mental disorder among those with a SUD were 42 percent and 51 percent, respectively. In comparison, in the general adult US population, the 12-month prevalence of a mental disorder was 15 percent and the 12-month prevalence of a SUD was 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/4\">",
"     4",
"    </a>",
"    ]. Findings for common disorders from two large epidemiologic studies conducted in the US are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Schizophrenia &mdash; Forty-seven percent of individuals with schizophrenia have had an SUD over their lifetime: 34 percent had an alcohol use disorder and 28 percent other drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/5\">",
"       5",
"      </a>",
"      ]. Polysubstance use is common. Cannabis and cocaine are also frequent drugs of choice.",
"     </li>",
"     <li>",
"      Mood disorders &mdash; Individuals with mood disorders have a lifetime SUD rate of 32 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/5\">",
"       5",
"      </a>",
"      ]. The comorbidity in bipolar disorder is twice that of major depression (56 versus 27 percent). Despite its lesser severity, dysthymia also has a high rate of SUD (31 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/5\">",
"       5",
"      </a>",
"      ]. Alcohol is the most common substance of",
"      <span class=\"nowrap\">",
"       abuse/dependence",
"      </span>",
"      across the mood disorders. In bipolar disorder, the next most commonly abused drugs appear to be marijuana and the stimulants, cocaine and amphetamines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anxiety disorders &mdash; Overall, 15 percent of individuals with an anxiety disorder have a co-occurring SUD. SUD is highest in generalized anxiety disorder (21 percent), PTSD (18 percent), and social phobia (17 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGIC THEORIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes for the comorbidity between mental disorders and SUDs are not known. Etiological theories can be categorized into four groups: common factors, secondary SUD, secondary mental disorder, and bidirectional models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/7\">",
"     7",
"    </a>",
"    ]. These models vary in their extent of supporting evidence and are not mutually exclusive. In any individual case, more than one mechanism may contribute to comorbidity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Common factors &mdash; This model hypothesizes that the comorbidity results from risk factors common to both disorders. A shared genetic vulnerability has been proposed to underlie dopaminergic and glutamatergic dysregulation in schizophrenia and substance abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Impaired myelin development has been studied as a possible precursor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/10\">",
"       10",
"      </a>",
"      ]. Impulsivity observed in substance abuse and inter-episode bipolar disorder may stem from a common neurologic defect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Secondary mental disorder &mdash; This model posits that substance use precipitates mental disorders. The temporal relationship found in epidemiologic studies tends to be consistent with the hypothesis. Most individuals with both disorders report that the first occurrence of the SUD preceded the mental disorder. Prospective longitudinal studies have found similar results, although differences in common age-of-onset for these disorders must be considered in interpreting these results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The strongest evidence for the model are findings of a dose-related association between cannabis use and the subsequent onset of schizophrenia. However, the significance of these findings remains controversial and a causative role has not been proven. The vast majority of cannabis users do not develop schizophrenia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4554?source=see_link&amp;anchor=H30#H30\">",
"       \"Cannabis use disorders: Treatment, prognosis, and long-term medical effects\", section on 'Psychotic disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Secondary substance use &mdash; The best known of these models has been described as the 'self-medication hypothesis' [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/13\">",
"       13",
"      </a>",
"      ]. It suggests that individuals selectively abuse alcohol or specific drugs to address a targeted deficit from a mental disorder. An example is an individual with hypomania or PTSD who may have begun drinking alcohol, in part, to overcome insomnia. Another would be a person with major depression using cocaine to relieve dysphoria. However, studies have not found patterns of selective drug use to reflect individual mental disorders as hypothesized [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/5\">",
"       5",
"      </a>",
"      ]. Moreover, the clinical utility of these substances is usually short lived and ultimately counterproductive.",
"     </li>",
"     <li>",
"      Bidirectional &mdash; This model suggests that the presence of either a mental disorder or SUD can contribute to the development of the other in a mutually reinforcing manner over time. This model is largely theoretical and lacks supporting evidence from research.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL CHALLENGES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Underrecognition",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a mental disorder and SUD co-occur, the secondary disorder frequently goes unrecognized and untreated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/14\">",
"     14",
"    </a>",
"    ]. A 2005 report by the US Institute of Medicine (IOM) found that in the US the two types of disorders have traditionally been treated in separate service systems with distinct cultures, training and practices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/15\">",
"     15",
"    </a>",
"    ]. One study found that among individuals with probable dual diagnoses who received treatment for one condition, fewer than one-third received treatment for the comorbid condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/16\">",
"     16",
"    </a>",
"    ]. Even when both conditions are treated, the IOM found, inadequate communication and coordination of care between providers are common and can adversely impact outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dual diagnoses are strongly associated with lower rates of adherence to medications and scheduled clinical visits. A prospective cohort study of 135 patients with schizophrenia found an eight-fold greater rate of medication non-compliance among subjects with a comorbid SUD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Course of illness",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with SUD alone &mdash; Individuals with SMI have impairments leaving them ill-prepared to address substance",
"      <span class=\"nowrap\">",
"       abuse/dependence.",
"      </span>",
"      They frequently have low motivation to change, cognitive deficits, and poor social skills [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/7\">",
"       7",
"      </a>",
"      ]. Compared with individuals with only a SUD, individuals with dual diagnosis are harder to engage in treatment, make slower progress, and are more likely to drop out of treatment. They are also more likely to be homeless and unemployed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Compared with SMI alone &mdash; Individuals with dual diagnoses have higher rates of relapse and poorer treatment outcomes compared with individuals with SMI and no SUD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. In addition, comorbid individuals are more frequently hospitalized and experience greater rates of violence, incarceration, and homelessness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/21-23\">",
"       21-23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The association between poorer outcomes and dual diagnoses can be observed early in the course of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/24\">",
"     24",
"    </a>",
"    ]. In a prospective observational study of 272 patients with first-episode psychosis, individuals with an active SUD had worse outcomes after one year than those without an SUD, including more psychotic symptoms, more severe depressive symptoms, poorer functional outcomes, and a greater rate of relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Suicidality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher suicide rates are another characteristic of dual diagnoses, most commonly seen among patients with major depression and alcohol disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/25\">",
"     25",
"    </a>",
"    ]. SUDs are also risk factors for suicide among individuals with schizophrenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/26\">",
"     26",
"    </a>",
"    ] and bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ASSESSMENT AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should have a high index of suspicion for a comorbid disorder when assessing patients with a mental disorder or SUD, given rates of co-occurrence described above. Individuals may be reluctant to disclose information about these conditions due to stigma, shame, or other reasons, so a non-judgemental approach to questioning is essential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated in the mental health or SUD specialty sectors should be assessed for the presence of comorbid disorders. A national panel has suggested routine use of validated, age-appropriate screening tools, based on findings of low rates of detection and treatment of comorbid disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/15\">",
"     15",
"    </a>",
"    ]. There is presently a lack of data showing improved outcomes from formal screening. Two instruments with demonstrated validity for screening of individuals with potential dual diagnosis are the Psychiatric Diagnostic Screening Questionnaire and the CAGE-AID (for alcohol and drug problems, (",
"    <a class=\"graphic graphic_table graphicRef51180 \" href=\"mobipreview.htm?17/16/17675\">",
"     table 1",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with positive screening results should have a full diagnostic assessment for the mental or substance-use disorder and its impact on functioning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosing a mental disorder in the presence of a known or suspected SUD (or a SUD in the presence of SMI) can be complex. One needs to distinguish a primary mental disorder from a substance-induced disorder. Alcohol and other drugs can induce distinct psychiatric syndromes during periods of intoxication, withdrawal, or chronic use. The table summarizes syndromes characteristic of these periods-psychosis, dysphoria, and anxiety (",
"    <a class=\"graphic graphic_table graphicRef58451 \" href=\"mobipreview.htm?13/7/13436\">",
"     table 2",
"    </a>",
"    ). However, individual presentations can vary.",
"   </p>",
"   <p>",
"    A methodical approach should be taken to diagnosis, drawing from the patient's current episode and past history. Follow-up questions should be direct and explicit. Vague answers should prompt further, more specific questions. Collateral sources of information and toxicological testing of urine or blood for substances may be needed. A basic consideration is the co-occurrence or temporal relationship between the psychiatric syndrome and substance abuse. Examples follow.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Does a history of depressive episodes precede the history of substance use (suggesting a primary mood disorder)? Does depression occur only during periods of alcohol abuse (suggesting an alcohol-induced disorder)?",
"     </li>",
"     <li>",
"      If the history is not known, the DSM-IV-TR recommends waiting about a month after cessation of alcohol to see if the symptoms spontaneously resolve or if a diagnosis of major depression is warranted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/30\">",
"       30",
"      </a>",
"      ]. However, evidence favors initiating treatment before this. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A family history of either mental illness or an SUD can also inform the diagnosis when the patient's history is unclear.",
"     </li>",
"     <li>",
"      The sudden exacerbation of psychotic symptoms in a previously stable, antipsychotic-responsive patient with schizophrenia may raise a question of undisclosed stimulant abuse.",
"     </li>",
"     <li>",
"      Abuse of prescribed benzodiazepines in treatment of an anxiety disorder can lead to diagnostic ambiguity as to whether re-emergent symptoms are due to the primary disorder or benzodiazepine withdrawal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional topics address diagnosis of individual mental disorders and SUDs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Suicidality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should ask explicitly about suicidal ideation. Further information on assessment and planning is available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there was a history of past suicide attempts, it is useful to ascertain whether the patient was intoxicated, withdrawing, or amid chronic use at those times.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary long term goals of treatment for dual diagnoses are reduced psychiatric symptoms, improved role functioning (eg, in work, relationships, and other activities), reduced substance use, and improved quality of life. As treatment for dual diagnosis can be challenging, a reasonable intermediate goal is to establish stable and appropriate care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment principles",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Where available, we recommend provision of integrated care for dual diagnosis, ie, treatment of both conditions by the same clinician or team. Despite the lack of convincing research evidence, integrated treatment is supported by a broad consensus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Where integrated treatment is not possible, we recommend close communication and coordination between clinicians. Agreement on a common treatment plan and sharing information about clinical status, treatment compliance, substance use, and level of risk can contribute to better outcomes.",
"     </li>",
"     <li>",
"      The clinician who is treating only one of the conditions should closely monitor the clinical status and treatment response of both disorders.",
"     </li>",
"     <li>",
"      Relapses should be anticipated. One should seek to maintain treatment despite periods of active substance use. Substance dependence is more likely than not a chronic or relapsing condition.",
"     </li>",
"     <li>",
"      Patients should be referred to self-help groups for peer support. Those specific to dual diagnosis where available may be particularly valuable. Open trials suggest that one such program, \"Double Trouble in Recovery\", may be useful [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Occasionally, patients with dual diagnosis may encounter anti-medication treatment philosophies in some substance abuse programs. Patients should be prepared for this possibility and educated about the importance of adherence to medication.",
"     </li>",
"     <li>",
"      Patients and families should be educated about both disorders, the interaction between them, and options for treatment. They should be aware of early signs of a crisis or relapse and have a prepared plan of action. Family support and involvement in care can play an important role in achieving better outcomes.",
"     </li>",
"     <li>",
"      The potential complexity of a treatment plan must be weighed against the patient's cognitive and self-care capacities. More intensive protocols, such as treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      , may require external support from family, friends, or professional caregivers.",
"     </li>",
"     <li>",
"      Ideally, a continuum of care is available to provide the patient with clinical services at the least intensive and restrictive level in which stability can be maintained. During episodes of greater clinical instability or relapse, more intensive levels of care may include intensive outpatient programs, residential, crisis stabilization, and inpatient care.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Medication treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with dual diagnoses are often excluded from trials of medications for primary mental disorders. However, certain classes of psychotropic medications have been tested in some dual diagnoses. Clinical findings are summarized below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Schizophrenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trials of antipsychotic drugs for schizophrenia have mostly found these agents to be effective for schizophrenic symptoms in the presence of comorbid SUD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. However, comorbid patients typically have had poorer treatment response compared with patients with schizophrenia alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most trials comparing first (typical) and second generation (atypical) antipsychotic medications have not found a difference between the two classes of medication for schizophrenia response in the dually diagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/32-35\">",
"     32-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two small observational studies of patients treated with antipsychotic medications suggest that comorbid SUD may be associated with a higher rate of tardive dyskinesia and other extrapyramidal side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. These patients should be monitored closely and early consideration should be given to use of an anticholingeric agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34952?source=see_link\">",
"     \"Tardive dyskinesia: Prevention and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alcohol use has been found to reduce plasma levels of antipsychotic drugs. However, patients with dual diagnoses do not generally require higher dosages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depot formulations should be strongly considered for patients with schizophrenia non-adherent to antipsychotics.",
"   </p>",
"   <p>",
"    The choice and clinical use of antipsychotic drugs in the treatment of schizophrenia are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29241?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 14 trials studying the treatment of depression in the context of an SUD found some evidence for efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with placebo, antidepressants led to a better response rate for depression (38 versus 52 percent; effect size 0.38; 95 percent CI, 0.18-0.58).",
"     </li>",
"     <li>",
"      Antidepressants also reduced substance use among depressed patients with the largest decreases in those patients who had the greatest decrease in depression. However, abstinence rates did not differ between antidepressant and control groups.",
"     </li>",
"     <li>",
"      Selective serotonin reuptake inhibitors (SSRIs) were found to be less effective than tricyclic and other antidepressants. A high placebo response in most of the SSRI studies may have contributed to this result and the finding remains to be confirmed by head-to-head studies. Clinicians should weigh the result from placebo-controlled trials against SSRIs' superior tolerability and low toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized trial of 170 outpatients with alcohol dependence and major depression examined the efficacy of combined treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    and sertraline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/40\">",
"     40",
"    </a>",
"    ]. Treatment with naltrexone and sertraline resulted in a higher rate of 14-week abstinence (54 percent) than treatment with naltrexone (21 percent), sertraline (28 percent) or placebo (23 percent) individually. The naltrexone-sertraline group showed a trend toward greater remission of depression, which was not statistically significant.",
"   </p>",
"   <p>",
"    Trials have not shown antidepressants to be efficacious for depression comorbid with cocaine or opiate use disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/41\">",
"     41",
"    </a>",
"    ]. However, large, definitive trials have not been conducted. Depressive symptoms associated with significant impairment warrant an antidepressant trial.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link&amp;anchor=H16#H16\">",
"       \"Initial treatment of depression in adults\", section on 'Antidepressants'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19209?source=see_link\">",
"       \"Pharmacotherapy for alcohol abuse and dependence\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Bipolar disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three trials have shown selective, positive results for valproate, Lithium, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    in patients with bipolar I disorder and SUD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial comparing adjunctive valproate and Lithium to Lithium alone for patients with bipolar disorder and alcohol dependence found valproate to reduce heavy alcohol use modestly, but not depressive or manic symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A six week trial of Lithium for adolescents with bipolar disorder and SUD found an increase in abstinent days and global functioning compared with placebo, but no effect on mood symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      for patients with bipolar disorder and alcohol",
"      <span class=\"nowrap\">",
"       abuse/dependence",
"      </span>",
"      showed no effects on substance use or manic symptoms but found a small reduction in depressive symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of definitive data, mood stabilizers are recommended for comorbid bipolar disorder, with priority given to lithium and valproate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Anxiety disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of anxiety disorders in the setting of SUD has been evaluated in a limited number of small studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial comparing buspirone with placebo for patients with generalized anxiety disorder and an alcohol use disorder found a reduction in anxiety, but mixed results for alcohol use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Only one study has compared an SSRI (sertraline) with placebo among patients with PTSD and alcohol-related disorders, finding no difference in alcohol use or PTSD symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/46\">",
"       46",
"      </a>",
"      ]. Both groups also received cognitive behavioral therapy (CBT).",
"     </li>",
"     <li>",
"      Benzodiazepines are more likely to be abused by patients with comorbid SMI and SUD than by those with an SMI alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/47\">",
"       47",
"      </a>",
"      ]. Their use should be avoided if possible in this population. However, some investigators suggest a role for benzodiazepines in treating anxiety disorders in patients with a former SUD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Substance use disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from a randomized trial supports the use of combined",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    and sertraline in patients with comorbid alcohol dependence and depression. Initial evidence also supports the use of naltrexone for alcohol dependence in patients with comorbid schizophrenia, and for patients with comorbid PTSD. The evidence for using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/17/5397?source=see_link\">",
"     disulfiram",
"    </a>",
"    to treat a dual diagnosis is less convincing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial of 170 patients with alcohol dependence and major depression compared the use of combined",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and sertraline (200",
"      <sup>",
"       <span class=\"nowrap\">",
"       </span>",
"      </sup>",
"      mg/day)",
"      to naltrexone alone, sertraline alone, and double placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/40\">",
"       40",
"      </a>",
"      ]. All patients also received weekly cognitive behavioral therapy. After 14 weeks of treatment, the naltrexone-sertraline combination led to a higher rate of abstinence from alcohol (53.7 percent) compared to naltrexone, sertraline, or double placebo (21.3, 27.5, and 23.1 percent, respectively). Combined naltrexone and sertraline also led to a longer delay",
"      <sup>",
"      </sup>",
"      before relapse to heavy drinking (median = 98 days) compared to 29, 23, and 26 days, respectively.",
"     </li>",
"     <li>",
"      A trial found",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      to reduce alcohol use in patients with comorbid schizophrenia who were receiving antipsychotic medication and participating in a relapse prevention group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/49\">",
"       49",
"      </a>",
"      ]. No differences were seen in symptoms of schizophrenia.",
"     </li>",
"     <li>",
"      Secondary analyses of a large placebo-controlled trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/17/5397?source=see_link\">",
"       disulfiram",
"      </a>",
"      for patients with heterogeneous comorbid mental disorders found both medications were associated with reduced alcohol use in PTSD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/50\">",
"       50",
"      </a>",
"      ], but not depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Drinking while taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/17/5397?source=see_link\">",
"       disulfiram",
"      </a>",
"      can lead to serious adverse effects. Thus, the cognitive status and judgment of patients with SMI should be evaluated before prescribing the medication. Older reports of disulfiram-induced psychosis have caused concern about its use for schizophrenia. &nbsp;However, research (mostly small, non-controlled trials) in this population over the past 15 years have not observed exacerbations of psychosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is little convincing evidence for the effectiveness of atypical antipsychotic drugs in reducing substance use among patients with a SUD and schizophrenia. Of four randomized trials, three were largely negative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/32,33,52\">",
"       32,33,52",
"      </a>",
"      ]. The fourth reported a small difference in positive urine screens for the group receiving long-acting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/35\">",
"       35",
"      </a>",
"      ]. The study had methodological weaknesses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other than for alcohol, there has not been extensive study of medications for SUD in the context of dual diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=see_link\">",
"     \"Cocaine abuse and dependence in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Psychosocial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intervention to treat individuals with dual diagnoses often target characteristic problems with motivation, cognition, and social skills. Examples include motivational interviewing (MI), cognitive behavioral therapy (CBT), and social skills training (SST). Two additional treatment models, assertive community treatment (ACT) and intensive case management (ICM), provide external support for patients with these deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Overall efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is a strong consensus in support of the psychosocial interventions among clinicians who treat dual diagnoses, their evidence base is not strong. A Cochrane systematic review of 25 randomized trials concluded that there was no rigorous, consistent evidence demonstrating the superiority of these treatments over routine care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/53\">",
"     53",
"    </a>",
"    ]. Many of the studies had methodological limitations causing published findings to be discounted. Below we report on some of the more rigorously conducted studies as well as results suggesting clinically meaningful directions for future research.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Specific interventions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Motivational interviewing &mdash; Two of five trials suggest that MI holds promise for engaging and treating individuals with dual diagnoses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/54-58\">",
"       54-58",
"      </a>",
"      ]. A trial of 93 patients found patients who received two MI sessions while hospitalized were more likely to attend an initial aftercare appointment than inpatients who did not receive MI (42 versus 16 percent; RR 0.69 CI 0.5 to 0.9) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/56\">",
"       56",
"      </a>",
"      ]. Another trial of 28 patients found that those who received MI were less likely to be using alcohol after six months than non-recipients (42 versus 92 percent, RR 0.36 CI 0.2 to 0.8) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/54\">",
"       54",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A description of MI and evidence of its effectiveness for SUD without comorbid mental illness can be found in additional topics. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=see_link\">",
"       \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cognitive behavioral therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A pooled analyses of 260 patients from four trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/59-62\">",
"       59-62",
"      </a>",
"      ] found that patients who received CBT for dual diagnoses were less likely to drop out of treatment compared with patients receiving standard care (18 versus 30 percent; n = 260, RR 0.61 CI 0.4 to 0.9; effect size 39 percent). These results should be interpreted with caution due to weaknesses in individual studies.",
"     </li>",
"     <li>",
"      Two trials compared an integrated CBT for PTSD and SUD with standard care. Both studies found reduced substance use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/63\">",
"       63",
"      </a>",
"      ]. One of two found a reduction in PTSD symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two trials of CBT combined with other interventions found mixed results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/65\">",
"       65",
"      </a>",
"      ]. One compared MI, CBT, and family education to routine care for comorbid schizophrenia, finding an increase in number of days abstinent and an average 10-point gain on the Global Assessment of Functioning Scale for the intervention group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another trial comparing CBT and medication management to medication management alone for patients with comorbid bipolar disorder found the CBT group was more likely to receive care, remain on medication, and report fewer days of manic symptoms. No difference was seen in substance use or depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/61\">",
"       61",
"      </a>",
"      ]. A full description of CBT is available elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=see_link\">",
"       \"Overview of psychotherapies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Social skills training &mdash; SST emphasizes teaching about refusing drugs, developing alternative social contacts and non-drug activities.",
"      <br/>",
"      <br/>",
"      The most rigorous of three trials testing SST for individuals with schizophrenia and SUD found patients in the intervention group were less likely to drop out of treatment (hazard ratio, 0.51 [95 percent CI 0.30-0.85]), more likely to test negative for substances (OR=4.4 95 percent CI, 2.1-9.0), and less likely to be hospitalized for a mental disorder or SUD compared with individuals receiving a supportive addictions therapy.",
"     </li>",
"     <li>",
"      Assertive community treatment &mdash; ACT is a multidisciplinary, team-based treatment model with relatively small caseloads and the capability to treat patients in their homes or communities. Four trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/67-70\">",
"       67-70",
"      </a>",
"      ] did not find evidence for ACT's effectiveness for dual diagnosis. It has been shown to be effective for individuals with SMI who are not selected for having a comorbid SUD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intensive case management &mdash; ICM differs from standard case management by having smaller caseloads and clinicians with greater qualifications and skills. It differs from ACT in that it does not necessarily use teams or provide treatment in the patient's home or community [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/72\">",
"       72",
"      </a>",
"      ]. Four trials did not find convincing evidence in support of ICM for dual diagnosis patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/73-75\">",
"       73-75",
"      </a>",
"      ]. This intervention has been shown to be effective for patients with SMI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36521/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe mental illness (SMI) and substance use disorders (SUD) co-occur at high rates: 15 percent of persons with a mental disorder and 42 percent of those with a SUD had the other condition in a national study. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes for the comorbidity are not known. Etiological theories include common factors, secondary SUD, secondary mental disorder, and bidirectional models. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiologic theories'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals with dual diagnosis are more likely to be nonadherent to treatment and have poorer outcomes than those with mental disorders or SUDs alone. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Course of illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In specialty mental health and SUD treatment settings, individuals should be assessed for the presence of a comorbid disorder. This can be done through routine screening with a validated, age-appropriate tool. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis needs to distinguish between primary mental disorders and substance-induced conditions. Assessment of the patient's presentation and history should identify the temporal relationships between episodes of mental illness and substance abuse. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals with dual diagnosis are at higher risk of suicide than those with either SMI or SUD alone and should be explicitly assessed and monitored. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=see_link\">",
"       \"Suicidal ideation and behavior in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Integrated care for dual diagnosis is preferred over split care. If care for the two conditions is carried out by two or more clinicians, communication and coordination between clinicians is essential. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the use of antipsychotic drugs for treating schizophrenia in the presence of comorbid SUDs (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). No advantage has been shown between first and second-generation antipsychotics in dual diagnosis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Schizophrenia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29241?source=see_link\">",
"       \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend the use of antidepressant medications in patients with depression in the presence of an active SUD (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In addition to reducing depressive symptoms, antidepressants can reduce substance use among patients who experience a robust reduction in depressive symptoms. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Depression'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that clinicians generally avoid using benzodiazepines in the treatment of anxiety disorders and comorbid SUD as there is increased potential for abuse. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Anxiety disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among medications for alcohol dependence, we suggest first-line use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      , which is best supported by research studies of patients with dual diagnosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Some evidence suggests that it may be less effective in the setting of comorbid depression. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Substance use disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychosocial treatments hold promise for as adjunctive treatment in the management of patients with dual diagnosis. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Psychosocial treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/1\">",
"      Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Organ 2004; 82:858.",
"     </a>",
"    </li>",
"    <li>",
"     New Freedom Commission on Mental Health. Achieving the Promise: Transforming Mental Health Care in America. DHHS, Final Report, Publication no. SMA-03-3832. Rockville, MD 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/3\">",
"      Kessler RC, Nelson CB, McGonagle KA, et al. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 1996; 66:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/4\">",
"      Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 2002; 59:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/5\">",
"      Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/6\">",
"      Sherwood Brown E, Suppes T, Adinoff B, Rajan Thomas N. Drug abuse and bipolar disorder: comorbidity or misdiagnosis? J Affect Disord 2001; 65:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/7\">",
"      Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict Behav 1998; 23:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/8\">",
"      Chambers RA, Bickel WK, Potenza MN. A scale-free systems theory of motivation and addiction. Neurosci Biobehav Rev 2007; 31:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/9\">",
"      Krystal JH, D'Souza DC, Gallinat J, et al. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotox Res 2006; 10:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/10\">",
"      Feng Y. Convergence and divergence in the etiology of myelin impairment in psychiatric disorders and drug addiction. Neurochem Res 2008; 33:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/11\">",
"      Swann AC, Dougherty DM, Pazzaglia PJ, et al. Impulsivity: a link between bipolar disorder and substance abuse. Bipolar Disord 2004; 6:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/12\">",
"      Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry 2004; 56:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/13\">",
"      Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985; 142:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/14\">",
"      Havassy BE, Alvidrez J, Owen KK. Comparisons of patients with comorbid psychiatric and substance use disorders: implications for treatment and service delivery. Am J Psychiatry 2004; 161:139.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Improving the Quality of Health Care for Mental and Substance-Use Conditions: Quality Chasm Series, National Academy Press 2006. p.210.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/16\">",
"      Watkins KE, Burnam A, Kung FY, Paddock S. A national survey of care for persons with co-occurring mental and substance use disorders. Psychiatr Serv 2001; 52:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/17\">",
"      Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996; 47:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/18\">",
"      Mueser, K. Psychosocial interventions for adults with severe mental illnesses and co-occurring substance use disorders: a review of specific interventions. J Dual Diagn 2005; 1:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/19\">",
"      Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/20\">",
"      Pages KP, Russo JE, Wingerson DK, et al. Predictors and outcome of discharge against medical advice from the psychiatric units of a general hospital. Psychiatr Serv 1998; 49:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/21\">",
"      Cuffel BJ, Shumway M, Chouljian TL, MacDonald T. A longitudinal study of substance use and community violence in schizophrenia. J Nerv Ment Dis 1994; 182:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/22\">",
"      Wallace C, Mullen PE, Burgess P. Criminal offending in schizophrenia over a 25-year period marked by deinstitutionalization and increasing prevalence of comorbid substance use disorders. Am J Psychiatry 2004; 161:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/23\">",
"      Drake RE, Osher FC, Wallach MA. Homelessness and dual diagnosis. Am Psychol 1991; 46:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/24\">",
"      Turkington A, Mulholland CC, Rushe TM, et al. Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. Br J Psychiatry 2009; 195:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/25\">",
"      Cornelius JR, Salloum IM, Mezzich J, et al. Disproportionate suicidality in patients with comorbid major depression and alcoholism. Am J Psychiatry 1995; 152:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/26\">",
"      Dassori AM, Mezzich JE, Keshavan M. Suicidal indicators in schizophrenia. Acta Psychiatr Scand 1990; 81:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/27\">",
"      McIntyre RS, Muzina DJ, Kemp DE, et al. Bipolar disorder and suicide: research synthesis and clinical translation. Curr Psychiatry Rep 2008; 10:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/28\">",
"      Zimmerman M, Sheeran T, Chelminski I, Young D. Screening for psychiatric disorders in outpatients with DSM-IV substance use disorders. J Subst Abuse Treat 2004; 26:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/29\">",
"      Tiet QQ, Finney JW, Moos RH. Screening psychiatric patients for illicit drug use disorders and problems. Clin Psychol Rev 2008; 28:578.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-IV-TR), 4th ed, APA Press, Washington DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/31\">",
"      Magura S. Effectiveness of dual focus mutual aid for co-occurring substance use and mental health disorders: a review and synthesis of the \"Double Trouble\" in Recovery evaluation. Subst Use Misuse 2008; 43:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/32\">",
"      Smelson DA, Ziedonis D, Williams J, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol 2006; 26:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/33\">",
"      Sayers SL, Campbell EC, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 2005; 193:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/34\">",
"      Green AI, Tohen MF, Hamer RM, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 2004; 66:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/35\">",
"      Rubio G, Mart&iacute;nez I, Ponce G, et al. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006; 51:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/36\">",
"      Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia in psychiatric patients with substance use disorders. Am J Drug Alcohol Abuse 1990; 16:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/37\">",
"      Potvin S, Pampoulova T, Mancini-Mari&euml; A, et al. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry 2006; 77:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/38\">",
"      Soni SD, Brownlee M. Alcohol abuse in chronic schizophrenics: implications for management in the community. Acta Psychiatr Scand 1991; 84:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/39\">",
"      Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 2004; 291:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/40\">",
"      Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 2010; 167:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/41\">",
"      Torrens M, Fonseca F, Mateu G, Farr&eacute; M. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend 2005; 78:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/42\">",
"      Salloum IM, Cornelius JR, Daley DC, et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 2005; 62:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/43\">",
"      Geller B, Cooper TB, Sun K, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998; 37:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/44\">",
"      Brown ES, Garza M, Carmody TJ. A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. J Clin Psychiatry 2008; 69:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/45\">",
"      Tollefson GD, Montague-Clouse J, Tollefson SL. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol 1992; 12:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/46\">",
"      Labbate LA, Sonne SC, Randal CL, et al. Does comorbid anxiety or depression affect clinical outcomes in patients with post-traumatic stress disorder and alcohol use disorders? Compr Psychiatry 2004; 45:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/47\">",
"      Brunette MF, Noordsy DL, Xie H, Drake RE. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv 2003; 54:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/48\">",
"      Posternak MA, Mueller TI. Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence. Am J Addict 2001; 10:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/49\">",
"      Petrakis IL, O'Malley S, Rounsaville B, et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 2004; 172:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/50\">",
"      Petrakis IL, Poling J, Levinson C, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biol Psychiatry 2006; 60:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/51\">",
"      Petrakis I, Ralevski E, Nich C, et al. Naltrexone and disulfiram in patients with alcohol dependence and current depression. J Clin Psychopharmacol 2007; 27:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/52\">",
"      Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. Am J Addict 2007; 16:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/53\">",
"      Cleary M, Hunt G, Matheson S, et al. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 2008; :CD001088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/54\">",
"      Graeber DA, Moyers TB, Griffith G, et al. A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. Community Ment Health J 2003; 39:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/55\">",
"      Kavanagh DJ, Young R, White A, et al. A brief motivational intervention for substance misuse in recent-onset psychosis. Drug Alcohol Rev 2004; 23:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/56\">",
"      Swanson AJ, Pantalon MV, Cohen KR. Motivational interviewing and treatment adherence among psychiatric and dually diagnosed patients. J Nerv Ment Dis 1999; 187:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/57\">",
"      Baker A, Lewin T, Reichler H, et al. Evaluation of a motivational interview for substance use within psychiatric in-patient services. Addiction 2002; 97:1329.",
"     </a>",
"    </li>",
"    <li>",
"     Hickman, ME. The effects of personal feedback on alcohol intake in dually diagnosed clients: an empirical study of William R. Miller's motivational enhancement therapy. Unpublished thesis. University Graduate School, Dept. Counseling Psychology, Indiana University 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/59\">",
"      Edwards J, Elkins K, Hinton M, et al. Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatr Scand 2006; 114:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/60\">",
"      Naeem F, Kingdon D, Turkington D. Cognitive behavior therapy for schizophrenia in patients with mild to moderate substance misuse problems. Cogn Behav Ther 2005; 34:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/61\">",
"      Schmitz JM, Averill P, Sayre S, et al. Cognitive-Behavioral Treatment of Bipolar Disorder and Substance Abuse: A Preliminary Randomized Study. Addictive Disorders and Their Treatment 2002; 1:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/62\">",
"      Weiss RD, Griffin ML, Kolodziej ME, et al. A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Am J Psychiatry 2007; 164:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/63\">",
"      Najavits LM, Gallop RJ, Weiss RD. Seeking safety therapy for adolescent girls with PTSD and substance use disorder: a randomized controlled trial. J Behav Health Serv Res 2006; 33:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/64\">",
"      Hien DA, Cohen LR, Miele GM, et al. Promising treatments for women with comorbid PTSD and substance use disorders. Am J Psychiatry 2004; 161:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/65\">",
"      Baker A, Bucci S, Lewin TJ, et al. Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial. Br J Psychiatry 2006; 188:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/66\">",
"      Barrowclough C, Haddock G, Tarrier N, et al. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 2001; 158:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/67\">",
"      Burnam MA, Morton SC, McGlynn EA, et al. An experimental evaluation of residential and nonresidential treatment for dually diagnosed homeless adults. J Addict Dis 1995; 14:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/68\">",
"      Chandler DW, Spicer G. Integrated treatment for jail recidivists with co-occurring psychiatric and substance use disorders. Community Ment Health J 2006; 42:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/69\">",
"      Drake RE, McHugo GJ, Clark RE, et al. Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial. Am J Orthopsychiatry 1998; 68:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/70\">",
"      Essock SM, Mueser KT, Drake RE, et al. Comparison of ACT and standard case management for delivering integrated treatment for co-occurring disorders. Psychiatr Serv 2006; 57:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/71\">",
"      Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders. Cochrane Database Syst Rev 2000; :CD001089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/72\">",
"      Mueser KT, Bond GR, Drake RE, Resnick SG. Models of community care for severe mental illness: a review of research on case management. Schizophr Bull 1998; 24:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/73\">",
"      Bond, GR, McDonel, EC, Miller, LD, Pensec, M. Assertive community treatment and reference groups: an evaluation of their effectiveness for young adults with serious mental illness and substance abuse problems. Psychosocial rehabilitation Journal 1991; 15:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/74\">",
"      Jerrell JM, Ridgely MS. Comparative effectiveness of three approaches to serving people with severe mental illness and substance abuse disorders. J Nerv Ment Dis 1995; 183:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/75\">",
"      Lehman AF, Herron JD, Schwartz RP, Myers CP. Rehabilitation for adults with severe mental illness and substance use disorders. A clinical trial. J Nerv Ment Dis 1993; 181:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36521/abstract/76\">",
"      Burns T, Catty J, Dash M, et al. Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression. BMJ 2007; 335:336.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7798 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_42_36521=[""].join("\n");
var outline_f35_42_36521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGIC THEORIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Underrecognition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Course of illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Suicidality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ASSESSMENT AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Suicidality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Medication treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Bipolar disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Anxiety disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Psychosocial treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Overall efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Specific interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7798\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7798|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/16/17675\" title=\"table 1\">",
"      Screening SUDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/7/13436\" title=\"table 2\">",
"      Pysch Sx of SUDs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4554?source=related_link\">",
"      Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29241?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34952?source=related_link\">",
"      Tardive dyskinesia: Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_42_36522="Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy";
var content_f35_42_36522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/42/36522/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36522/contributors\">",
"     Martin S. Maron, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36522/contributors\">",
"     Perry M Elliott, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/42/36522/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36522/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/42/36522/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/42/36522/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/42/36522/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy (HCM) is a genetically determined heart muscle disease most often (60 to 70 percent) caused by mutations in one of several sarcomere genes which encode components of the contractile apparatus of the heart. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HCM is characterized by left ventricular hypertrophy of various morphologies, with a wide array of clinical manifestations and hemodynamic abnormalities (",
"    <a class=\"graphic graphic_figure graphicRef58156 \" href=\"mobipreview.htm?11/9/11411\">",
"     figure 1",
"    </a>",
"    ). Depending in part upon the site and extent of cardiac hypertrophy, HCM patients can develop one or more of the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LV outflow obstruction (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=see_link\">",
"       \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diastolic dysfunction",
"     </li>",
"     <li>",
"      Myocardial ischemia",
"     </li>",
"     <li>",
"      Mitral regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These structural and functional abnormalities can produce a variety of symptoms, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Presyncope or syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In broad terms, the symptoms related to HCM can be categorized as those related to heart failure (HF), chest pain, or arrhythmias. Patients with HCM have an increased incidence of both supraventricular and ventricular arrhythmias and are at an increased risk for sudden cardiac death (SCD). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the majority of patients with HCM, LVH is not progressive, and HCM is compatible with normal longevity in the vast majority with a 1 percent annual mortality rate among non-referral based cohorts. A small subset of patients, however, remains at risk for a number of adverse disease-related complications including: sudden death, usually in the absence of symptoms; progressive heart failure symptoms occasionally associated with systolic dysfunction; and atrial fibrillation with risk of thromboembolic stroke.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy will be reviewed here. Other issues such as the natural history and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32841?source=see_link\">",
"     \"Natural history of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10105?source=see_link\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274510\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of HCM in the general population, as determined from echocardiographic studies in the United States, Japan, and China, is approximately 1 out of every 500 adults (0.2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274517\">",
"    <span class=\"h1\">",
"     HISTOLOGIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathology in patients with HCM reveals hypertrophied myocytes arranged in a chaotic and disorganized fashion with a varying amount of interstitial fibrosis intertwined among the myocyte. In addition, the intramural coronary arterioles are structurally abnormal with decreased luminal cross-sectional area and impaired vasodilatory capacity resulting in blunted myocardial blood flow during stress (ie, \"small vessel ischemia\"). Over time, repetitive bouts of small vessel ischemia lead to myocyte cell death and ultimately repair in the form of replacement fibrosis (",
"    <a class=\"graphic graphic_picture graphicRef55914 \" href=\"mobipreview.htm?11/5/11352\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274524\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with HCM have no or only minor symptoms; thus, affected individuals are often diagnosed as a result of family screening, detection of a murmur during routine examination, or the identification of an abnormal ECG. However, among those who come to clinical attention at referral centers, left ventricular outflow tract (LVOT) gradients and symptoms of dyspnea, fatigue, chest pain, and syncope are the most common clinical manifestations. Patients with mild to moderate limitation usually experience slow progression of symptoms with advancing age in association with a modest deterioration in left ventricular function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274531\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of HCM are variable, and there is not a strong correlation between the presence or magnitude of LVOT obstruction, the extent of LV hypertrophy, and symptoms. Some patients with severe LVOT obstruction remain asymptomatic for many years, while others without LVOT obstruction may have significant limitation.",
"   </p>",
"   <p>",
"    While many patients with HCM are asymptomatic, others develop one or more of the following symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dyspnea on exertion",
"     </li>",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Atypical or anginal chest pain",
"     </li>",
"     <li>",
"      Presyncope and syncope, particularly during or immediately following exertion",
"     </li>",
"     <li>",
"      Palpitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Advanced heart failure symptoms of orthopnea, paroxysmal nocturnal dyspnea, and edema are uncommon. The frequency of symptoms at diagnosis varies considerably depending on whether the population being studied is a cross section of the overall population or patients at a referral center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 320 patients from three referral centers, transthoracic echocardiography was performed in all patients, with subsequent stress echocardiography only in those whose LVOT gradient was &lt;50 mmHg at rest [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/7\">",
"       7",
"      </a>",
"      ]. The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      169 patients (59 percent) had NYHA Class II or greater dyspnea at presentation.",
"     </li>",
"     <li>",
"      119 patients (37 percent) had a resting LVOT gradient &ge;50 mmHg, while 201 patients (63 percent) had a resting LVOT gradient &lt;50 mmHg (mean 4 mmHg). With exercise, 76 (24 percent) developed an LVOT gradient &ge;50 mmHg, and 46 (14 percent) developed dyspnea with exertion.",
"     </li>",
"     <li>",
"      95 patients (30 percent) were asymptomatic with little or no gradient (&le;30 mmHg) at rest or with exertion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 277 outpatients from a regional cohort (non-referral population) who were followed for eight years, approximately 90 percent were asymptomatic at presentation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/8\">",
"       8",
"      </a>",
"      ]. During the eight-year follow-up, 69 percent remained asymptomatic or had only mild symptoms, and survival in adults was similar to a normal control age-matched population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, among patients referred for evaluation of HCM, both heart failure symptoms and outflow gradients are common, although in many cases exercise testing may be necessary to demonstrate these abnormalities.",
"   </p>",
"   <p>",
"    The clinical presentation also may be affected by gender. In a review of 969 consecutive patients from the United States and Italy, women were significantly older at presentation than men (47 versus 38 years), more symptomatic (New York Heart Association class 1.8 versus 1.4) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ), and more likely to have left ventricular outflow tract obstruction (37 versus 23 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/9\">",
"     9",
"    </a>",
"    ]. At a mean follow-up of 6.2 years, women had significantly higher rates of progression to NYHA class III or IV and death from heart failure or stroke.",
"   </p>",
"   <p>",
"    Symptoms can be induced by a variety of mechanisms which may include LVOT obstruction, impaired myocardial function, brady- or tachyarrhythmias, or impaired filling due to diastolic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/10\">",
"     10",
"    </a>",
"    ]. The importance of these mechanisms may change with time and stage of disease. Some patients, for example, are initially symptomatic because of obstruction. As the myocardial disease worsens over time, the heart may enlarge, obstruction lessens, and symptoms are primarily due to systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=see_link&amp;anchor=H8#H8\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\", section on 'Pathophysiology and evolution of LV outflow obstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274538\">",
"    <span class=\"h3\">",
"     Relationship of symptoms to age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age of the patient at diagnosis and the presence or absence of symptoms provide important prognostic information. In general, patients diagnosed during childhood or adolescence have more symptoms and a poorer prognosis compared with those diagnosed as adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32841?source=see_link\">",
"     \"Natural history of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274545\">",
"    <span class=\"h3\">",
"     Relationship of symptoms to pressure gradient",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pressure gradient between the LVOT and aorta is present in the majority of HCM patients (75 percent), either at rest or following provocation (",
"    <a class=\"graphic graphic_waveform graphicRef65202 graphicRef50580 \" href=\"mobipreview.htm?13/44/14026\">",
"     waveform 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/11\">",
"     11",
"    </a>",
"    ]. Outflow tract gradients in HCM are dynamic, characterized by spontaneous variability on a day-to-day (or even hourly) basis, and influenced by factors that alter myocardial contractility and loading conditions (eg, dehydration, ingestion of alcohol, or heavy meals). As such, for patients who do not have evidence of LVOT obstruction under resting conditions, an attempt should be made at provoking gradients as the presence of LVOT obstruction will affect management decisions. Exercise (stress) echocardiography using a standard symptom limited Bruce protocol is the preferred method as this mimics most closely the conditions that patients would be experiencing provocable gradients with daily activities. Alternatively, pharmacologic agents (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/1/33813?source=see_link\">",
"     amyl nitrite",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    ) and Valsalva maneuver can also be employed to induce gradients, although these are non-physiologic maneuvers that may not reflect the true magnitude of outflow gradients experienced during routine daily activities. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Echocardiography'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Exercise testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, despite the presence of LVOT obstruction, there is not a predictable correlation between the degree of LVOT obstruction and symptoms. Some patients with severe LVOT obstruction remain asymptomatic for many years; at the other extreme, cardiac arrest or sudden death may be the initial presentation in those with or without obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274552\">",
"    <span class=\"h3\">",
"     Dyspnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspnea on exertion is the most common symptom in persons with HCM, occurring in over 90 percent of symptomatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/10\">",
"     10",
"    </a>",
"    ]. Dyspnea can result from a variety of mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diastolic dysfunction due to myocardial hypertrophy",
"     </li>",
"     <li>",
"      Impaired left ventricular emptying due to LVOT obstruction, resulting in increased left ventricular end-diastolic pressure",
"     </li>",
"     <li>",
"      Mitral regurgitation",
"     </li>",
"     <li>",
"      Systolic dysfunction in a patient with more extensive myocardial involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Paroxysmal nocturnal dyspnea and orthopnea are uncommon presenting symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274559\">",
"    <span class=\"h3\">",
"     Chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical exertional chest pain (ie, angina) occurs in 25 to 30 percent of patients with HCM, usually in the setting of a normal coronary arteriogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Some patients also complain of prolonged episodes of atypical chest pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/14\">",
"     14",
"    </a>",
"    ]. This chest pain is commonly precipitated or worsened by heavy meals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34042?source=see_link\">",
"     \"Diagnostic approach to chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several of the pathophysiologic features of hypertrophic cardiomyopathy predispose to the development of microvascular angina, which may be induced by an increase in myocardial oxygen demand or a reduction in myocardial blood flow and oxygen supply [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/13\">",
"     13",
"    </a>",
"    ]. Factors that increase myocardial oxygen demand include myocyte hypertrophy and increased muscle mass, myocyte disarray (",
"    <a class=\"graphic graphic_picture graphicRef73467 \" href=\"mobipreview.htm?40/33/41494\">",
"     picture 2",
"    </a>",
"    ), and left ventricular outflow tract obstruction and increased wall stress due to elevated diastolic pressures. Factors that reduce myocardial blood flow in HCM, particularly with exertion, include impaired vasodilator reserve, myocardial bridging with systolic and early diastolic compression of intramural vessels, small vessel disease (",
"    <a class=\"graphic graphic_picture graphicRef55914 \" href=\"mobipreview.htm?11/5/11352\">",
"     picture 1",
"    </a>",
"    ) and microvascular dysfunction, myocardial fibrosis, and increased capillary separation and inadequate capillary density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/13,15-20\">",
"     13,15-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many studies have shown that, during pacing or pharmacologic stress, myocardial blood flow is abnormal in patients with HCM and often associated with metabolic evidence for myocardial ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/12,15,19,21,22\">",
"     12,15,19,21,22",
"    </a>",
"    ]. Myocardial perfusion in patients with HCM can be assessed using exercise or pharmacologic stress testing. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Exercise testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274566\">",
"    <span class=\"h3\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both supraventricular arrhythmias, primarily atrial fibrillation, and ventricular arrhythmias occur in HCM. Patients with an arrhythmia may present with palpitations, increasing dyspnea, presyncope, or syncope, with occasional patients presenting with sudden cardiac death due to sustained ventricular arrhythmias.",
"   </p>",
"   <p>",
"    The arrhythmias associated with HCM, as well as their treatment, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274573\">",
"    <span class=\"h3\">",
"     Syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 15 to 25 percent of patients with HCM report at least one syncopal episode. Another 20 percent complain of presyncope. Multiple mechanisms may lead to an inadequate cardiac output or abnormal peripheral vascular reflexes, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atrial fibrillation",
"     </li>",
"     <li>",
"      Conduction abnormalities and atrioventricular nodal block [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/23-27\">",
"       23-27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      LVOT obstruction",
"     </li>",
"     <li>",
"      Ventricular baroreflex activation with inappropriate vasodilatation",
"     </li>",
"     <li>",
"      Myocardial ischemia during exertion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the reported predictors of syncope in patients with HCM are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age less than 30 years",
"     </li>",
"     <li>",
"      Small left ventricular end-diastolic volume and small left ventricular cavity size (irrespective of obstruction and hypertrophy)",
"     </li>",
"     <li>",
"      Episodes of nonsustained ventricular tachycardia on 72-hour ambulatory electrocardiographic monitoring [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/23,28\">",
"       23,28",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unexplained syncope (ie, not related to",
"    <span class=\"nowrap\">",
"     neurocardiogenic/vasovagal",
"    </span>",
"    causes) is considered a marker for increased risk of sudden death, particularly when recent and when occurring in young patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274580\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination in a patient with HCM may be normal or may reveal nonspecific abnormalities such as a fourth heart sound, systolic murmur,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a left ventricular lift. Many of the classically described physical examination findings in patients with HCM are associated with LVOT obstruction. Persons with minimal or no LVOT obstruction may have normal or nearly normal physical examinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274587\">",
"    <span class=\"h3\">",
"     Systolic murmurs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HCM may develop several types of systolic murmurs, but the two most common are related to LVOT obstruction and mitral regurgitation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant LVOT obstruction, often due to a combination of LV upper septal hypertrophy and systolic anterior motion (SAM) of the mitral valve, results in a harsh crescendo-decrescendo systolic murmur that begins slightly after S1 and is heard best at the apex and lower left sternal border. The murmur may radiate to the axilla and base, but usually not into the neck. It may reflect both aortic outflow obstruction and mitral regurgitation in patients with a large gradient (",
"      <a class=\"graphic graphic_waveform graphicRef52365 \" href=\"mobipreview.htm?34/62/35822\">",
"       waveform 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link&amp;anchor=H18#H18\">",
"       \"Auscultation of cardiac murmurs\", section on 'Subvalvular outflow obstruction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      SAM of the mitral valve, or abnormal mitral valve anatomy related to papillary muscle or chordae tendineae abnormalities, can lead to impaired leaflet coaptation and mitral regurgitation, usually with a posteriorly directed jet, which produces a mid-late systolic murmur at the apex. Centrally directed mitral regurgitation, usually associated with primary mitral valve pathology, classically results in a holosystolic murmur heard loudest at the apex which radiates to the axilla. However, if the regurgitant jet is eccentrically directed, the murmur can radiate toward the base of the heart and may be confused with the murmur of LVOT obstruction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=see_link&amp;anchor=H10#H10\">",
"       \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\", section on 'Development of mitral regurgitation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link&amp;anchor=H24#H24\">",
"       \"Auscultation of cardiac murmurs\", section on 'Mitral regurgitation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The systolic murmur related to LVOT obstruction in HCM is often similar to that of valvular aortic stenosis and subvalvular aortic stenosis (subaortic stenosis), and differentiating these conditions is difficult on routine auscultation. However, the patient can be asked to perform a series of maneuvers and position changes which can aid in making the correct diagnosis. Maneuvers that affect the degree of LVOT obstruction cause a change in intensity of the outflow tract crescendo-decrescendo murmur (",
"    <a class=\"graphic graphic_table graphicRef51024 \" href=\"mobipreview.htm?42/11/43196\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=see_link\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increase in intensity, due to enhancement of obstruction, is seen with the assumption of an upright posture from a squatting, sitting, or supine position; the Valsalva maneuver; during the more forceful contraction that follows the compensatory pause after a ventricular premature beat; and following the administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      A decrease in intensity, due to attenuation of obstruction, is heard after going from a standing to a sitting or squatting position, with handgrip, and following passive elevation of the legs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The murmur in valvular aortic stenosis does not change substantially, or decreases slightly following the Valsalva maneuver and usually radiates into the neck, while the murmur in subaortic stenosis (most commonly seen in children) tends to decrease following Valsalva maneuver. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41876?source=see_link\">",
"     \"Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274594\">",
"    <span class=\"h3\">",
"     Other physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;While a number of other physical findings may be observed in patients with HCM, none is pathognomonic for HCM.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first heart sound is typically normal. In patients without severe obstruction, the second heart sound splits normally; however, the split may be paradoxic if there is severe left ventricular outflow obstruction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=see_link\">",
"       \"Auscultation of heart sounds\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A third or fourth heart sound is common in young patients but rarely heard in later life.",
"     </li>",
"     <li>",
"      The arterial or carotid pulse may be brisk in upstroke and bifid; this results from sudden deceleration of blood due to the development of midsystolic obstruction to blood flow and partial closure of the aortic valve. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33013?source=see_link\">",
"       \"Examination of the arterial pulse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inspection of the neck veins may reveal a prominent \"a\" wave. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33719?source=see_link\">",
"       \"Examination of the jugular venous pulse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is often a diffuse, forceful LV apical impulse. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9909?source=see_link\">",
"       \"Examination of the precordial pulsation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A presystolic apical impulse may be felt, reflecting atrial systole.",
"     </li>",
"     <li>",
"      A systolic thrill may be appreciated at the apex or lower left sternal border.",
"     </li>",
"     <li>",
"      A parasternal lift suggests significant mitral regurgitation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pulmonary hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18608369\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of tests have been used in the evaluation of patients with possible HCM. Appropriate testing as indicated when the diagnosis of HCM is being considered, or when suggestive clinical signs or symptoms are present, can be used:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      To establish the diagnosis of HCM",
"     </li>",
"     <li>",
"      To identify the presence or severity of left ventricular outflow tract (LVOT) obstruction",
"     </li>",
"     <li>",
"      To identify the presence or severity of mitral regurgitation",
"     </li>",
"     <li>",
"      To assess the risk for arrhythmia (both supraventricular and ventricular)",
"     </li>",
"     <li>",
"      To assess overall left ventricular function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to performing a comprehensive cardiac history and physical examination and an electrocardiogram (ECG), cardiac imaging to identify left ventricular hypertrophy (LVH) should be performed in all patients. Typically, the presence or absence of LVH can be satisfactorily identified using echocardiography, although another imaging modality such as cardiac magnetic resonance (CMR) may be necessary in persons with non-diagnostic or suboptimal quality echocardiograms. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Echocardiography'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H24\">",
"     'Cardiovascular magnetic resonance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In persons with ECG and echocardiographic (or CMR) evidence of HCM, ambulatory ECG monitoring and exercise stress testing should be performed for additional prognostic information and risk stratification purposes. Additional testing may not be necessary in an asymptomatic or mildly symptomatic patient; such patients may be discovered because of a positive family history or an abnormal ECG obtained for some other reason. In contrast, a more thorough and detailed evaluation is necessary for symptoms such as syncope, or prior to and following surgical myectomy or septal ablation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10105?source=see_link\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H612576623\">",
"    <span class=\"h2\">",
"     Electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electrocardiogram (ECG) should be performed in all patients when considering a diagnosis of HCM. ECG testing is the most sensitive routinely performed diagnostic test for HCM, but the ECG abnormalities are not specific to HCM and should prompt further diagnostic evaluation, usually with echocardiography.",
"   </p>",
"   <p>",
"    A normal ECG is uncommon, seen in less than 10 percent of patients with HCM. In a cohort of 2485 consecutive patients with HCM who were evaluated at a single center, a normal ECG was seen in only 135 patients (5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/13/3285?source=see_link\">",
"     \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Typically, the ECG is abnormal with localized or widespread repolarization changes (",
"    <a class=\"graphic graphic_waveform graphicRef76497 \" href=\"mobipreview.htm?41/57/42906\">",
"     waveform 3",
"    </a>",
"    ). Prominent voltages with repolarization changes are typical of HCM associated with storage disease (eg, Danon's disease), while prominent voltages in isolation are rare as an ECG manifestation in HCM. Other ECG findings may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prominent abnormal Q waves, particularly in the inferior (II, III, and aVF) and lateral leads (I, aVL, and V4-V6). These changes reflect septal depolarization of the hypertrophied myopathic tissue. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/0/36868?source=see_link\">",
"       \"Pathogenesis and diagnosis of Q waves on the electrocardiogram\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      P wave abnormalities, reflecting left atrial or biatrial enlargement. The combination of left ventricular hypertrophy (LVH) with right atrial enlargement is strongly suggestive of HCM.",
"     </li>",
"     <li>",
"      Left axis deviation.",
"     </li>",
"     <li>",
"      Deeply inverted T waves (so-called \"giant negative T waves\") may be seen in the mid-precordial leads (V2 through V4) in patients with the apical variant of HCM. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=see_link&amp;anchor=H5#H5\">",
"       \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\", section on 'Apical HCM'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive transthoracic echocardiography (TTE) with two-dimensional, color Doppler, spectral Doppler, and tissue Doppler imaging should be performed in all patients when considering a diagnosis of HCM. TTE can demonstrate cardiac morphology, systolic and diastolic function, the presence and severity of any LVOT gradient, and the degree of mitral regurgitation (",
"    <a class=\"graphic graphic_figure graphicRef78478 \" href=\"mobipreview.htm?26/44/27343\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78895 \" href=\"mobipreview.htm?38/34/39471\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef79426 \" href=\"mobipreview.htm?0/20/321\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef65618 \" href=\"mobipreview.htm?29/63/30705\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87655 \" href=\"mobipreview.htm?33/8/33923\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/11,31-35\">",
"     11,31-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     LV hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical diagnosis of HCM is confirmed when unexplained increased LV wall thickness &ge;15 mm is imaged anywhere in the LV wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/35\">",
"     35",
"    </a>",
"    ]. A wall thickness of &ge;13 mm may also be considered diagnostic of HCM, particularly when identified in a patient whose family member also has HCM. The most common location for LV hypertrophy is the basal anterior septum in continuity with the anterior free wall, with the posterior septum (at the mid-LV level) the third most common location. Although LV hypertrophy often involves a substantial portion of the LV wall, an important minority of HCM patients (10 percent) have increased wall thickness confined to only one or two LV segments. Although typically asymmetric in distribution, any pattern of LV wall thickening (",
"    <a class=\"graphic graphic_figure graphicRef58156 \" href=\"mobipreview.htm?11/9/11411\">",
"     figure 1",
"    </a>",
"    ) can be seen in HCM, including apical and concentric LV hypertrophy in a small minority (1 percent).",
"   </p>",
"   <p>",
"    The distribution of LVH on 2-D echocardiography is assessed in a variety of views but primarily in the parasternal short-axis plane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The presence and extent of LVH is evaluated in diastole at the level of the mitral valve and the papillary muscle (",
"    <a class=\"graphic graphic_movie graphicRef76594 \" href=\"mobipreview.htm?3/25/3472\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef54527 \" href=\"mobipreview.htm?40/20/41295\">",
"     movie 4",
"    </a>",
"    ). Parasternal long-axis, and apical 2- and 4-chamber views are also used to integrate the information obtained from the short-axis images (",
"    <a class=\"graphic graphic_movie graphicRef65618 \" href=\"mobipreview.htm?29/63/30705\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef52853 \" href=\"mobipreview.htm?6/26/6563\">",
"     movie 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524640286\">",
"    <span class=\"h3\">",
"     Systolic anterior motion of the mitral valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HCM frequently have systolic anterior motion (SAM) of the mitral valve, which positions the mitral valve within the LVOT. SAM of the mitral valve may result in LVOT obstruction when there is contact between the mitral valve and the septum. The greater the duration of mitral-septal contact, the higher the LVOT obstruction (",
"    <a class=\"graphic graphic_figure graphicRef55841 \" href=\"mobipreview.htm?14/51/15157\">",
"     figure 3",
"    </a>",
"    ). The presence of SAM is not a requirement for a diagnosis of HCM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     LVOT obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography can be used to accurately measure noninvasively the presence and magnitude of LV outflow gradients using continuous-wave Doppler techniques. The apical long-axis imaging window provides the best views to obtain Doppler estimates of the LVOT pressure gradient, and particular care must be taken to separate the LVOT signals from those due to mitral regurgitation (",
"    <a class=\"graphic graphic_waveform graphicRef52365 \" href=\"mobipreview.htm?34/62/35822\">",
"     waveform 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/33\">",
"     33",
"    </a>",
"    ]. The aortic valve motion may display early-systolic closure and a \"peak and dome\" configuration of aortic pressure and velocity, which corresponds to transient mid systolic obstruction and a reduction in stroke volume (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75078 \" href=\"mobipreview.htm?8/21/8532\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Outflow tract gradients in HCM are dynamic, characterized by spontaneous variability on a day-to-day (or even hourly) basis, and are influenced by factors that alter myocardial contractility and loading conditions (eg, dehydration, ingestion of alcohol, or heavy meals). Therefore, for patients who do not have obstruction under resting conditions, provoking gradients for the purpose of management decisions is crucial. Exercise (stress) echocardiography using a standard symptom limited Bruce protocol is the preferred method as this mimics most closely the conditions that patients would be experiencing on a daily basis. Alternatively, pharmacologic agents (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/1/33813?source=see_link\">",
"     amyl nitrite",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    ) and Valsalva maneuver can also been employed to induce gradients, although these are non-physiologic maneuvers which may not reflect the true magnitude of outflow gradients experienced during routine daily activities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=see_link\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A pressure gradient between the LVOT and aorta is present in the majority of HCM patients (75 percent) at rest or with provocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/11\">",
"     11",
"    </a>",
"    ]. As an example, in a cohort of 201 patients with HCM and no resting LVOT gradient who underwent exercise testing, 106 (53 percent) developed LVOT gradients &ge;30 mmHg, including 76 of whom developed gradients &ge;50 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/7\">",
"     7",
"    </a>",
"    ]. These findings suggest that patients with symptomatic HCM without LVOT obstruction at rest should undergo exercise echocardiography to assess for potential latent obstruction since identification of such obstruction would provide a therapeutic target and may prompt more aggressive medical therapy and consideration of septal reduction therapies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10105?source=see_link\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H273557\">",
"    <span class=\"h2\">",
"     Ambulatory ECG monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulatory ECG monitoring should be performed for 24 to 48 hours in all patients diagnosed with HCM (based on clinical and imaging findings) as part of the risk assessment for ventricular arrhythmias and risk for sudden death. In addition, in patients with palpitations in whom the etiology is uncertain or if there is suspicion for atrial",
"    <span class=\"nowrap\">",
"     fibrillation/flutter,",
"    </span>",
"    ambulatory monitoring should also be considered.",
"   </p>",
"   <p>",
"    Ambulatory ECG monitoring and continuous loop recorders can identify nonsustained atrial and ventricular arrhythmias in patients with HCM and help to establish whether an arrhythmia is the cause of palpitation or impaired consciousness. Nonsustained ventricular tachycardia on Holter monitoring is associated with an increased risk for SCD, even in the asymptomatic patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=see_link&amp;anchor=H6#H6\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\", section on 'Nonsustained VT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We proceed with exercise stress testing in all patients with known or suspected HCM (based on clinical and imaging findings) as part of the risk stratification (ie, abnormal BP response to exercise) and for the assessment of LV outflow tract (LVOT) gradient. Exercise treadmill testing is the preferred method of stress, rather than using a pharmacologic stress agent, as a maximal treadmill or bicycle exercise stress test provides an objective measurement of functional capacity and information on the integrity of vascular responses and the risk of exercise related ischemia, arrhythmia, and obstruction. In addition, the results of exercise stress testing may lead to a change in patient management (eg, inducible ventricular arrhythmias or inducible LVOT gradient). The decision to add an imaging modality such as echocardiography or myocardial perfusion imaging to the stress test should be based on the usual indications for imaging during stress testing (eg, baseline electrocardiogram is uninterpretable). However, for the assessment of LVOT gradients, echocardiographic imaging should be performed in conjunction with the stress test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whenever feasible, initial exercise testing should be performed prior to the institution of therapy, although follow-up exercise testing on treatment may be indicated to assess the efficacy of a particular treatment. During exercise, some patients, particularly those who develop angina with marked ST segment changes, atrial fibrillation, hypotension, or large (&gt;100 mmHg) gradients, may be at risk of developing serious ventricular arrhythmia. However, the incidence of sustained",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    during exercise testing appears to be very low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35945?source=see_link&amp;anchor=H16#H16\">",
"     \"Performance of exercise ECG testing\", section on 'Exercise test procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinically important findings during exercise testing may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Development of symptoms such as angina, dyspnea, palpitation, or presyncope",
"     </li>",
"     <li>",
"      An increase in or development of LVOT gradient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/7,36\">",
"       7,36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Failure of blood pressure to increase appropriately with exercise or exercise-induced hypotension (see",
"      <a class=\"local\" href=\"#H20\">",
"       'BP response'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Clinically significant arrhythmias (eg, atrial fibrillation, ventricular tachycardia) at maximum exercise or immediately after exercise",
"     </li>",
"     <li>",
"      Severe ST segment depression during exercise may reflect myocardial ischemia, particularly if the ST and T of the resting electrocardiogram are normal",
"     </li>",
"     <li>",
"      An increase in, or the development of, mitral regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Myocardial ischemia during exercise testing commonly occurs in the absence of significant coronary artery disease, and has been reported to be associated with future risk of adverse cardiac events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/37\">",
"     37",
"    </a>",
"    ]. The pathophysiology of myocardial ischemia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15144?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\", section on 'Pathophysiology of angina'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the majority of exercise testing with imaging will involve echocardiography or SPECT myocardial perfusion imaging, positron emission tomography (PET) at baseline and after infusion of the coronary vasodilator",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    is another method of evaluating myocardial perfusion. The normal increase in myocardial blood flow in response to dipyridamole is impaired in patients with HCM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/19,38,39\">",
"     19,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Cardiopulmonary exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiopulmonary exercise testing to assess between respiratory and circulatory causes of exercise intolerance has no clear prognostic value and therefore is not part of the routine evaluation of HCM patients. However, cardiopulmonary exercise testing may rarely be considered for those patients in whom the etiology of dyspnea remains uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33398?source=see_link\">",
"     \"Functional exercise testing: Ventilatory gas analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the abnormalities that have been associated with HCM are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reductions in peak oxygen uptake and the anaerobic threshold, which are present in most patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An impaired stroke volume response to exercise, which can be caused by diastolic dysfunction, left ventricular outflow tract obstruction, or systolic impairment",
"     </li>",
"     <li>",
"      Chronotropic incompetence",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     BP response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal blood pressure response to maximum upright exercise testing includes at least a 20 mmHg increase in systolic pressure from rest to peak exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/41\">",
"     41",
"    </a>",
"    ]. However, 20 to 40 percent of patients with HCM fail to augment their baseline blood pressure during exercise; in some of these patients, the blood pressure falls below baseline values during or immediately following exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/25,41-44\">",
"     25,41-44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35945?source=see_link&amp;anchor=H20#H20\">",
"     \"Performance of exercise ECG testing\", section on 'BP measurements'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most patients, an abnormal exercise blood pressure is associated with an appropriate increase in cardiac output and inappropriate peripheral vasodilatation. Occasionally, however, the abnormal BP response is due to failure to increase cardiac output or the development of global myocardial ischemia or LVOT obstruction.",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/25,44\">",
"     25,44",
"    </a>",
"    ]. The exact trigger for a drop in BP during exercise is usually not known. However, an abnormal blood pressure response during a maximal symptom-limited exercise test is associated with an increased risk for SCD, particularly in patients younger than 40 years of age and in those with a family history of premature SCD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=see_link&amp;anchor=H17#H17\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\", section on 'Physical activity and SCD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Cardiovascular magnetic resonance",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the assessment of anatomic structures, cardiovascular magnetic resonance imaging (CMR) may provide additional information beyond that which is available from echocardiography. CMR may allow for identification of LV hypertrophy in segments not visualized well with echocardiography, better characterize structural abnormalities of the mitral valve and papillary muscles, and, when intravenous contrast with gadolinium is used, allow for identification of myocardial fibrosis. We suggest performing CMR for diagnostic purposes in selected patients in whom the diagnosis of HCM remains uncertain following echocardiography. It is reasonable to consider performing CMR for additional risk stratification purposes in all patients with suspected or diagnosed HCM if expense is not an issue (ie, as part of a research protocol). In addition, in patients with HCM being considered for invasive septal reduction therapy in whom the mitral valve and papillary muscle anatomy are not well defined with echocardiography, CMR can be performed to clarify if a patient is better suited for alcohol septal ablation or surgical myectomy.",
"   </p>",
"   <p>",
"    Cardiovascular magnetic resonance, with its high spatial resolution and tomographic imaging capability, has emerged as a technique particularly well suited to characterizing the diverse phenotypic expression of HCM (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87656 \" href=\"mobipreview.htm?33/45/34514\">",
"     image 4",
"    </a>",
"    ). CMR can identify areas of segmental LV hypertrophy (ie, anterolateral wall or apex) not reliably visualized by echocardiography (or underestimated in terms of extent) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87657 \" href=\"mobipreview.htm?9/27/9651\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. In a study of 48 patients with a suspected or confirmed HCM diagnosis who underwent both echocardiography and CMR, maximal left ventricular thickness was similar with both techniques, but CMR identified areas of thickening in the anterolateral left ventricular free wall in three patients (6 percent) in whom echocardiography showed no areas of hypertrophy, thereby making a new diagnosis of HCM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its ability to identify additional regions of LV hypertrophy not seen with echo, CMR is helpful in characterizing structural abnormalities of the mitral valve (ie, elongation leaflets) and papillary muscles (ie, accessory and apically displaced or anomalous insertion into the mitral valve leaflet) and can more precisely identify the mechanisms responsible for left ventricular outflow tract obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Because of the importance of mitral valve and papillary muscle anatomy in patients with left ventricular outflow tract (LVOT) obstruction who are being considered for invasive septal reduction therapy, CMR should be performed as part of the evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, with the intravenous injection of gadolinium, areas of hyperenhancement (ie, late gadolinium enhancement [LGE]) representing myocardial fibrosis within the myocardium can be identified with contrast-enhanced CMR. The amount of LGE can be quantified as a percent of the total LV mass. Approximately half of HCM patients demonstrate LGE, with a diverse pattern and location (not related to a coronary vascular distribution), although most commonly involving hypertrophied segments of the LV wall and at the junctions of the ventricular septum and right ventricular free wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/50\">",
"     50",
"    </a>",
"    ]. Observational studies have suggested that HCM patients with LGE were at greater risk for ventricular tachyarrhythmias on ambulatory 24-hour Holter ECG compared with those without LGE, suggesting that myocardial fibrosis may represent the structural nidus responsible for the generation of potentially lethal reentry ventricular tachyarrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/51\">",
"     51",
"    </a>",
"    ]. However, the independent predictive value of LGE in identifying HCM patients at risk for sudden death is still uncertain, and therefore management decisions about ICD therapy for primary prevention should not be made based solely on the results of the CMR study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32841?source=see_link&amp;anchor=H36997658#H36997658\">",
"     \"Natural history of hypertrophic cardiomyopathy\", section on 'Hypertrophy and fibrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to detecting LV hypertrophy and myocardial fibrosis, CMR can provide additional information in patients with HCM, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification and quantification of right ventricular hypertrophy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/53\">",
"       53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Evidence of microvascular dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/54\">",
"       54",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Exercise testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32841?source=see_link&amp;anchor=H9#H9\">",
"       \"Natural history of hypertrophic cardiomyopathy\", section on 'Mortality'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Assessment of regional myocardial function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Assessment of diastolic function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Subtle structural abnormalities that may precede hypertrophy (eg, myocardial crypts) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;We typically reserve invasive hemodynamic assessment using cardiac catheterization for patients with suspected HCM and one or more of the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persons in whom the additional diagnosis of restrictive cardiomyopathy or constrictive pericarditis is being considered.",
"     </li>",
"     <li>",
"      Persons in whom invasive coronary angiography is being performed for the evaluation of obstructive coronary disease.",
"     </li>",
"     <li>",
"      Persons in whom a suspicion for LV outflow tract obstruction is present but the clinical and imaging data are discrepant.",
"     </li>",
"     <li>",
"      Persons in whom endomyocardial biopsy is indicated to exclude non-sarcomeric disease (eg, Fabry disease, amyloidosis, Danon disease). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link\">",
"       \"Genetics of hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pre-cardiac transplantation evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cardiac catheterization is rarely required for diagnosis or clinical evaluation of HCM. In most patients, echocardiography provides sufficient information regarding cardiac output, LV filling pressure or left atrial pressure, and LVOT pressure gradient such that cardiac catheterization is not necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/41/3737?source=see_link&amp;anchor=H8#H8\">",
"     \"Hemodynamics of valvular disorders as measured by cardiac catheterization\", section on 'Hypertrophic cardiomyopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29752?source=see_link&amp;anchor=H15#H15\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\", section on 'Cardiac catheterization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5796613\">",
"    <span class=\"h3\">",
"     Coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary angiography should be performed in patients with apparent anginal chest pain when knowledge of coronary anatomy may affect therapy or when cardiac surgery is planned. Although the epicardial coronary arteries are usually large and normal in patients presenting with angina, coronary artery disease may coexist with HCM and must be ruled out [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/35,59\">",
"     35,59",
"    </a>",
"    ]. In the absence of obstructive epicardial coronary artery disease, angina may be due to regionally impaired coronary flow and altered coronary flow reserve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15396849\">",
"    <span class=\"h3\">",
"     Genetic testing for HCM",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of 2012, over 1400 mutations in 13 genes of the cardiac sarcomere have been associated with HCM. Due to this substantial genetic heterogeneity, clinic genetic testing can identify a disease-causing sarcomere protein mutation in substantially less than half of patients with a phenotype of HCM, and disease expression among first-degree family members with HCM can be dramatically different [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/61\">",
"     61",
"    </a>",
"    ]. In addition, identifying HCM patients at risk for adverse disease-related events including sudden death cannot be predicted based on specific mutations, and specific HCM phenotypes have diverse mutations associated with them, suggesting it is not possible to predict phenotype based on a specific mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/62\">",
"     62",
"    </a>",
"    ]. As a result, management decisions such as ICD therapy for primary prevention cannot be made solely based on results derived from genetic testing.",
"   </p>",
"   <p>",
"    For these reasons, routine genetic testing is not recommended for diagnostic purposes, unless clinical evaluation raises suspicion for another genetic condition known to cause LV hypertrophy (ie, Fabry disease, lysosomal storage diseases, etc.). The role of genetic testing in assessing for family members at risk for developing HCM is discussed in greater detail elsewhere. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Screening of first-degree relatives'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link&amp;anchor=H24#H24\">",
"     \"Genetics of hypertrophic cardiomyopathy\", section on 'Genetic testing and screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Electrophysiology studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope and presyncope in patients with HCM may be due to arrhythmias, LVOT obstruction, or inappropriate vasodilatation despite an adequate cardiac output. However, an invasive electrophysiology study rarely identifies the underlying mechanism and is not indicated to determine the need for ICD therapy for primary prevention of sudden death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=see_link&amp;anchor=H20#H20\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\", section on 'EP testing and ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Plasma BNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The range of values associated with plasma brain natriuretic peptide (BNP) and N-terminal pro-BNP concentration is quite broad and does not correlate well with heart failure symptoms in patients with HCM. As a result, we do not order this test as part of the diagnostic or prognostic evaluation of patients with suspected HCM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15396729\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an individual patient, the diagnosis of HCM may be suspected based on the following: family history of HCM, unexplained symptoms (ie, dyspnea, chest pain, fatigue, palpitations), systolic ejection murmur, and abnormal 12-lead electrocardiogram or syncope (or presyncope). The presence of one or more of these clinical findings may prompt further testing with echocardiography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CMR imaging to confirm diagnosis. The presence of increased LV wall thickening &ge;15 mm anywhere in the LV wall in the absence of any other identifiable cause such as hypertension or valve disease is consistent with a diagnosis of HCM. Other common findings such as mitral valve systolic anterior motion (SAM) or hyperdynamic LV are not obligatory for an HCM diagnosis. (See",
"    <a class=\"local\" href=\"#H2599080\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of the advances in non-invasive imaging, invasive assessments to make the diagnosis of HCM are rarely necessary. On occasion, however, invasive hemodynamic assessment using cardiac catheterization may identify an LVOT gradient which could not be confirmed using non-invasive techniques and may be necessary to exclude coronary artery disease.",
"   </p>",
"   <p>",
"    While the presence of a pathogenic sarcomeric mutation may be helpful for determining if family members are at risk for developing HCM, genetic testing for HCM should not be performed routinely for diagnostic purposes. (See",
"    <a class=\"local\" href=\"#H15396849\">",
"     'Genetic testing for HCM'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2599080\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2599189\">",
"    <span class=\"h2\">",
"     Differential diagnosis of LVH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the patient presenting with LVH, HCM must be distinguished from acquired causes of cardiac hypertrophy. The most common causes are hypertension and aortic stenosis; in a minority, HCM may coexist with either. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18247?source=see_link\">",
"     \"Definition and pathogenesis of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rare cause of cardiac hypertrophy is Fabry disease, an X-linked recessive glycolipid storage disease. Although classic multisystem Fabry disease is rare, isolated cardiac involvement may be relatively common in patients with otherwise unexplained concentric LVH (up to 5 percent). It has been suggested that, among patients with LVH, the echocardiographic findings in Fabry disease are different from those in other forms of LVH including HCM (",
"    <a class=\"graphic graphic_figure graphicRef55283 \" href=\"mobipreview.htm?8/61/9175\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17111?source=see_link&amp;anchor=H4#H4\">",
"     \"Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy\", section on 'Left ventricular hypertrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1381606\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-standing systemic hypertension is the most common cause of LV hypertrophy, particularly when it has been untreated or incompletely treated. Most persons with hypertension as the cause of LV hypertrophy will be beyond adolescence, when HCM is most commonly identified. The hypertrophy seen in hypertension, however, rarely leads to wall thicknesses in excess of 1.5 cm. Additionally, hypertension is usually suspected in persons with an extended history of elevated blood pressures (10 or more years), particularly in those with other evidence of end-organ damage due to hypertension (eg, retinopathy, nephropathy). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17959?source=see_link\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1381614\">",
"    <span class=\"h3\">",
"     Aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valvular AS due to stenosis of a congenital bicuspid aortic valve is more common in younger persons (less than 50 years of age), while in those older than 50 years of age, valvular AS is typically due to atherosclerotic narrowing of the valve. In both situations, concentric LV hypertrophy develops, which is different than the eccentric hypertrophy seen in HCM. Valvular AS can usually be distinguished from other causes of LV hypertrophy by echocardiography or invasive cardiac catheterization, which allow for visualization of the restricted leaflet motion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=see_link\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Valvular aortic stenosis also causes an increased pressure gradient between the LV and aorta. (See",
"    <a class=\"local\" href=\"#H5796716\">",
"     'Valvular aortic stenosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2599226\">",
"    <span class=\"h3\">",
"     Athlete's heart",
"    </span>",
"    &nbsp;&mdash;&nbsp;Highly trained athletes can also develop cardiac hypertrophy (sometimes called \"athlete's heart\"), resulting in wall thickness measurements in a range that can overlap with those seen in patients with HCM (ie, wall thickness \"grey zone\" of 13 to 15 mm). As a result, a number of noninvasive measures have been proposed to help differentiate athlete's heart from HCM (",
"    <a class=\"graphic graphic_figure graphicRef87658 \" href=\"mobipreview.htm?33/3/33855\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various exercise training disciplines appear to have qualitatively and quantitatively different effects on cardiac structure and function. While both endurance and strength training induce increases in left ventricular mass, strength training generally leads to greater hypertrophy. Since athletes with a cardiomyopathy can be at risk of arrhythmias during physical exertion, it is important to exclude such disorders before attributing cardiovascular, electrophysiological, or structural changes to athletic training. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=see_link&amp;anchor=H13#H13\">",
"     \"Risk of sudden cardiac death in athletes\", section on 'Hypertrophic cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2599233\">",
"    <span class=\"h4\">",
"     Criteria to distinguish HCM from athlete's heart",
"    </span>",
"    &nbsp;&mdash;&nbsp;In individuals with a possible diagnosis of athlete's heart versus HCM, family history, ECG, and LV cavity dimensions may help distinguish HCM from cardiovascular adaptation in an athlete. The evidence associated with these findings is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30777?source=see_link&amp;anchor=H1613344#H1613344\">",
"     \"Definition and classification of the cardiomyopathies\", section on 'Athlete's heart'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ECG &ndash; The ECG changes that develop as part of the cardiovascular adaptation in an endurance athlete include sinus bradycardia, increased QRS voltage, tall peaked T wave, J point elevation, and U waves. Pathological Q waves, left axis deviation, and T wave inversion, however, strongly favor a diagnosis of HCM.",
"     </li>",
"     <li>",
"      Extent and pattern of LVH &ndash; As noted above, the magnitude of expected LV wall thickening varies with degree and type of athletic training. A finding of a greater degree of LVH than expected for the degree and type of athletic training favors a diagnosis of HCM. In this regard, only high-level endurance training has been associated with LVH of 13 to 15 mm. Of note, the maximal LV wall thickness achieved by women athletes almost never exceeds 14 mm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Doppler and tissue Dopper echocardiography &ndash; Depressed Ea velocities found in patients with HCM contrast with the normal or above normal Ea velocities seen in trained athletes who may also have left ventricular hypertrophy, although Ea velocities for these populations have not been directly compared within a study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/65,66\">",
"       65,66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac magnetic resonance (CMR) imaging &ndash; CMR can most accurately compare maximal LV wall thickness measurements before and after a period of systematic deconditioning. Patients in whom wall thickness regresses greater than 2 mm supports a diagnosis of athlete's heart, while hypertrophy that remains unchanged suggests HCM. It does not appear that competitive athletes demonstrate late gadolinium enhancement (LGE, which suggests myocardial fibrosis), and therefore the presence of LGE may also provide additional information to confirm a diagnosis of HCM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/67,68\">",
"       67,68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Functional exercise testing &ndash; Lower than expected levels of peak oxygen consumption (VO2peak) may aid in the differentiation between HCM and physiologic LVH in an athlete. In a study that compared eight athletic men with genetically proven HCM and mild LVH to eight matched elite athletes with the same left ventricular wall thickness, the elite athletes without HCM had a significantly greater peak VO2, anaerobic threshold (percent of the predicted peak VO2), and oxygen pulse",
"      <span class=\"nowrap\">",
"       (mL/beat)",
"      </span>",
"      than patients with HCM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/69\">",
"       69",
"      </a>",
"      ]. A peak VO2 &gt;50",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per min or &gt;20 percent above the predicted VO2max, an O2 pulse &gt;20",
"      <span class=\"nowrap\">",
"       mL/beat,",
"      </span>",
"      or an anaerobic threshold &gt;55 percent of the predicted VO2max were indicators of physiologic left ventricular hypertrophy rather than HCM. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33398?source=see_link\">",
"       \"Functional exercise testing: Ventilatory gas analysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic testing for HCM can also be considered. The identification of a disease-causing sarcomere mutation in an athlete with a maximal LV wall thickness in the \"grey zone\" would provide a definitive diagnosis of HCM. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link&amp;anchor=H24#H24\">",
"       \"Genetics of hypertrophic cardiomyopathy\", section on 'Genetic testing and screening'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5796692\">",
"    <span class=\"h2\">",
"     Differential diagnosis of increased LV to aortic gradient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than the dynamic subaortic (LVOT) obstruction seen in HCM, several other anatomic and physiologic abnormalities can be associated with increased pressure gradients between the LV and the aorta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5796700\">",
"    <span class=\"h3\">",
"     Volume depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with significant volume depletion in the setting of normal LV systolic function will often develop hyperdynamic ventricular function in an effort to maintain cardiac output. Hyperdynamic LV function results in more vigorous ejection of blood from the heart at a higher velocity than normal, leading to an intracavitary gradient which may be mistaken for an increased LVOT gradient. An intracavitary gradient is usually suspected from the clinical scenario (eg, hypotension, tachycardia, other signs of hypovolemia) and almost always disappears following fluid resuscitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5796708\">",
"    <span class=\"h3\">",
"     Subaortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fixed subvalvular aortic stenosis (AS) is a congenital abnormality typically caused by a thin membrane of tissue in the left ventricular outflow tract which is typically seen on two-dimensional echocardiography as well as both color and spectral Doppler echocardiography. Fixed subaortic stenosis can usually be distinguished from HCM and valvular AS by echocardiography or invasive cardiac catheterization.",
"   </p>",
"   <p>",
"    Unlike the dynamic LVOT obstruction seen in persons with HCM, there is typically no evidence of systolic anterior motion of the mitral valve, and the ventricular wall thickness is normal (although long-standing LV hypertension due to a significant gradient across the membrane can lead to concentric LV hypertrophy). Unlike valvular AS, the aortic valve leaflets are usually normal (although long-standing high-velocity turbulent flow across the membrane over years to decades may result in aortic valve damage). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33207?source=see_link\">",
"     \"Subvalvar aortic stenosis (subaortic stenosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5796716\">",
"    <span class=\"h3\">",
"     Valvular aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to potentially causing LV hypertrophy, narrowing of the aortic valve opening can lead to a significant pressure gradient between the LV and the aorta. As with subaortic stenosis, valvular AS can usually be distinguished from other pathology by echocardiography or invasive cardiac catheterization. (See",
"    <a class=\"local\" href=\"#H1381614\">",
"     'Aortic stenosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524640927\">",
"    <span class=\"h1\">",
"     GENOTYPE POSITIVE/PHENOTYPE NEGATIVE HCM PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the use of genetic testing, HCM family members who carry a disease-causing sarcomere mutation but without LV hypertrophy can now be identified (so-called genotype",
"    <span class=\"nowrap\">",
"     positive/phenotype",
"    </span>",
"    negative patients). In about 50 percent of these individuals, the ECG will be abnormal. Although these patients have no increased wall thickness, a number of observations have suggested that the myocardium may still not be structurally normal. For example, abnormalities such as myocardial fibrosis by contrast-CMR, collagen biomarkers, mitral leaflet elongation, diastolic dysfunction, and blood-filled myocardial crypts have all been shown to occur in gene carriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of developing clinical evidence of HCM with LV hypertrophy in family members who have a sarcomere mutation is uncertain. However, clinical follow-up with longitudinal screening should continue based on the current screening recommendations. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Screening of first-degree relatives'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The risk of sudden death in gene carriers is also unknown but considered to be very low, and therefore consideration for prophylactic ICD should be resolved on an individual case basis. However, current society guidelines do not recommend excluding genotype",
"    <span class=\"nowrap\">",
"     positive/phenotype",
"    </span>",
"    negative HCM family members from participating in organized competitive sports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SCREENING OF FIRST-DEGREE RELATIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy is an autosomal dominant disorder, and most mutations have a high degree of penetrance. As a result, first-degree family members of an affected individual should be evaluated for possible inheritance of the disease. We agree with the recommendations of others that the components of family screening should include history, physical examination, electrocardiography (ECG), and echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/31,35,73\">",
"     31,35,73",
"    </a>",
"    ]. We do not recommend routine genetic screening of first-degree relatives unless a definite HCM-causing mutation has been identified in the index case.",
"   </p>",
"   <p>",
"    Among first-degree adult relatives of patients with HCM, otherwise unexplained echocardiographic and ECG abnormalities identified during screening examinations have a high probability of reflecting the expression of HCM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/74\">",
"     74",
"    </a>",
"    ]. Screening is not routinely recommended before the age of 12 unless the child has clinical manifestations of HCM, a high-risk family history, or is participating in intense competitive sports.",
"   </p>",
"   <p>",
"    Family members who have a normal evaluation should not necessarily be assumed to be free of risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because hypertrophy usually develops during adolescence, clinical evaluation should be repeated annually from 12 to 18 years of age.",
"     </li>",
"     <li>",
"      Due to the possibility of delayed-onset hypertrophy, it is recommended that adult family members with normal ECGs and echocardiograms who are over the age of 18 be reevaluated approximately every five years. There may be a role for tissue Doppler echocardiography in such patients, where abnormalities in contraction and relaxation velocities can suggest pre-clinical myocardial dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/42/36522/abstract/75-77\">",
"       75-77",
"      </a>",
"      ]. However, these abnormalities are not considered diagnostic for HCM and rarely precede the development of ECG abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The identification of gene mutations for HCM has led to interest in the development of DNA-based testing of patients with HCM and screening of family members. Genetic screening may accurately define the risk of disease development, but it is not universally available and presents additional possible concerns. Additionally, not all persons with a genotype-positive mutation will have the HCM phenotype identified by ECG or echocardiography. The issue of genetic testing and screening for HCM with genetic testing is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link&amp;anchor=H24#H24\">",
"     \"Genetics of hypertrophic cardiomyopathy\", section on 'Genetic testing and screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/28/35266?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/24/36226?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/49/18197?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertrophic cardiomyopathy (HCM) is a genetic cardiomyopathy caused by mutations of the cardiac sarcomere, resulting in heterogeneous phenotypic expression with respect to the extent, location, and distribution of left ventricle (LV) wall thickening as well as a diverse clinical course including sudden death, heart failure, and stroke. The prevalence of hypertrophic cardiomyopathy (HCM) in the general population is 1 in 500 adults. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H274510\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histopathology in patients with HCM reveals disorganized myocyte architecture, including hypertrophied myocytes in a disarray pattern with bizarre-shaped nuclei, abnormal intramural coronary arteries, and interstitial as well as replacement fibrosis (",
"      <a class=\"graphic graphic_picture graphicRef55914 \" href=\"mobipreview.htm?11/5/11352\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H274517\">",
"       'Histologic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While many patients with HCM remain asymptomatic, it is not uncommon for patients to develop one or more of the following symptoms: dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, chest pain, palpitations,",
"      <span class=\"nowrap\">",
"       presyncope/syncope,",
"      </span>",
"      postural lightheadedness, fatigue, or edema. (See",
"      <a class=\"local\" href=\"#H274531\">",
"       'Signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination in HCM may be normal or may reveal nonspecific abnormalities such as a fourth heart sound, systolic murmur,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a left ventricular lift. Patients with LVOT obstruction may have a harsh crescendo-decrescendo systolic murmur, which develops slightly after S1 and is heard best at the apex and lower left sternal border. Several physical exam maneuvers can affect the degree of obstruction, resulting in a change in murmur intensity.",
"     </li>",
"     <li>",
"      The evaluation for HCM in an individual patient may be prompted by a family history of HCM, systolic ejection murmur, abnormal 12-lead electrocardiogram showing otherwise unexplained evidence of left ventricular hypertrophy, and clinical symptoms including syncope. In addition to performing a comprehensive cardiac history and physical examination and an electrocardiogram (ECG) in all patients with suspected HCM, cardiac imaging to identify left ventricular hypertrophy (LVH) should be performed. (See",
"      <a class=\"local\" href=\"#H18608369\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the ECG is abnormal in 90 percent of HCM patients (",
"      <a class=\"graphic graphic_waveform graphicRef76497 \" href=\"mobipreview.htm?41/57/42906\">",
"       waveform 3",
"      </a>",
"      ), no specific pattern is diagnostic. Typically, the ECG shows repolarization abnormalities but also may include prominent abnormal Q waves, P wave abnormalities, left axis deviation, and deeply inverted T waves. (See",
"      <a class=\"local\" href=\"#H612576623\">",
"       'Electrocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two-dimensional echocardiography can be used to reliably diagnose patients with HCM when an area of increased LV wall thickness is imaged anywhere in the LV wall in the absence of another cause. Echocardiographic findings suggestive of HCM include LV hypertrophy (particularly when asymmetric and involving the septum or anterolateral wall), an increased LV outflow tract (LVOT) gradient, and systolic anterior motion of the mitral valve leaflets, particularly when associated with an increased LVOT gradient. In addition, cardiovascular magnetic resonance (CMR) can be used to clarify a diagnosis of HCM or the extent of wall thickness in those patients in whom LV wall thickness measurements remain uncertain with two-dimensional echocardiography. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Echocardiography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Cardiovascular magnetic resonance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with HCM have LVOT obstruction under resting conditions or following exercise. Because of this, we proceed with exercise stress testing in all patients with known or suspected HCM as part of the risk stratification process. Exercise should be performed as the stress agent rather than using a pharmacologic stress agent, as a maximal treadmill or bicycle exercise stress test provides an objective measurement of functional capacity and information on the integrity of vascular responses and the risk of exercise related ischemia, arrhythmia, and obstruction. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Exercise testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic testing is available for clinical use but is predominately reserved for identifying patients who may have a disease which appears phenotypically similar to sarcomere HCM, such as Fabry disease or a",
"      <span class=\"nowrap\">",
"       lysosomal/glycogen",
"      </span>",
"      storage disease, or to help identify family members who may be at risk of developing HCM. (See",
"      <a class=\"local\" href=\"#H15396849\">",
"       'Genetic testing for HCM'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of HCM can usually be made following echocardiography",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CMR imaging, and invasive diagnostic assessments are rarely necessary. We typically reserve invasive hemodynamic assessment using cardiac catheterization for patients with suspected HCM to exclude obstructive coronary artery disease, distinguish pericardial constriction from severe restrictive physiology, to perform endomyocardial biopsy to exclude non-sarcomeric causes of HCM, or for pre-cardiac transplant assessment. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Cardiac catheterization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the patient presenting with LVH, HCM must be distinguished from acquired causes of cardiac hypertrophy, including hypertension, aortic stenosis, and athlete's heart. Other than the dynamic subaortic (LVOT) obstruction seen in HCM, several other anatomic and physiologic abnormalities can be associated with increased pressure gradients between the LV and the aorta, including volume depletion, subaortic stenosis, and valvular aortic stenosis. (See",
"      <a class=\"local\" href=\"#H2599080\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HCM is an autosomal dominant disorder, and most mutations have a high degree of penetrance. As a result, first-degree family members of an affected individual should be evaluated for possible inheritance of the disease. The components of family screening should include history, physical examination, electrocardiography (ECG), and echocardiography. We do not recommend routine genetic screening of first-degree relatives unless a definite HCM-causing mutation has been identified in the index case. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Screening of first-degree relatives'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/1\">",
"      Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995; 92:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/2\">",
"      Maron BJ, Mathenge R, Casey SA, et al. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol 1999; 33:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/3\">",
"      Hada Y, Sakamoto T, Amano K, et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am J Cardiol 1987; 59:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/4\">",
"      Zou Y, Song L, Wang Z, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med 2004; 116:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/5\">",
"      Morita H, Larson MG, Barr SC, et al. Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation 2006; 113:2697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/6\">",
"      Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000; 35:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/7\">",
"      Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006; 114:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/8\">",
"      Maron BJ, Casey SA, Poliac LC, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/9\">",
"      Olivotto I, Maron MS, Adabag AS, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/10\">",
"      Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995; 92:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/11\">",
"      Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/12\">",
"      Elliott PM, Kaski JC, Prasad K, et al. Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. Eur Heart J 1996; 17:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/13\">",
"      Pasternac A, Noble J, Streulens Y, et al. Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation 1982; 65:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/14\">",
"      Webb JG, Sasson Z, Rakowski H, et al. Apical hypertrophic cardiomyopathy: clinical follow-up and diagnostic correlates. J Am Coll Cardiol 1990; 15:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/15\">",
"      Cannon RO 3rd, Rosing DR, Maron BJ, et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 1985; 71:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/16\">",
"      Cannon RO 3rd, Schenke WH, Maron BJ, et al. Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 1987; 10:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/17\">",
"      Ikeda H, Shimamatsu M, Yoshiga O, et al. Impaired myocardial perfusion in patients with hypertrophic cardiomyopathy: assessment with digital subtraction coronary arteriography. Heart Vessels 1988; 4:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/18\">",
"      Krams R, Kofflard MJ, Duncker DJ, et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 1998; 97:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/19\">",
"      Camici P, Chiriatti G, Lorenzoni R, et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 1991; 17:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/20\">",
"      Tanaka M, Fujiwara H, Onodera T, et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation 1987; 75:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/21\">",
"      Grover-McKay M, Schwaiger M, Krivokapich J, et al. Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1989; 13:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/22\">",
"      O'Gara PT, Bonow RO, Maron BJ, et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation 1987; 76:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/23\">",
"      Nienaber CA, Hiller S, Spielmann RP, et al. Syncope in hypertrophic cardiomyopathy: multivariate analysis of prognostic determinants. J Am Coll Cardiol 1990; 15:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/24\">",
"      Gilligan DM, Nihoyannopoulos P, Chan WL, Oakley CM. Investigation of a hemodynamic basis for syncope in hypertrophic cardiomyopathy. Use of a head-up tilt test. Circulation 1992; 85:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/25\">",
"      Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ. Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation 1991; 84:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/26\">",
"      Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992; 86:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/27\">",
"      Tamura M, Harada K, Ito T, et al. Abrupt aggravation of atrioventricular block and syncope in hypertrophic cardiomyopathy. Arch Dis Child 1995; 73:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/28\">",
"      Manganelli F, Betocchi S, Losi MA, et al. Influence of left ventricular cavity size on clinical presentation in hypertrophic cardiomyopathy. Am J Cardiol 1999; 83:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/29\">",
"      Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009; 119:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/30\">",
"      McLeod CJ, Ackerman MJ, Nishimura RA, et al. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J Am Coll Cardiol 2009; 54:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/31\">",
"      Nishimura RA, Holmes DR Jr. Clinical practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004; 350:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/32\">",
"      Pollick C, Morgan CD, Gilbert BW, et al. Muscular subaortic stenosis: the temporal relationship between systolic anterior motion of the anterior mitral leaflet and the pressure gradient. Circulation 1982; 66:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/33\">",
"      Maron BJ, Gottdiener JS, Arce J, et al. Dynamic subaortic obstruction in hypertrophic cardiomyopathy: analysis by pulsed Doppler echocardiography. J Am Coll Cardiol 1985; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/34\">",
"      Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1992; 19:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/35\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/36\">",
"      Shah JS, Esteban MT, Thaman R, et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart 2008; 94:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/37\">",
"      Peteiro J, Bouzas-Mosquera A, Fernandez X, et al. Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2012; 25:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/38\">",
"      Cecchi F, Olivotto I, Gistri R, et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003; 349:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/39\">",
"      Olivotto I, Cecchi F, Gistri R, et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006; 47:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/40\">",
"      Jones S, Elliott PM, Sharma S, et al. Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy. Heart 1998; 80:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/41\">",
"      Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997; 96:2987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/42\">",
"      Frenneaux MP, Counihan PJ, Caforio AL, et al. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 1990; 82:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/43\">",
"      Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/44\">",
"      Thaman R, Elliott PM, Shah JS, et al. Reversal of inappropriate peripheral vascular responses in hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/45\">",
"      Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005; 112:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/46\">",
"      Posma JL, Blanksma PK, van der Wall EE, et al. Assessment of quantitative hypertrophy scores in hypertrophic cardiomyopathy: magnetic resonance imaging versus echocardiography. Am Heart J 1996; 132:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/47\">",
"      Maron MS, Lesser JR, Maron BJ. Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. Am J Cardiol 2010; 105:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/48\">",
"      Maron MS, Olivotto I, Harrigan C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation 2011; 124:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/49\">",
"      Harrigan CJ, Appelbaum E, Maron BJ, et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2008; 101:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/50\">",
"      Maron MS, Appelbaum E, Harrigan CJ, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008; 1:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/51\">",
"      Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008; 51:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/52\">",
"      Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2012; 14:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/53\">",
"      Maron MS, Hauser TH, Dubrow E, et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol 2007; 100:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/54\">",
"      Petersen SE, Jerosch-Herold M, Hudsmith LE, et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 2007; 115:2418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/55\">",
"      Dong SJ, MacGregor JH, Crawley AP, et al. Left ventricular wall thickness and regional systolic function in patients with hypertrophic cardiomyopathy. A three-dimensional tagged magnetic resonance imaging study. Circulation 1994; 90:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/56\">",
"      Kramer CM, Reichek N, Ferrari VA, et al. Regional heterogeneity of function in hypertrophic cardiomyopathy. Circulation 1994; 90:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/57\">",
"      Paelinck BP, de Roos A, Bax JJ, et al. Feasibility of tissue magnetic resonance imaging: a pilot study in comparison with tissue Doppler imaging and invasive measurement. J Am Coll Cardiol 2005; 45:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/58\">",
"      Germans T, Wilde AA, Dijkmans PA, et al. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol 2006; 48:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/59\">",
"      Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for coronary angiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions. Circulation 1999; 99:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/60\">",
"      Kyriakidis MK, Dernellis JM, Androulakis AE, et al. Changes in phasic coronary blood flow velocity profile and relative coronary flow reserve in patients with hypertrophic obstructive cardiomyopathy. Circulation 1997; 96:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/61\">",
"      Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012; 60:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/62\">",
"      Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/63\">",
"      Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation 1995; 91:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/64\">",
"      Pelliccia A, Maron MS, Maron BJ. Assessment of left ventricular hypertrophy in a trained athlete: differential diagnosis of physiologic athlete's heart from pathologic hypertrophy. Prog Cardiovasc Dis 2012; 54:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/65\">",
"      Prasad A, Popovic ZB, Arbab-Zadeh A, et al. The effects of aging and physical activity on Doppler measures of diastolic function. Am J Cardiol 2007; 99:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/66\">",
"      Griffet V, Gu&eacute;rard S, Galoisy-Guibal L, et al. [Normal values of the peak early diastolic Ea using myocardial tissue Doppler in 100 elite athletes]. Arch Mal Coeur Vaiss 2007; 100:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/67\">",
"      O'Hanlon R, Wilson M, Wage R, et al. Troponin release following endurance exercise: is inflammation the cause? a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2010; 12:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/68\">",
"      Maron BJ. Distinguishing hypertrophic cardiomyopathy from athlete's heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening. Br J Sports Med 2009; 43:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/69\">",
"      Sharma S, Elliott PM, Whyte G, et al. Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol 2000; 36:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/70\">",
"      Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet 2013; 381:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/71\">",
"      Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy. Am J Cardiol 2011; 107:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/72\">",
"      Maron BJ, Ackerman MJ, Nishimura RA, et al. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol 2005; 45:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/73\">",
"      Maron BJ, Seidman JG, Seidman CE. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 44:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/74\">",
"      McKenna WJ, Spirito P, Desnos M, et al. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 1997; 77:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/75\">",
"      Nagueh SF, Bachinski LL, Meyer D, et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 2001; 104:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/76\">",
"      Ho CY, Sweitzer NK, McDonough B, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002; 105:2992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/42/36522/abstract/77\">",
"      Nagueh SF, McFalls J, Meyer D, et al. Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation 2003; 108:395.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4948 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_42_36522=[""].join("\n");
var outline_f35_42_36522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H274510\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H274517\">",
"      HISTOLOGIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H274524\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H274531\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H274538\">",
"      - Relationship of symptoms to age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H274545\">",
"      - Relationship of symptoms to pressure gradient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H274552\">",
"      - Dyspnea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H274559\">",
"      - Chest pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H274566\">",
"      - Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H274573\">",
"      - Syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H274580\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H274587\">",
"      - Systolic murmurs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H274594\">",
"      - Other physical findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18608369\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H612576623\">",
"      Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - LV hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H524640286\">",
"      - Systolic anterior motion of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - LVOT obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H273557\">",
"      Ambulatory ECG monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Cardiopulmonary exercise testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - BP response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5796613\">",
"      - Coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15396849\">",
"      - Genetic testing for HCM",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Electrophysiology studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Plasma BNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15396729\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2599080\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2599189\">",
"      Differential diagnosis of LVH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1381606\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1381614\">",
"      - Aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2599226\">",
"      - Athlete's heart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2599233\">",
"      Criteria to distinguish HCM from athlete's heart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5796692\">",
"      Differential diagnosis of increased LV to aortic gradient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5796700\">",
"      - Volume depletion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5796708\">",
"      - Subaortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5796716\">",
"      - Valvular aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H524640927\">",
"      GENOTYPE POSITIVE/PHENOTYPE NEGATIVE HCM PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SCREENING OF FIRST-DEGREE RELATIVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4948\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4948|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/34/39471\" title=\"diagnostic image 1\">",
"      Long axis hypertrophic CM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/8/33923\" title=\"diagnostic image 2\">",
"      Apical 5-chamber MV SAM in HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/21/8532\" title=\"diagnostic image 3\">",
"      M mode aorta hypertrophic CM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/45/34514\" title=\"diagnostic image 4\">",
"      CMR septal LVH in HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/27/9651\" title=\"diagnostic image 5\">",
"      Echo vs CMR LVH in HCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4948|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/9/11411\" title=\"figure 1\">",
"      Morphologic variants HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/44/27343\" title=\"figure 2\">",
"      Color Doppler HCM with MR and LVOT obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/51/15157\" title=\"figure 3\">",
"      M mode mitral valve HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/61/9175\" title=\"figure 4\">",
"      Echo in Fabry disease with LVH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/3/33855\" title=\"figure 5\">",
"      Pathologic LVH vs Physiologic LVH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4948|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/5/11352\" title=\"picture 1\">",
"      HCM myocyte disarray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/33/41494\" title=\"picture 2\">",
"      Small vessel disease in HCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4948|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?0/20/321\" title=\"movie 1\">",
"      Apical 3 chamber echo HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?29/63/30705\" title=\"movie 2\">",
"      Long axis echo HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?3/25/3472\" title=\"movie 3\">",
"      Short axis echo 1 HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?40/20/41295\" title=\"movie 4\">",
"      Short axis echo 2 HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?6/26/6563\" title=\"movie 5\">",
"      Apical 4-chamber echo HCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4948|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/11/43196\" title=\"table 2\">",
"      Causes LV outflow obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4948|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?29/22/30054\" title=\"waveform 1A\">",
"      Invasive hemodynamic tracing HCM with LVOT obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?19/6/19558\" title=\"waveform 1B\">",
"      Invasive hemodynamic tracing LV and aortic pressures HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?34/62/35822\" title=\"waveform 2\">",
"      CW Doppler HCM with LVOT obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?41/57/42906\" title=\"waveform 3\">",
"      ECG ST-T changes with LVH tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28199?source=related_link\">",
"      Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17111?source=related_link\">",
"      Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18247?source=related_link\">",
"      Definition and pathogenesis of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34042?source=related_link\">",
"      Diagnostic approach to chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9909?source=related_link\">",
"      Examination of the precordial pulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33398?source=related_link\">",
"      Functional exercise testing: Ventilatory gas analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10105?source=related_link\">",
"      Medical therapy in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32841?source=related_link\">",
"      Natural history of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7514?source=related_link\">",
"      Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/0/36868?source=related_link\">",
"      Pathogenesis and diagnosis of Q waves on the electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15144?source=related_link\">",
"      Pathophysiology and clinical presentation of ischemic chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/49/18197?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/28/35266?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/24/36226?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41876?source=related_link\">",
"      Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33207?source=related_link\">",
"      Subvalvar aortic stenosis (subaortic stenosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_42_36523="Comp oral lavage solutions";
var content_f35_42_36523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Composition of oral solutions for gastrointestinal lavage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Golytely",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nulytely",
"       </td>",
"       <td class=\"subtitle1\">",
"        Colytely",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Na+ (meg/L)",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        125",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        K+ (meq/L)",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cl- (meq/L)",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HC0",
"        <sub>",
"         3",
"        </sub>",
"        - (meq/L)",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S0",
"        <sub>",
"         4",
"        </sub>",
"        = (meq/L)",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PEG* (gm/L)",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osmolality",
"       </td>",
"       <td>",
"        280",
"       </td>",
"       <td>",
"        288",
"       </td>",
"       <td>",
"        280",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * PEG 3350.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Keefe, EB. Colonoscopy preps: What's best? Gastrointest Enclosc 1996; 43:524.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_42_36523=[""].join("\n");
var outline_f35_42_36523=null;
var title_f35_42_36524="Atypical Spitz histo";
var content_f35_42_36524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic features of atypical Spitz tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Architecture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Diameter usually &gt;5 and often &gt;10 mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Involvement of the subcutaneous tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Ulceration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Poor circumscription",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Extensive pagetoid scatter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Effacement of the epidermis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Prominent confluence of melanocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; High cellular density",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Lack of zonation and maturation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Asymmetry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Absent or few eosinophilic hyaline globules (Kamino bodies)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Proliferation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Significant mitotic rate (2 to 6/mm",
"        <sup>",
"         2",
"        </sup>",
"        ) (particularly &gt;6/mm",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Deep or marginal dermal mitoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Proliferative index (Ki-67 expression)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        - Between 2 to 10 percent",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        - &ge;10 to 15 percent",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cytology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Granular versus ground glass cytoplasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; High nuclear to cytoplasmic ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Loss of delicate or dispersed chromatin pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Thickening of nuclear membranes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Hyperchromatism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Large nucleoli",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Vollmer RT. Use of Bayes rule and MIB-1 proliferation index to discriminate Spitz nevus from malignant melanoma. Am J Clin Pathol 2004; 122:499.",
"       </li>",
"       <li>",
"        Kapur P, Selim MA, Roy LC, et al. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. Mod Pathol 2005; 18:197.",
"       </li>",
"      </ol>",
"      Reprinted by permission from Macmillan Publishers Ltd: Modern Pathology. Barnhill RL. The Spitzoid lesion: Rethinking spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment. Mod Pathol 2006; 19 Suppl 2:S21. Copyright &copy; 2006.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_42_36524=[""].join("\n");
var outline_f35_42_36524=null;
var title_f35_42_36525="Hirschspr assoc syndr";
var content_f35_42_36525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Monogenic syndromes associated with Hirschsprung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mode of inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosomal locus / gene symbol",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent with Hirschsprung disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bardet-Biedl syndrome",
"       </td>",
"       <td>",
"        Retinal dystrophy, obesity, intellectual disability, polydactyly, hypogenitalism, renal abnormalities",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        At least 11 loci / genes",
"       </td>",
"       <td>",
"        2 to 10 percent*",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cartilage-hair hypoplasia",
"       </td>",
"       <td>",
"        Short-limbed dwarfism, sparse hair, immune defects",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        9p21-p12 / RMRP",
"       </td>",
"       <td>",
"        7 to 9 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        CCHS",
"       </td>",
"       <td>",
"        Hypoxia, reduced ventilatory drive, neuroblastoma",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        <p>",
"         4p12 / PHOX2B",
"        </p>",
"        <p>",
"         10q11.2 / RET",
"        </p>",
"        <p>",
"         5p13.1-p12 / GDNF",
"        </p>",
"        <p>",
"         20q13.2-q13.3 / EDN3",
"        </p>",
"        <p>",
"         11p13 / BDNF",
"        </p>",
"       </td>",
"       <td>",
"        20 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Familial dysautonomia (Riley-Day syndrome)",
"       </td>",
"       <td>",
"        Sensory and autonomic dysfunction (including abnormal sweat, tear, and saliva production)",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        9q31 / IKBKAP",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fryns syndrome",
"       </td>",
"       <td>",
"        Distal digital hypoplasia, diaphragmatic hernia, CHD, craniofacial, intellectual disability",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Goldberg-Shprintzen syndrome",
"       </td>",
"       <td>",
"        Craniofacial, microcephaly, intellectual disability, PMG",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        <p>",
"         10q22.1 / KIAA1279",
"        </p>",
"        <p>",
"         Others?",
"        </p>",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Intestinal neuronal dysplasia",
"       </td>",
"       <td>",
"        Abnormal intestinal innervation with giant ganglia",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        &le;20 percent*",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        L1 syndrome",
"       </td>",
"       <td>",
"        Intellectual disability, hydrocephalus, ACC, adducted thumbs",
"       </td>",
"       <td>",
"        XLR",
"       </td>",
"       <td>",
"        Xq28 / L1CAM",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        MEN 2A/FMTC",
"       </td>",
"       <td>",
"        MTC, pheochromocytoma, hyperparathyroidism&bull;",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        10q11.2 / RET",
"       </td>",
"       <td>",
"        &le;1 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        MEN 2B",
"       </td>",
"       <td>",
"        MTC, pheochromocytoma, mucosal and intestinal neuromas, skeletal abnormalities, corneal changes",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        10q11.2 / RET",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Mowat-Wilson syndrome",
"       </td>",
"       <td>",
"        Intellectual disability, microcephaly, craniofacial, CHD, ACC, epilepsy, short stature",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        2q22 / ZFHX1B",
"       </td>",
"       <td>",
"        41 to 71 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Neurofibromatosis 1",
"       </td>",
"       <td>",
"        Caf&eacute;-au-lait macules, neurofibromas, Lisch nodules",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        <p>",
"         17q11.2 / NF1",
"        </p>",
"        <p>",
"         5p13.1-p12 / GDNF?",
"        </p>",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Smith-Lemli-Opitz syndrome",
"       </td>",
"       <td>",
"        Intellectual disability, hypospadias, 2/3 syndactyly, CHD, craniofacial",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        11q12-q13 / DHCR7",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Waardenburg syndrome type 4 (Waardenburg-Shah syndrome)",
"       </td>",
"       <td rowspan=\"2\">",
"        Pigmentary abnormalities, deafness",
"       </td>",
"       <td>",
"        AR (usually)",
"       </td>",
"       <td>",
"        <p>",
"         13q22 / EDNRB",
"        </p>",
"        <p>",
"         20q13.2-q13.3 / EDN3",
"        </p>",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        22q13 / SOX10",
"       </td>",
"       <td>",
"        Almost 100 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CHD: congenital heart disease; PMG: polymicrogyria; AD: autosomal dominant; AR: autosomal recessive; XLR: X-linked recessive; MTC: medullary thyroid carcinoma; DHCR7: 7-dehydrocholesterol reductase; ACC: agenesis of the corpus callosum; ZFHX1B: zinc finger homeobox protein 1b; RMRP: RNAse mitochondrial RNA processing; BDNF: brain-derived neurotrophic factor; L1CAM: neural cell adhesion molecule L1; NF1: neurofibromin; CCHS: congenital central hypoventilation syndrome; MEN: multiple endocrine neoplasia.",
"     <br>",
"      * Limited data are available.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       In FMTC, affected individuals do not have pheochromocytoma or hyperparathyroidism.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Parisi, MA (updated December 2006). Hirschsprung Disease Overview. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright &copy; University of Washington, Seattle. 1997-2010. Available at file://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=hirschsprung-ov. Accessed May 31, 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_42_36525=[""].join("\n");
var outline_f35_42_36525=null;
var title_f35_42_36526="Antioxidants and mortality MI";
var content_f35_42_36526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Antioxidants do not reduce mortality or major coronary events after a myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 244px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier estimates of total and cardiac mortality fail to show a benefit from supplemental therapy with alpha-tocopherol or &beta;-carotene in men with a previous myocardial infarction. Compared to placebo, there was a significant increase in cardiac mortality among patients treated with beta carotene (p = 0.007) and those treated with both beta carotene and alpha-tocopherol (p = 0.03).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Rapola, JM, Virtamo, J, Ripatti, S, et al Lancet 1997; 349:1715.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_42_36526=[""].join("\n");
var outline_f35_42_36526=null;
var title_f35_42_36527="Paravertebral mass MRI II";
var content_f35_42_36527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Invasive neuroblastoma on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 236px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal T1-weighted section through the mass shows both chest wall invasion (large arrow) and extension into the spinal canal (small arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_42_36527=[""].join("\n");
var outline_f35_42_36527=null;
